An immunogenic personal neoantigen vaccine for patie

Citation Report

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1 | Checkpoint Inhibition in Hodgkin Lymphoma - a Review. Oncology Research and Treatment, 2017, 40, 654-660. | 0.8 | 19 |
| 2 | Immuno-Oncology—The Translational Runway for Gene Therapy: Gene Therapeutics to Address Multiple Immune Targets. Human Gene Therapy, 2017, 28, 1130-1137. | 1.4 | 3 |
| 3 | Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell, 2017, 171, 1259-1271.e11. | 13.5 | 968 |
| 4 | Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. Seminars in Immunology, 2017, 34, 114-122. | 2.7 | 29 |
| 5 | Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach. Bioconjugate Chemistry, 2017, 28, 2756-2771. | 1.8 | 36 |
| 6 | Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. OncoImmunology, 2017, 6, e1386829. | 2.1 | 209 |
| 7 | The promises of immunotherapy in gliomas. Current Opinion in Neurology, 2017, 30, 650-658. | 1.8 | 16 |
| 8 | Determining T-cell specificity to understand and treat disease. Nature Biomedical Engineering, 2017, 1, 784-795. | 11.6 | 10 |
| 9 | Neoantigen Vaccines Pass the Immunogenicity Test. Trends in Molecular Medicine, 2017, 23, 869-871. | 3.5 | 45 |
| 11 | Personal training by vaccination. Nature Reviews Cancer, 2017, 17, 451-451. | 12.8 | 5 |
| 12 | Personal training by vaccination. Nature Reviews Immunology, 2017, 17, 468-468. | 10.6 | 0 |
| 13 | Tools to define the melanoma–associated immunopeptidome. Immunology, 2017, 152, 536-544. | 2.0 | 14 |
| 14 | Making It Personal: Neoantigen Vaccines in Metastatic Melanoma. Immunity, 2017, 47, 221-223. | 6.6 | 31 |
| 15 | Notable advances 2017. Nature Medicine, 2017, 23, 1387-1389. | 15.2 | 0 |
| 16 | Personalized peptide vaccines for cancer therapy: current progress and state of the art. Expert Review of Precision Medicine and Drug Development, 2017, 2, 371-381. | 0.4 | 9 |
| 17 | Trial watch: DNA-based vaccines for oncological indications. OncoImmunology, 2017, 6, e1398878. | 2.1 | 30 |
| 18 | Neoantigens in the immuno-oncology space. Future Oncology, 2017, 13, 2209-2211. | 1.1 | 3 |
| 19 | Precision T-cell therapy targets tumours. Nature, 2017, 547, 165-167. | 13.7 | 23 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 20 | Informatics for cancer immunotherapy. Annals of Oncology, 2017, 28, xii56-xii73. | 0.6 | 19 |
| 21 | Preclinical and clinical development of neoantigen vaccines. Annals of Oncology, 2017, 28, xii11-xii17. | 0.6 | 160 |
| 22 | MCVdb: A database for knowledge discovery in Merkel cell polyomavirus with applications in T cell immunology and vaccinology. , 2017, , . | | 1 |
| 23 | Booming cancer immunotherapy fighting tumors. Science China Life Sciences, 2017, 60, 1445-1449. | 2.3 | 6 |
| 24 | Novel tools to assist neoepitope targeting in personalized cancer immunotherapy. Annals of Oncology, 2017, 28, xii3-xii10. | 0.6 | 31 |
| 25 | Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles. Immune Network, 2017, 17, 378. | 1.6 | 70 |
| 26 | Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells. Medical Sciences (Basel, Switzerland), 2017, 5, 28. | 1.3 | 22 |
| 27 | Calling cancer's bluff with neoantigen vaccines. Nature, 2017, 552, S76-S77. | 13.7 | 3 |
| 28 | How T cells spot tumour cells. Nature, 2017, 551, 444-446. | 13.7 | 15 |
| 29 | PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. Frontiers in Immunology, 2017, 8, 1597. | 2.2 | 225 |
| 30 | The benefits of immunotherapy combinations. Nature, 2017, 552, S67-S69. | 13.7 | 111 |
| 31 | Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. Cancers, 2017, 9, 164. | 1.7 | 26 |
| 32 | The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy. Frontiers in Immunology, 2017, 8, 1113. | 2.2 | 13 |
| 33 | 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization. Frontiers in Immunology, 2017, 8, 1367. | 2.2 | 133 |
| 34 | Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. Frontiers in Immunology, 2017, 8, 1547. | 2.2 | 125 |
| 35 | An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes. Frontiers in Immunology, 2017, 8, 1566. | 2.2 | 103 |
| 36 | Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma. Frontiers in Immunology, 2017, 8, 1594. | 2.2 | 48 |
| 37 | The Future of Immunotherapy: A 20-Year Perspective. Frontiers in Immunology, 2017, 8, 1668. | 2.2 | 76 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 38 | Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy. Frontiers in Immunology, 2017, 8, 1679. | 2.2 | 171 |
| 39 | Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients. Frontiers in Immunology, 2017, 8, 1702. | 2.2 | 48 |
| 40 | The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy. Frontiers in Immunology, 2017, 8, 1718. | 2.2 | 36 |
| 41 | Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?. Frontiers in Immunology, 2017, 8, 1848. | 2.2 | 73 |
| 42 | Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling. PLoS ONE, 2017, 12, e0182786. | 1.1 | 91 |
| 43 | Virus like particles as a platform for cancer vaccine development. PeerJ, 2017, 5, e4053. | 0.9 | 62 |
| 44 | Vaccination-induced skin-resident memory CD8$^+$T cells mediate strong protection against cutaneous melanoma. OncoImmunology, 2018, 7, e1442163. | 2.1 | 62 |
| 45 | Advances of Immune Checkpoint Inhibitors in Tumor Immunotherapy. IOP Conference Series: Materials Science and Engineering, 2018, 301, 012020. | 0.3 | 3 |
| 46 | Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality. Biomaterials, 2018, 164, 80-97. | 5.7 | 78 |
| 47 | Computational prediction of neoantigens: do we need more data or new approaches?. Annals of Oncology, 2018, 29, 799-801. | 0.6 | 4 |
| 48 | Targeting Neoantigens for Personalised Immunotherapy. BioDrugs, 2018, 32, 99-109. | 2.2 | 11 |
| 49 | Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition. Cancer Immunology Research, 2018, 6, 617-627. | 1.6 | 13 |
| 50 | Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. Ca-A Cancer Journal for Clinicians, 2018, 68, 217-231. | 157.7 | 117 |
| 51 | Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). International Journal of Oncology, 2018, 52, 1041-1056. | 1.4 | 4 |
| 52 | Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. OncoImmunology, 2018, 7, e1445457. | 2.1 | 13 |
| 53 | A facile approach to enhance antigen response for personalized cancer vaccination. Nature Materials, 2018, 17, 528-534. | 13.3 | 313 |
| 54 | Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 1379-1389. | 1.3 | 85 |
| 55 | Systems Immunology: Learning the Rules of the Immune System. Annual Review of Immunology, 2018, 36, 813-842. | 9.5 | 70 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 56 | The role of cytokines in T‑cell memory in health and disease. Immunological Reviews, 2018, 283, 176-193. | 2.8 | 135 |
| 57 | Melanoma: What do all the mutations mean?. Cancer, 2018, 124, 3490-3499. | 2.0 | 131 |
| 58 | Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry. Immunology, 2018, 154, 331-345. | 2.0 | 101 |
| 59 | Quo Vadis―Do Immunotherapies Have a Role in Glioblastoma?. Current Treatment Options in Neurology, 2018, 20, 14. | 0.7 | 22 |
| 60 | Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell, 2018, 173, 305-320.e10. | 13.5 | 272 |
| 61 | Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell, 2018, 33, 581-598. | 7.7 | 393 |
| 62 | Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer. Cancer Immunology, Immunotherapy, 2018, 67, 1897-1910. | 2.0 | 42 |
| 63 | Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Science Translational Medicine, 2018, 10, . | 5.8 | 326 |
| 64 | Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response. Journal of Immunology, 2018, 200, 3464-3474. | 0.4 | 16 |
| 65 | Personalized cancer vaccines: adjuvants are important, too. Cancer Immunology, Immunotherapy, 2018, 67, 1911-1918. | 2.0 | 44 |
| 66 | Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 2018, 33, 843-852.e4. | 7.7 | 827 |
| 67 | Cancer immunotherapy‑targeted glypican‑3 or neoantigens. Cancer Science, 2018, 109, 531-541. | 1.7 | 40 |
| 68 | Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. Cancer Science, 2018, 109, 542-549. | 1.7 | 45 |
| 69 | Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. Trends in Cancer, 2018, 4, 119-137. | 3.8 | 247 |
| 70 | Present status and future perspective of peptide‑based vaccine therapy for urological cancer. Cancer Science, 2018, 109, 550-559. | 1.7 | 42 |
| 71 | Breaking self-tolerance during autoimmunity and cancer immunity: Myeloid cells and type I IFN response regulation. Journal of Leukocyte Biology, 2018, 103, 1117-1129. | 1.5 | 11 |
| 72 | Therapeutic cancer vaccines: From initial findings to prospects. Immunology Letters, 2018, 196, 11-21. | 1.1 | 75 |
| 73 | Cancer immunotherapy beyond immune checkpoint inhibitors. Journal of Hematology and Oncology, 2018, 11, 8. | 6.9 | 174 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 74 | Cell membrane-coated nanocarriers: the emerging targeted delivery system for cancer theranostics. Drug Discovery Today, 2018, 23, 891-899. | 3.2 | 112 |
| 75 | A roadmap towards personalized immunology. Npj Systems Biology and Applications, 2018, 4, 9. | 1.4 | 43 |
| 76 | A modified HLA-A*0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses. Cellular and Molecular Immunology, 2018, 15, 768-781. | 4.8 | 13 |
| 77 | Precision medicine in diabetes: an opportunity for clinical translation. Annals of the New York Academy of Sciences, 2018, 1411, 140-152. | 1.8 | 32 |
| 78 | Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. Gut, 2018, 67, 1168-1180. | 6.1 | 139 |
| 79 | Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma. Annals of Oncology, 2018, 29, 271-279. | 0.6 | 106 |
| 80 | Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer Journal (Sudbury, Mass ), 2018, 24, 47-53. | 1.0 | 287 |
| 81 | Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model. Human Vaccines and Immunotherapeutics, 2018, 14, 931-940. | 1.4 | 20 |
| 82 | Cancer transcriptome profiling at the juncture of clinical translation. Nature Reviews Genetics, 2018, 19, 93-109. | 7.7 | 202 |
| 83 | Improving Cancer Immunotherapies through Empirical Neoantigen Selection. Trends in Cancer, 2018, 4, 97-100. | 3.8 | 15 |
| 84 | Therapeutic Cancer Vaccines: How Much Closer Are We?. BioDrugs, 2018, 32, 1-7. | 2.2 | 15 |
| 85 | High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome. Molecular and Cellular Proteomics, 2018, 17, 533-548. | 2.5 | 224 |
| 86 | Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a033704. | 2.3 | 10 |
| 87 | Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell, 2018, 172, 549-563.e16. | 13.5 | 226 |
| 88 | mRNA vaccines â€" a new era in vaccinology. Nature Reviews Drug Discovery, 2018, 17, 261-279. | 21.5 | 2,668 |
| 89 | Quantification of a recombinant antigen in an immuno-stimulatory whole yeast cell-based therapeutic vaccine. Analytical Biochemistry, 2018, 545, 65-71. | 1.1 | 8 |
| 90 | Mechanisms of resistance to immune checkpoint inhibitors. British Journal of Cancer, 2018, 118, 9-16. | 2.9 | 944 |
| 91 | Inhibitors of the PD-1 Pathway in Tumor Therapy. Journal of Immunology, 2018, 200, 375-383. | 0.4 | 112 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 92 | Hitting the Target: How T Cells Detect and Eliminate Tumors. Journal of Immunology, 2018, 200, 392-399. | 0.4 | 67 |
| 93 | Membranal and Blood–Soluble HLA Class II Peptidome Analyses Using Data–Dependent and Independent Acquisition. Proteomics, 2018, 18, e1700246. | 1.3 | 32 |
| 94 | The Role of Mass Spectrometry and Proteogenomics in the Advancement of HLA Epitope Prediction. Proteomics, 2018, 18, e1700259. | 1.3 | 49 |
| 95 | High-Dimensional Profiling of Tumor-Specific Immune Responses: Asking T Cells about What They "See" in Cancer. Cancer Immunology Research, 2018, 6, 2-9. | 1.6 | 15 |
| 96 | Vaccinating with Stem Cells to Stop Cancer. Trends in Molecular Medicine, 2018, 24, 524-526. | 3.5 | 4 |
| 97 | Population-level distribution and putative immunogenicity of cancer neoepitopes. BMC Cancer, 2018, 18, 414. | 1.1 | 32 |
| 98 | The perfect personalized cancer therapy: cancer vaccines against neoantigens. Journal of Experimental and Clinical Cancer Research, 2018, 37, 86. | 3.5 | 82 |
| 99 | Correlates of immune and clinical activity of novel cancer vaccines. Seminars in Immunology, 2018, 39, 119-136. | 2.7 | 54 |
| 100 | The opposing roles of CD4$^+$ T cells in anti–tumour immunity. Immunology, 2018, 154, 582-592. | 2.0 | 92 |
| 101 | The emerging clinical relevance of genomics in cancer medicine. Nature Reviews Clinical Oncology, 2018, 15, 353-365. | 12.5 | 351 |
| 102 | Vaccine Strategies in Gliomas. Current Treatment Options in Neurology, 2018, 20, 11. | 0.7 | 12 |
| 104 | Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer. Journal of Dental Research, 2018, 97, 627-634. | 2.5 | 31 |
| 105 | Immune checkpoint blockade therapy. Journal of Allergy and Clinical Immunology, 2018, 142, 1403-1414. | 1.5 | 79 |
| 106 | Aluminum hydroxide colloid vaccine encapsulated in yeast shells with enhanced humoral and cellular immune responses. Biomaterials, 2018, 167, 32-43. | 5.7 | 31 |
| 107 | Personalized vaccines for cancer immunotherapy. Science, 2018, 359, 1355-1360. | 6.0 | 697 |
| 108 | Immune signatures predicting responses to immunomodulatory antibody therapy. Current Opinion in Immunology, 2018, 51, 91-96. | 2.4 | 7 |
| 109 | Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. Melanoma Research, 2018, 28, 211-221. | 0.6 | 21 |
| 110 | Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma. Melanoma Research, 2018, 28, 171-184. | 0.6 | 18 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 111 | Personalized neoantigen vaccines: A new approach to cancer immunotherapy. Bioorganic and Medicinal Chemistry, 2018, 26, 2842-2849. | 1.4 | 85 |
| 112 | Age and immunity: What is â€œimmunosenescenceâ€?. Experimental Gerontology, 2018, 105, 4-9. | 1.2 | 337 |
| 113 | Combination therapy strategies for improving PDâ€‘1 blockade efficacy: a new era in cancer immunotherapy. Journal of Internal Medicine, 2018, 283, 110-120. | 2.7 | 162 |
| 114 | Progress in biopharmaceutical development. Biotechnology and Applied Biochemistry, 2018, 65, 306-322. | 1.4 | 207 |
| 115 | Advances in immunotherapy for pediatric acute myeloid leukemia. Expert Opinion on Biological Therapy, 2018, 18, 51-63. | 1.4 | 13 |
| 116 | Cancer vaccines on the move. Nature Reviews Clinical Oncology, 2018, 15, 9-10. | 12.5 | 127 |
| 117 | An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors. Molecular Therapy, 2018, 26, 379-389. | 3.7 | 78 |
| 118 | Immune correlates of clinical outcome in melanoma. Immunology, 2018, 153, 415-422. | 2.0 | 9 |
| 119 | Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nature Reviews Immunology, 2018, 18, 168-182. | 10.6 | 736 |
| 120 | Medical bioinformatics in melanoma. Current Opinion in Oncology, 2018, 30, 113-117. | 1.1 | 13 |
| 121 | Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human. Clinical Cancer Research, 2018, 24, 766-776. | 3.2 | 68 |
| 122 | Veterinary Oncology Immunotherapies. Veterinary Clinics of North America - Small Animal Practice, 2018, 48, 257-277. | 0.5 | 8 |
| 123 | Immuno-oncology from the perspective of somatic evolution. Seminars in Cancer Biology, 2018, 52, 75-85. | 4.3 | 15 |
| 125 | Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. Journal of Clinical Oncology, 2018, 36, 942-950. | 0.8 | 273 |
| 126 | Cancer Vaccines: Dendritic Cell-Based Vaccines and Related Approaches. , 2018, , 260-260. | | 0 |
| 127 | Network assessment of demethylation treatment in melanoma: Differential transcriptome-methylome and antigen profile signatures. PLoS ONE, 2018, 13, e0206686. | 1.1 | 2 |
| 129 | Lost in the crowd: identifying targetable MHC class I neoepitopes for cancer immunotherapy. Expert Review of Proteomics, 2018, 15, 1065-1077. | 1.3 | 12 |
| 130 | Vaccination With a FAT1-Derived B Cell Epitope Combined With Tumor-Specific B and T Cell Epitopes Elicits Additive Protection in Cancer Mouse Models. Frontiers in Oncology, 2018, 8, 481. | 1.3 | 18 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 131 | The Dilemma of Cure and Damage in Oligodendroglioma: Ways to Tip the Balance Away from the Damage. Cancers, 2018, 10, 431. | 1.7 | 7 |
| 132 | Perspective: cancer vaccines in the era of immune checkpoint blockade. Mammalian Genome, 2018, 29, 703-713. | 1.0 | 20 |
| 133 | Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening. Scientific Reports, 2018, 8, 17366. | 1.6 | 13 |
| 134 | The role of neoantigen in immune checkpoint blockade therapy. Experimental Hematology and Oncology, 2018, 7, 28. | 2.0 | 99 |
| 135 | Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells. Oncotarget, 2018, 9, 11009-11019. | 0.8 | 44 |
| 136 | The 2018 Nobel Prize in medicine goes to cancer immunotherapy. BMC Cancer, 2018, 18, 1086. | 1.1 | 54 |
| 137 | A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data. Nature Genetics, 2018, 50, 1735-1743. | 9.4 | 62 |
| 138 | Cancer research in the era of immunogenomics. ESMO Open, 2018, 3, e000475. | 2.0 | 14 |
| 139 | Adoptive Cell Transfer: Is it a Promising Immunotherapy for Colorectal Cancer?. Theranostics, 2018, 8, 5784-5800. | 4.6 | 42 |
| 140 | The clinical promise of immunotherapy in triple-negative breast cancer. Cancer Management and Research, 2018, Volume 10, 6823-6833. | 0.9 | 113 |
| 142 | Progress of immune checkpoint therapy in the clinic (Review). Oncology Reports, 2019, 41, 3-14. | 1.2 | 24 |
| 143 | CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response. OncoImmunology, 2018, 7, e1502904. | 2.1 | 11 |
| 144 | Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. Journal of Hematology and Oncology, 2018, 11, 142. | 6.9 | 95 |
| 145 | Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. Journal of Immunology Research, 2018, 2018, 1-9. | 0.9 | 75 |
| 146 | Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers. Frontiers in Oncology, 2018, 8, 563. | 1.3 | 35 |
| 147 | Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Medicine, 2018, 10, 93. | 3.6 | 121 |
| 148 | Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly (I : C) promote melanoma regression. Theranostics, 2018, 8, 6307-6321. | 4.6 | 89 |
| 149 | Noncoding regions are the main source of targetable tumor-specific antigens. Science Translational Medicine, 2018, 10, . | 5.8 | 374 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 150 | Network Representation of T-Cell Repertoireâ€" A Novel Tool to Analyze Immune Response to Cancer Formation. Frontiers in Immunology, 2018, 9, 2913. | 2.2 | 15 |
| 151 | Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors. Current Oncology Reports, 2018, 20, 1. | 1.8 | 30 |
| 152 | Emerging ways to treat breast cancer: will promises be met?. Cellular Oncology (Dordrecht), 2018, 41, 605-621. | 2.1 | 43 |
| 153 | Stochastic modeling of tumor progression and immune evasion. Journal of Theoretical Biology, 2018, 458, 148-155. | 0.8 | 15 |
| 154 | The prevalent Boxer MHC class Ia allotype dog leukocyte antigen (DLA)â€88*034:01 preferentially binds nonamer peptides with a defined motif. Hla, 2018, 92, 403-407. | 0.4 | 7 |
| 155 | Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy. Gynecologic Oncology, 2018, 151, 1-3. | 0.6 | 20 |
| 156 | Automated closed-system manufacturing of human monocyte-derived dendritic cells for cancer immunotherapy. Journal of Immunological Methods, 2018, 463, 89-96. | 0.6 | 11 |
| 157 | A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell, 2018, 175, 313-326. | 13.5 | 985 |
| 158 | Open Source Tool for VH-replacement Products Discovery and Analysis. , 2018, , . | | 0 |
| 159 | Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology. Frontiers in Oncology, 2018, 8, 430. | 1.3 | 57 |
| 160 | Protein Barcodes Enable High-Dimensional Single-Cell CRISPR Screens. Cell, 2018, 175, 1141-1155.e16. | 13.5 | 107 |
| 161 | Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. Frontiers in Immunology, 2018, 9, 2265. | 2.2 | 107 |
| 162 | Exploring optimal sequencing of radiation and immunotherapy combinations. Advances in Radiation Oncology, 2018, 3, 494-505. | 0.6 | 26 |
| 163 | Encapsulation of Poly I:C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors. International Journal of Pharmaceutics, 2018, 553, 327-337. | 2.6 | 31 |
| 164 | Generation of cancer vaccine immunogens derived from major histocompatibility complex (MHC) class I molecules using variable epitope libraries. Immunology Letters, 2018, 204, 47-54. | 1.1 | 17 |
| 165 | Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. Journal of Translational Medicine, 2018, 16, 286. | 1.8 | 24 |
| 166 | The Mouse Hospital and Its Integration in Ultra-Precision Approaches to Cancer Care. Frontiers in Oncology, 2018, 8, 340. | 1.3 | 20 |
| 168 | Cationic Liposomes: A Flexible Vaccine Delivery System for Physicochemically Diverse Antigenic Peptides. Pharmaceutical Research, 2018, 35, 207. | 1.7 | 44 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 169 | Immunoengineering through cancer vaccines â€“ A personalized and multi-step vaccine approach towards precise cancer immunity. Journal of Controlled Release, 2018, 289, 125-145. | 4.8 | 31 |
| 170 | Trial watch: Peptide-based vaccines in anticancer therapy. OncoImmunology, 2018, 7, e1511506. | 2.1 | 121 |
| 171 | TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis. Genomics, Proteomics and Bioinformatics, 2018, 16, 276-282. | 3.0 | 97 |
| 172 | Immune lipoprotein nanostructures inspired relay drug delivery for amplifying antitumor efficiency. Biomaterials, 2018, 185, 205-218. | 5.7 | 32 |
| 173 | Unimicellar hyperstars as multi-antigen cancer nanovaccines displaying clustered epitopes of immunostimulating peptides. Biomaterials Science, 2018, 6, 2850-2858. | 2.6 | 9 |
| 174 | Evolutionary Pressure against MHC Class II Binding Cancer Mutations. Cell, 2018, 175, 416-428.e13. | 13.5 | 176 |
| 175 | BSA-bioinspired gold nanorods loaded with immunoadjuvant for the treatment of melanoma by combined photothermal therapy and immunotherapy. Nanoscale, 2018, 10, 21640-21647. | 2.8 | 118 |
| 176 | Immediate and substantial evolution of T-cell repertoire in peripheral blood and tumor microenvironment of patients with esophageal squamous cell carcinoma treated with preoperative chemotherapy. Carcinogenesis, 2018, 39, 1389-1398. | 1.3 | 13 |
| 177 | Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. Cancer Discovery, 2018, 8, 1366-1375. | 7.7 | 80 |
| 178 | Translational Biomarkers: Application in the Clinical Development of Combination Therapies. , 2018, , 223-248. | | 0 |
| 179 | Smart vaccine delivery based on microneedle arrays decorated with ultra-pH-responsive copolymers for cancer immunotherapy. Biomaterials, 2018, 185, 13-24. | 5.7 | 142 |
| 180 | In Silico Analysis of the Minor Histocompatibility Antigen Landscape Based on the 1000 Genomes Project. Frontiers in Immunology, 2018, 9, 1819. | 2.2 | 31 |
| 181 | Immunological-based approaches for cancer therapy. Clinics, 2018, 73, e429s. | 0.6 | 7 |
| 182 | Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice. Cancer Immunology Research, 2018, 6, 1301-1313. | 1.6 | 27 |
| 183 | A carboxymethyl dextran-based polymeric conjugate as the antigen carrier for cancer immunotherapy. Biomaterials Research, 2018, 22, 21. | 3.2 | 19 |
| 184 | Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8+ T Cells in Head and Neck Cancer. Cancer Research, 2018, 78, 6159-6170. | 0.4 | 61 |
| 185 | Identifying neoantigens for use in immunotherapy. Mammalian Genome, 2018, 29, 714-730. | 1.0 | 28 |
| 186 | Chromosome Yâ€“encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant. Blood Advances, 2018, 2, 2419-2429. | 2.5 | 11 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 187 | Subcellular Localization of Antigen in Keratinocytes Dictates Delivery of CD4+ T-cell Help for the CTL Response upon Therapeutic DNA Vaccination into the Skin. Cancer Immunology Research, 2018, 6, 835-847. | 1.6 | 10 |
| 188 | Less cholesterol means better tumor killing for cytotoxic T9 cells. Journal of Experimental Medicine, 2018, 215, 1505-1506. | 4.2 | 1 |
| 189 | Smart delivery of vaccines. Nature Materials, 2018, 17, 482-483. | 13.3 | 18 |
| 190 | Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. Journal of Molecular Biology, 2018, 430, 2014-2029. | 2.0 | 42 |
| 191 | Regulation of innate and adaptive antitumor immunity by IAP antagonists. Immunotherapy, 2018, 10, 787-796. | 1.0 | 51 |
| 192 | Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature, 2018, 557, 575-579. | 13.7 | 942 |
| 193 | MHCflurry: Open-Source Class I MHC Binding Affinity Prediction. Cell Systems, 2018, 7, 129-132.e4. | 2.9 | 311 |
| 194 | Novel tumour antigens and the development of optimal vaccine design. , 2018, 6, 31-47. | 1.4 | 11 |
| 195 | Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma. American Journal of Clinical Dermatology, 2018, 19, 657-670. | 3.3 | 14 |
| 196 | Vaccine immunotherapy with ARNAX induces tumorâ€specific memory T cells and durable antiâ€tumor immunity in mouse models. Cancer Science, 2018, 109, 2119-2129. | 1.7 | 22 |
| 197 | Chimeric Antigen Receptor Therapy. New England Journal of Medicine, 2018, 379, 64-73. | 13.9 | 1,488 |
| 198 | Challenges towards the realization of individualized cancer vaccines. Nature Biomedical Engineering, 2018, 2, 566-569. | 11.6 | 40 |
| 199 | Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. , 2018, 6, 40. | | 110 |
| 200 | Engineering PD-1-Presenting Platelets for Cancer Immunotherapy. Nano Letters, 2018, 18, 5716-5725. | 4.5 | 172 |
| 201 | Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines. Biomaterials, 2018, 182, 82-91. | 5.7 | 77 |
| 202 | Targeting STING with cyclic di-GMP greatly augmented immune responses of glycopeptide cancer vaccines. Chemical Communications, 2018, 54, 9655-9658. | 2.2 | 43 |
| 203 | MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design. BMC Genomics, 2018, 19, 582. | 1.2 | 42 |
| 204 | Immunotherapy for glioblastoma: going viral. Nature Medicine, 2018, 24, 1094-1096. | 15.2 | 25 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 205 | Peptide Delivery Systems for Cancer Vaccines. Advanced Therapeutics, 2018, 1, 1800060. | 1.6 | 30 |
| 206 | Ilixadencel â€" an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration. Pharmaceutical Research, 2018, 35, 156. | 1.7 | 16 |
| 207 | Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy. Advanced Functional Materials, 2018, 28, 1802540. | 7.8 | 92 |
| 208 | CD4+ T cell help in cancer immunology and immunotherapy. Nature Reviews Immunology, 2018, 18, 635-647. | 10.6 | 1,030 |
| 209 | Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3. Cancer Immunology, Immunotherapy, 2018, 67, 1559-1569. | 2.0 | 9 |
| 210 | Pathways in melanoma development. Italian Journal of Dermatology and Venereology, 2018, 153, 68-76. | 0.1 | 4 |
| 211 | Recombinant *Listeria* promotes tumor rejection by CD8 [+] T cell-dependent remodeling of the tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 8179-8184. | 3.3 | 60 |
| 212 | An Update on Immunotherapy for Solid Tumors: A Review. Annals of Surgical Oncology, 2018, 25, 3404-3412. | 0.7 | 66 |
| 213 | Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2018, 17, 2132-2145. | 2.5 | 41 |
| 214 | Current Strategies and Applications for Precision Drug Design. Frontiers in Pharmacology, 2018, 9, 787. | 1.6 | 32 |
| 215 | Computational Pipeline for the PGV-001 Neoantigen Vaccine Trial. Frontiers in Immunology, 2017, 8, 1807. | 2.2 | 57 |
| 216 | Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Frontiers in Immunology, 2018, 9, 14. | 2.2 | 356 |
| 217 | A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations. Frontiers in Immunology, 2018, 9, 99. | 2.2 | 35 |
| 218 | Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells. Frontiers in Immunology, 2018, 9, 385. | 2.2 | 144 |
| 219 | Combination Immunotherapy: Taking Cancer Vaccines to the Next Level. Frontiers in Immunology, 2018, 9, 610. | 2.2 | 46 |
| 220 | Photochemical Internalization of Peptide Antigens Provides a Novel Strategy to Realize Therapeutic Cancer Vaccination. Frontiers in Immunology, 2018, 9, 650. | 2.2 | 31 |
| 221 | Targeting Head and Neck Cancer by Vaccination. Frontiers in Immunology, 2018, 9, 830. | 2.2 | 42 |
| 222 | Approaches to Improve Chemically Defined Synthetic Peptide Vaccines. Frontiers in Immunology, 2018, 9, 884. | 2.2 | 54 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 223 | Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG. Frontiers in Immunology, 2018, 9, 1412. | 2.2 | 40 |
| 224 | Dendritic Cells in the Cross Hair for the Generation of Tailored Vaccines. Frontiers in Immunology, 2018, 9, 1484. | 2.2 | 17 |
| 225 | Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. Annals of Gastroenterological Surgery, 2018, 2, 289-303. | 1.2 | 35 |
| 226 | Current Strategies to Enhance Anti-Tumour Immunity. Biomedicines, 2018, 6, 37. | 1.4 | 11 |
| 227 | Myosin II Synergizes with F-Actin to Promote DNGR-1-Dependent Cross-Presentation of Dead Cell-Associated Antigens. Cell Reports, 2018, 24, 419-428. | 2.9 | 30 |
| 228 | Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. Cancers, 2018, 10, 62. | 1.7 | 73 |
| 229 | Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes. Clinical Cancer Research, 2018, 24, 6115-6124. | 3.2 | 14 |
| 230 | Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877742. | 1.4 | 7 |
| 231 | An Introduction to the Computational Challenges in Next Generation Sequencing. Communications in Computer and Information Science, 2018, , 37-45. | 0.4 | 0 |
| 232 | Novel frontiers in detecting cancer metastasis. Clinical and Experimental Metastasis, 2018, 35, 403-412. | 1.7 | 8 |
| 233 | Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy. Frontiers in Immunology, 2018, 9, 1499. | 2.2 | 119 |
| 234 | Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different. Trends in Immunology, 2018, 39, 536-548. | 2.9 | 152 |
| 235 | Vaccine therapy in hematologic malignancies. Blood, 2018, 131, 2640-2650. | 0.6 | 41 |
| 237 | Big Data Approaches for Modeling Response and Resistance to Cancer Drugs. Annual Review of Biomedical Data Science, 2018, 1, 1-27. | 2.8 | 27 |
| 238 | Personalized medicine: a new horizon for medical therapy. Precision Clinical Medicine, 2018, 1, 1-2. | 1.3 | 11 |
| 239 | Predicting Antigen Presentationâ€"What Could We Learn From a Million Peptides?. Frontiers in Immunology, 2018, 9, 1716. | 2.2 | 159 |
| 240 | Next Generation Cancer Vaccinesâ€"Make It Personal!. Vaccines, 2018, 6, 52. | 2.1 | 20 |
| 241 | Pan-cancer analysis of neoepitopes. Scientific Reports, 2018, 8, 12735. | 1.6 | 17 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 242 | Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nature Genetics, 2018, 50, 1271-1281. | 9.4 | 438 |
| 243 | A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. Blood, 2018, 132, 1911-1921. | 0.6 | 44 |
| 244 | Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer. Frontiers in Immunology, 2018, 9, 2030. | 2.2 | 77 |
| 245 | A cancer vaccine approach for personalized treatment of Lynch Syndrome. Scientific Reports, 2018, 8, 12122. | 1.6 | 25 |
| 246 | Intron retention is a source of neoepitopes in cancer. Nature Biotechnology, 2018, 36, 1056-1058. | 9.4 | 212 |
| 247 | PEGylated tumor cell membrane vesicles as a new vaccine platform for cancer immunotherapy. Biomaterials, 2018, 182, 157-166. | 5.7 | 79 |
| 248 | Personalized cancer neoantigen vaccines come of age. Theranostics, 2018, 8, 4238-4246. | 4.6 | 51 |
| 249 | Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen. Journal of Immunology, 2018, 201, 1875-1888. | 0.4 | 20 |
| 250 | Cloning and expansion of antigen-specific T cells using iPS cell technology: Possible use of regenerated T cells in personalized medicine. Personalized Medicine Universe, 2018, 7, 7-12. | 0.1 | 0 |
| 251 | PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells. Journal of Immunology, 2018, 201, 792-803. | 0.4 | 31 |
| 252 | Immunobiology of theÂMelanoma Microenvironment. , 2018, , 133-142. | | 0 |
| 253 | Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cellâ€"rich and exhausted T-effector microenvironment. Blood, 2018, 132, 825-836. | 0.6 | 121 |
| 254 | Immunotherapy and next-generation sequencing guided therapy for precision oncology: what have we learnt and what does the future hold?. Expert Review of Precision Medicine and Drug Development, 2018, 3, 205-213. | 0.4 | 7 |
| 255 | Immunization with tumor neoantigens displayed on T7 phage nanoparticles elicits plasma antibody and vaccine-draining lymph node B cell responses. Journal of Immunological Methods, 2018, 460, 51-62. | 0.6 | 23 |
| 256 | Cancer immunotherapy: broadening the scope of targetable tumours. Open Biology, 2018, 8, . | 1.5 | 162 |
| 257 | Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability. Cancer Immunology Research, 2018, 6, 1025-1038. | 1.6 | 58 |
| 258 | New tools for <scp>MHC</scp> research from machine learning and predictive algorithms to the tumour immunopeptidome. Immunology, 2018, 154, 329-330. | 2.0 | 3 |
| 259 | Functional genomics: paving the way for more successful cancer immunotherapy. Briefings in Functional Genomics, 2019, 18, 86-98. | 1.3 | 6 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 260 | Extraction of Immune Epitope Information. , 2019, , 39-46. | | 1 |
| 261 | Therapeutic cancer vaccine: building the future from lessons of the past. Seminars in Immunopathology, 2019, 41, 69-85. | 2.8 | 56 |
| 262 | Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer. Briefings in Functional Genomics, 2019, 18, 119-128. | 1.3 | 4 |
| 263 | Does patient age influence anti-cancer immunity?. Seminars in Immunopathology, 2019, 41, 125-131. | 2.8 | 60 |
| 264 | Proteogenomic discovery of cancer antigens: Neoantigens and beyond. Pathology International, 2019, 69, 511-518. | 0.6 | 9 |
| 265 | Engineering patient-specific cancer immunotherapies. Nature Biomedical Engineering, 2019, 3, 768-782. | 11.6 | 123 |
| 266 | Immunotherapy in Ovarian Cancer: Are We There Yet?. Journal of Clinical Oncology, 2019, 37, 2460-2471. | 0.8 | 73 |
| 267 | A stochastic individual-based model to explore the role of spatial interactions and antigen recognition in the immune response against solid tumours. Journal of Theoretical Biology, 2019, 480, 43-55. | 0.8 | 13 |
| 268 | Alternative mRNA splicing in cancer immunotherapy. Nature Reviews Immunology, 2019, 19, 675-687. | 10.6 | 169 |
| 269 | Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics. Leukemia and Lymphoma, 2019, 60, 3350-3362. | 0.6 | 1 |
| 270 | Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer. Expert Opinion on Investigational Drugs, 2019, 28, 695-708. | 1.9 | 38 |
| 271 | Induced pluripotent stem cells as a novel cancer vaccine. Expert Opinion on Biological Therapy, 2019, 19, 1191-1197. | 1.4 | 10 |
| 272 | Mutation-Derived Neoantigens for Cancer Immunotherapy. Frontiers in Immunology, 2019, 10, 1856. | 2.2 | 78 |
| 273 | Therapeutic vaccine strategies to induce tumor-specific T-cell responses. Bone Marrow Transplantation, 2019, 54, 806-809. | 1.3 | 2 |
| 274 | Neoantigen-Targeting Vaccine Promotes T-Cell Response in Glioblastoma. Neurosurgery, 2019, 85, E207-E209. | 0.6 | 0 |
| 275 | A PEGylated megamer-based microRNA delivery system activatable by stepwise microenvironment stimulation. Chemical Communications, 2019, 55, 9363-9366. | 2.2 | 14 |
| 276 | Single-cell RNA sequencing of lung adenocarcinoma reveals heterogeneity of immune responseâ€"related genes. JCI Insight, 2019, 4, . | 2.3 | 64 |
| 277 | Immuno-oncology for surgeons. British Journal of Surgery, 2019, 106, 1273-1282. | 0.1 | 2 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 278 | Proteogenomics: advances in cancer antigen research. Immunological Medicine, 2019, 42, 65-70. | 1.4 | 10 |
| 279 | Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy. Medicine (United States), 2019, 98, e15582. | 0.4 | 63 |
| 280 | Highly conserved influenza T cell epitopes induce broadly protective immunity. Vaccine, 2019, 37, 5371-5381. | 1.7 | 39 |
| 281 | Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. Critical Reviews in Oncology/Hematology, 2019, 142, 35-43. | 2.0 | 18 |
| 282 | DeepLigand: accurate prediction of MHC class I ligands using peptide embedding. Bioinformatics, 2019, 35, i278-i283. | 1.8 | 32 |
| 283 | A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy. Advanced Drug Delivery Reviews, 2019, 147, 37-43. | 6.6 | 26 |
| 284 | A surface charge dependent enhanced Th1 antigen-specific immune response in lymph nodes by transfersome-based nanovaccine-loaded dissolving microneedle-assisted transdermal immunization. Journal of Materials Chemistry B, 2019, 7, 4854-4866. | 2.9 | 38 |
| 285 | Cellular Therapy for Melanoma. , 2019, , 1-33. | | 0 |
| 286 | Neoantigens Derived from Recurrently Mutated Genes as Potential Immunotherapy Targets for Gastric Cancer. BioMed Research International, 2019, 2019, 1-11. | 0.9 | 24 |
| 287 | Randomized phase <scp>II</scp> trial of survivin 2B peptide vaccination for patients with <scp>HLA</scp>â€A24â€positive pancreatic adenocarcinoma. Cancer Science, 2019, 110, 2378-2385. | 1.7 | 40 |
| 288 | Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing. Frontiers in Immunology, 2019, 10, 1505. | 2.2 | 34 |
| 289 | Augmenting adaptive immunity: progress and challenges in the quantitative engineering and analysis of adaptive immune receptor repertoires. Molecular Systems Design and Engineering, 2019, 4, 701-736. | 1.7 | 57 |
| 290 | T cell receptorâ€based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunological Reviews, 2019, 290, 127-147. | 2.8 | 180 |
| 291 | Divergent Peptide Presentations of HLA-A*30 Alleles Revealed by Structures With Pathogen Peptides. Frontiers in Immunology, 2019, 10, 1709. | 2.2 | 12 |
| 292 | Fibroblasts in cancer: Defining target structures for therapeutic intervention. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1872, 111-121. | 3.3 | 14 |
| 293 | A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freundâ€™s adjuvant in melanoma patients. , 2019, 7, 163. | | 59 |
| 294 | Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy. Advanced Drug Delivery Reviews, 2019, 141, 104-124. | 6.6 | 14 |
| 295 | Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. Cancer Discovery, 2019, 9, 1192-1207. | 7.7 | 65 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 296 | Immunotherapy in Ovarian Cancer. Surgical Oncology Clinics of North America, 2019, 28, 447-464. | 0.6 | 27 |
| 297 | Vaccine Strategy in Melanoma. Surgical Oncology Clinics of North America, 2019, 28, 337-351. | 0.6 | 17 |
| 298 | Alternative tumour-specific antigens. Nature Reviews Cancer, 2019, 19, 465-478. | 12.8 | 206 |
| 299 | Comparison of Three Different Assays for the Detection of Tumor Antigen-Induced Lymphocyte Transformation In Vitro. DNA and Cell Biology, 2019, 38, 1402-1410. | 0.9 | 1 |
| 300 | Therapy with multi-epitope virus-like particles of B19 parvovirus reduce tumor growth and lung metastasis in an aggressive breast cancer mouse model. Vaccine, 2019, 37, 7256-7268. | 1.7 | 15 |
| 301 | Protecting Tumors by Preventing Human Papilloma Virus Antigen Presentation: Insights from Emerging Bioinformatics Algorithms. Cancers, 2019, 11, 1543. | 1.7 | 4 |
| 302 | Monalizumab: inhibiting the novel immune checkpoint NKG2A. , 2019, 7, 263. | | 182 |
| 303 | Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade. Cell Systems, 2019, 9, 375-382.e4. | 2.9 | 88 |
| 304 | MHCquant: Automated and Reproducible Data Analysis for Immunopeptidomics. Journal of Proteome Research, 2019, 18, 3876-3884. | 1.8 | 35 |
| 305 | Three decades of messenger RNA vaccine development. Nano Today, 2019, 28, 100766. | 6.2 | 177 |
| 306 | Cellular therapy approaches harnessing the power of the immune system for personalized cancer treatment. Seminars in Immunology, 2019, 42, 101306. | 2.7 | 17 |
| 307 | Predicting HLA class II antigen presentation through integrated deep learning. Nature Biotechnology, 2019, 37, 1332-1343. | 9.4 | 218 |
| 308 | Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes. Nature Biotechnology, 2019, 37, 1283-1286. | 9.4 | 208 |
| 309 | Teamwork by different T-cell types boosts tumour destruction by immunotherapy. Nature, 2019, 574, 639-640. | 13.7 | 5 |
| 310 | Adenosineâ€toâ€Inosine RNA Editing in Mouse and Human Brain Proteomes. Proteomics, 2019, 19, 1900195. | 1.3 | 17 |
| 311 | Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. Journal of Hematology and Oncology, 2019, 12, 111. | 6.9 | 93 |
| 312 | Insights Into Mechanisms of Tumor and Immune System Interaction: Association With Wound Healing. Frontiers in Oncology, 2019, 9, 1115. | 1.3 | 21 |
| 313 | Quantitative Proteomics and Metabolomics Reveal Biomarkers of Disease as Potential Immunotherapy Targets and Indicators of Therapeutic Efficacy. Theranostics, 2019, 9, 7872-7888. | 4.6 | 27 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 314 | Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy. Critical Reviews in Immunology, 2019, 39, 93-103. | 1.0 | 16 |
| 315 | Automated Good Manufacturing Practice–compliant generation of human monocyte-derived dendritic cells from a complete apheresis product using a hollow-fiber bioreactor system overcomes a major hurdle in the manufacture of dendritic cells for cancer vaccines. Cytotherapy, 2019, 21, 1166-1178. | 0.3 | 10 |
| 316 | Novel Targets for the Treatment of Melanoma. Current Oncology Reports, 2019, 21, 97. | 1.8 | 15 |
| 318 | An agonistic anti–Toll–like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy. Immunology, 2019, 158, 136-149. | 2.0 | 10 |
| 319 | Machine Learning for Cancer Immunotherapies Based on Epitope Recognition by T Cell Receptors. Frontiers in Genetics, 2019, 10, 1141. | 1.1 | 34 |
| 320 | DeepHLApan: A Deep Learning Approach for Neoantigen Prediction Considering Both HLA-Peptide Binding and Immunogenicity. Frontiers in Immunology, 2019, 10, 2559. | 2.2 | 84 |
| 322 | Technology Opportunity Analysis: Combining SAO Networks and Link Prediction. IEEE Transactions on Engineering Management, 2021, 68, 1288-1298. | 2.4 | 21 |
| 323 | Red blood cell–derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy. Science Advances, 2019, 5, eaaw6870. | 4.7 | 228 |
| 324 | A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma–A Proof of Antigen Discovery Feasibility in Three Patients. Frontiers in Immunology, 2019, 10, 1832. | 2.2 | 73 |
| 325 | Structure Based Prediction of Neoantigen Immunogenicity. Frontiers in Immunology, 2019, 10, 2047. | 2.2 | 77 |
| 326 | Novel Biomarkers for Personalized Cancer Immunotherapy. Cancers, 2019, 11, 1223. | 1.7 | 36 |
| 327 | Neoantigen vaccine: an emerging tumor immunotherapy. Molecular Cancer, 2019, 18, 128. | 7.9 | 398 |
| 328 | Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood. Cell Reports, 2019, 28, 2728-2738.e7. | 2.9 | 65 |
| 329 | Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy. , 2019, 7, 238. | | 33 |
| 330 | Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction. Immunity, 2019, 51, 766-779.e17. | 6.6 | 187 |
| 331 | Tumor neoantigens: from basic research to clinical applications. Journal of Hematology and Oncology, 2019, 12, 93. | 6.9 | 266 |
| 332 | Best practices for bioinformatic characterization of neoantigens for clinical utility. Genome Medicine, 2019, 11, 56. | 3.6 | 146 |
| 333 | Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. Journal of Clinical Investigation, 2019, 129, 2056-2070. | 3.9 | 159 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 334 | Glycan-Modified Melanoma-Derived Apoptotic Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination. Cancers, 2019, 11, 1266. | 1.7 | 47 |
| 335 | Toward in silico Identification of Tumor Neoantigens in Immunotherapy. Trends in Molecular Medicine, 2019, 25, 980-992. | 3.5 | 36 |
| 336 | Next-generation computational tools for interrogating cancer immunity. Nature Reviews Genetics, 2019, 20, 724-746. | 7.7 | 131 |
| 337 | A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control. OncoImmunology, 2019, 8, 1652539. | 2.1 | 45 |
| 338 | Quantifying Antibody Responses Induced by Antigen-Agnostic Immunotherapies. Molecular Therapy - Methods and Clinical Development, 2019, 14, 189-196. | 1.8 | 3 |
| 339 | False-negative errors in next-generation sequencing contribute substantially to inconsistency of mutation databases. PLoS ONE, 2019, 14, e0222535. | 1.1 | 11 |
| 340 | To each his own: a personalized vaccine for metastatic melanoma. Gland Surgery, 2019, 8, 329-333. | 0.5 | 2 |
| 341 | Particulate carrier systems as adjuvants for cancer vaccines. Biomaterials Science, 2019, 7, 4873-4887. | 2.6 | 17 |
| 342 | Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. Frontiers in Pharmacology, 2019, 10, 1184. | 1.6 | 50 |
| 343 | Development of N-Acetylated Dipalmitoyl-S-Glyceryl Cysteine Analogs as Efficient TLR2/TLR6 Agonists. Molecules, 2019, 24, 3512. | 1.7 | 5 |
| 344 | RNA Transcription and Splicing Errors as a Source of Cancer Frameshift Neoantigens for Vaccines. Scientific Reports, 2019, 9, 14184. | 1.6 | 32 |
| 345 | Positron Emission Tomography-Guided Photodynamic Therapy with Biodegradable Mesoporous Silica Nanoparticles for Personalized Cancer Immunotherapy. ACS Nano, 2019, 13, 12148-12161. | 7.3 | 138 |
| 346 | Past, Current, and Future of Immunotherapies for Prostate Cancer. Frontiers in Oncology, 2019, 9, 884. | 1.3 | 89 |
| 347 | Direct Detection and Quantification of Neoantigens. Cancer Immunology Research, 2019, 7, 1748-1754. | 1.6 | 40 |
| 348 | Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes. Cancer Immunology Research, 2019, 7, 1591-1604. | 1.6 | 48 |
| 349 | Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer. International Journal of Molecular Sciences, 2019, 20, 4624. | 1.8 | 5 |
| 350 | Epitope-loaded nanoemulsion delivery system with ability of extending antigen release elicits potent Th1 response for intranasal vaccine against Helicobacter pylori. Journal of Nanobiotechnology, 2019, 17, 6. | 4.2 | 16 |
| 351 | Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. OncoImmunology, 2019, 8, e1561106. | 2.1 | 50 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 352 | Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines. Annual Review of Medicine, 2019, 70, 395-407. | 5.0 | 54 |
| 353 | Cold Tumors: A Therapeutic Challenge for Immunotherapy. Frontiers in Immunology, 2019, 10, 168. | 2.2 | 733 |
| 354 | Using T Cell Receptor Repertoires to Understand the Principles of Adaptive Immune Recognition. Annual Review of Immunology, 2019, 37, 547-570. | 9.5 | 122 |
| 355 | Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer. Medical Sciences (Basel, Switzerland), 2019, 7, 14. | 1.3 | 33 |
| 356 | Multiple Knockout of Classical HLA Class II Î²-Chains by CRISPR/Cas9 Genome Editing Driven by a Single Guide RNA. Journal of Immunology, 2019, 202, 1895-1903. | 0.4 | 9 |
| 357 | Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy. Frontiers in Immunology, 2018, 9, 3176. | 2.2 | 261 |
| 358 | Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma. Oncogene, 2019, 38, 3756-3762. | 2.6 | 30 |
| 359 | The Development of Tumor Neoantigen Vaccine Immunotherapy. E3S Web of Conferences, 2019, 78, 01005. | 0.2 | 0 |
| 360 | A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge. Cancer Immunology Research, 2019, 7, 174-182. | 1.6 | 75 |
| 361 | Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas. Scientific Reports, 2019, 9, 358. | 1.6 | 33 |
| 362 | Epigenetic therapy in immune-oncology. Nature Reviews Cancer, 2019, 19, 151-161. | 12.8 | 345 |
| 363 | Level of neo-epitope predecessor and mutation type determine T cell activation of MHC binding peptides. , 2019, 7, 135. | | 18 |
| 364 | Precision Medicine in Cancer Therapy. Cancer Treatment and Research, 2019, , . | 0.2 | 4 |
| 365 | Targeted Gene Sequencing Panels: Applicability for Neoantigen Profiling of Colon and Rectal Adenocarcinoma. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2019, 13, 146-153. | 0.2 | 1 |
| 366 | Precision Medicine-Enabled Cancer Immunotherapy. Cancer Treatment and Research, 2019, 178, 189-205. | 0.2 | 9 |
| 367 | Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade. Nature Communications, 2019, 10, 2688. | 5.8 | 63 |
| 368 | Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation. Clinical Cancer Research, 2019, 25, 6392-6405. | 3.2 | 37 |
| 369 | Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. Genome Medicine, 2019, 11, 40. | 3.6 | 179 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 370 | Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. , 2019, 7, 156. | | 65 |
| 371 | Prospects for a personalized peptide vaccine against lung cancer. Expert Review of Vaccines, 2019, 18, 703-709. | 2.0 | 9 |
| 372 | Determinants for Neoantigen Identification. Frontiers in Immunology, 2019, 10, 1392. | 2.2 | 99 |
| 374 | Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma. World Neurosurgery, 2019, 129, 90-100. | 0.7 | 52 |
| 375 | Nanovaccines for cancer immunotherapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2019, 11, e1559. | 3.3 | 76 |
| 376 | Concepts of Personalized Medicine in Neuro-oncology. , 2019, , 153-158. | | 0 |
| 377 | Quantification of Uncertainty in Peptide-MHC Binding Prediction Improves High-Affinity Peptide Selection for Therapeutic Design. Cell Systems, 2019, 9, 159-166.e3. | 2.9 | 46 |
| 378 | Cancer Immunotherapies. Veterinary Clinics of North America - Small Animal Practice, 2019, 49, 881-902. | 0.5 | 31 |
| 379 | The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy. Japanese Journal of Clinical Oncology, 2019, 49, 596-603. | 0.6 | 10 |
| 380 | Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. Frontiers in Immunology, 2019, 10, 990. | 2.2 | 86 |
| 381 | Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs. Journal of Molecular Medicine, 2019, 97, 1139-1153. | 1.7 | 4 |
| 382 | Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy. Molecular Aspects of Medicine, 2019, 69, 123-129. | 2.7 | 30 |
| 383 | Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine. Frontiers in Immunology, 2019, 10, 1015. | 2.2 | 39 |
| 384 | Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. Chemical Society Reviews, 2019, 48, 3771-3810. | 18.7 | 292 |
| 385 | Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2019, 18, 1255-1268. | 2.5 | 45 |
| 386 | Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy. Theranostics, 2019, 9, 2299-2314. | 4.6 | 88 |
| 387 | ACME: pan-specific peptide–MHC class I binding prediction through attention-based deep neural networks. Bioinformatics, 2019, 35, 4946-4954. | 1.8 | 79 |
| 388 | Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. Blood, 2019, 134, 199-210. | 0.6 | 54 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 389 | Immunotherapy in Older Adults with Cancer. Current Oncology Reports, 2019, 21, 56. | 1.8 | 16 |
| 390 | An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e70-e78. | 1.8 | 35 |
| 391 | HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy. Frontiers in Immunology, 2019, 10, 1081. | 2.2 | 56 |
| 392 | Current Status of Immunotherapies for Treating Pancreatic Cancer. Current Oncology Reports, 2019, 21, 60. | 1.8 | 38 |
| 393 | Translation of cancer immunotherapy from the bench to the bedside. Advances in Cancer Research, 2019, 143, 1-62. | 1.9 | 28 |
| 395 | Prospect of Plasmacytoid Dendritic Cells in Enhancing Anti-Tumor Immunity of Oncolytic Herpes Viruses. Cancers, 2019, 11, 651. | 1.7 | 12 |
| 396 | Vaccination with Tumor-Ganglioside Glycomimetics Activates a Selective Immunity that Affords Cancer Therapy. Cell Chemical Biology, 2019, 26, 1013-1026.e4. | 2.5 | 20 |
| 397 | Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma. Cancer Immunology Research, 2019, 7, 1148-1161. | 1.6 | 56 |
| 398 | Balancing sensitivity and specificity in distinguishing TCR groups by CDR sequence similarity. BMC Bioinformatics, 2019, 20, 241. | 1.2 | 18 |
| 399 | Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor. ACS Nano, 2019, 13, 6477-6490. | 7.3 | 36 |
| 400 | Induction of neoantigen-reactive T cells from healthy donors. Nature Protocols, 2019, 14, 1926-1943. | 5.5 | 78 |
| 401 | Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164. | 1.8 | 459 |
| 402 | High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells. Clinical Cancer Research, 2019, 25, 4320-4331. | 3.2 | 15 |
| 403 | Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nature Medicine, 2019, 25, 767-775. | 15.2 | 282 |
| 404 | Recognition of polymer configurations by unsupervised learning. Physical Review E, 2019, 99, 043307. | 0.8 | 12 |
| 405 | A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients. Scientific Reports, 2019, 9, 6577. | 1.6 | 21 |
| 406 | Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic *KRAS* and *ERBB2* (*Her2*) Driver Mutations. Cancer Immunology Research, 2019, 7, 910-922. | 1.6 | 68 |
| 407 | Immunotherapeutic effects of intratumoral nanoplexed poly I:C. , 2019, 7, 116. | | 91 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 408 | Liposomal Antitumor Vaccines Targeting Mucin 1 Elicit a Lipid–Dependent Immunodominant Response. Chemistry - an Asian Journal, 2019, 14, 2116-2121. | 1.7 | 25 |
| 409 | BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer. BMC Cancer, 2019, 19, 387. | 1.1 | 17 |
| 410 | ClinOmicsTrailbc: a visual analytics tool for breast cancer treatment stratification. Bioinformatics, 2019, 35, 5171-5181. | 1.8 | 11 |
| 412 | Cancer nanomedicine for combination cancer immunotherapy. Nature Reviews Materials, 2019, 4, 398-414. | 23.3 | 658 |
| 413 | Next-Generation Cancer Immunotherapy Targeting Glypican-3. Frontiers in Oncology, 2019, 9, 248. | 1.3 | 86 |
| 414 | Antigen Targets for the Development of Immunotherapies in Leukemia. International Journal of Molecular Sciences, 2019, 20, 1397. | 1.8 | 10 |
| 415 | Synthetic, Supramolecular, and Self–Adjuvanting CD8$^{+}$ T–Cell Epitope Vaccine Increases the Therapeutic Antitumor Immunity. Advanced Therapeutics, 2019, 2, 1900010. | 1.6 | 15 |
| 416 | Performance Evaluation of MHC Class-I Binding Prediction Tools Based on an Experimentally Validated MHC–Peptide Binding Data Set. Cancer Immunology Research, 2019, 7, 719-736. | 1.6 | 53 |
| 417 | PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Human Vaccines and Immunotherapeutics, 2019, 15, 1111-1122. | 1.4 | 297 |
| 418 | Peptides as cancer vaccines. Current Opinion in Pharmacology, 2019, 47, 20-26. | 1.7 | 75 |
| 419 | Genomic correlates of response to immune checkpoint blockade. Nature Medicine, 2019, 25, 389-402. | 15.2 | 346 |
| 420 | The neoepitope landscape of breast cancer: implications for immunotherapy. BMC Cancer, 2019, 19, 200. | 1.1 | 68 |
| 421 | Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations. Cancers, 2019, 11, 266. | 1.7 | 23 |
| 422 | Microsatellite instability in endometrial cancer: New purpose for an old test. Cancer, 2019, 125, 2154-2163. | 2.0 | 23 |
| 423 | Genomic Medicine–Progress, Pitfalls, and Promise. Cell, 2019, 177, 45-57. | 13.5 | 143 |
| 424 | Immunotherapy of Melanoma: Facts and Hopes. Clinical Cancer Research, 2019, 25, 5191-5201. | 3.2 | 181 |
| 425 | Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9. Journal of Interferon and Cytokine Research, 2019, 39, 233-245. | 0.5 | 21 |
| 426 | The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy. Trends in Immunology, 2019, 40, 292-309. | 2.9 | 61 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 427 | Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells. OncoImmunology, 2019, 8, e1560919. | 2.1 | 29 |
| 428 | Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors. Cancer Discovery, 2019, 9, 476-481. | 7.7 | 48 |
| 429 | The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. Journal of Autoimmunity, 2019, 100, 17-26. | 3.0 | 33 |
| 430 | Cancerâ€testis antigens in canine histiocytic sarcoma and other malignancies. Veterinary and Comparative Oncology, 2019, 17, 317-328. | 0.8 | 4 |
| 431 | Elevated signature of a gene module coexpressed with CDC20 marks genomic instability in glioma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6975-6984. | 3.3 | 37 |
| 432 | Induction of tumor-specific CTL responses using the C-terminal fragment of Viral protein R as cell penetrating peptide. Scientific Reports, 2019, 9, 3937. | 1.6 | 15 |
| 433 | Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination. Journal of Gene Medicine, 2019, 21, e3089. | 1.4 | 19 |
| 434 | Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity. Frontiers in Immunology, 2019, 10, 824. | 2.2 | 29 |
| 435 | Cationic Nanoliposomes Are Efficiently Taken up by Alveolar Macrophages but Have Little Access to Dendritic Cells and Interstitial Macrophages in the Normal and CpG-Stimulated Lungs. Molecular Pharmaceutics, 2019, 16, 2048-2059. | 2.3 | 9 |
| 436 | Current Landscape of Immunotherapy in Breast Cancer. JAMA Oncology, 2019, 5, 1205. | 3.4 | 260 |
| 437 | Chronic lymphocytic leukaemia: the role of T cells in a B cell disease. British Journal of Haematology, 2019, 186, 220-233. | 1.2 | 17 |
| 438 | Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade. Frontiers in Immunology, 2019, 10, 467. | 2.2 | 122 |
| 439 | Emerging Nanoâ€‹Microapproaches for Cancer Immunotherapy. Advanced Science, 2019, 6, 1801847. | 5.6 | 136 |
| 440 | Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature, 2019, 566, 270-274. | 13.7 | 681 |
| 441 | Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy. Cancers, 2019, 11, 176. | 1.7 | 18 |
| 442 | Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA. Frontiers in Immunology, 2019, 10, 2. | 2.2 | 8 |
| 443 | Activation of CD8+ T Cell Responses after Melanoma Antigen Targeting to CD169+ Antigen Presenting Cells in Mice and Humans. Cancers, 2019, 11, 183. | 1.7 | 21 |
| 444 | Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth. Journal of Experimental and Clinical Cancer Research, 2019, 38, 78. | 3.5 | 32 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 445 | Leveraging biomaterials for cancer immunotherapy: targeting pattern recognition receptors. Materials Today Nano, 2019, 5, 100029. | 2.3 | 30 |
| 446 | Turning the corner on therapeutic cancer vaccines. Npj Vaccines, 2019, 4, 7. | 2.9 | 490 |
| 447 | Breaking tolerance with engineered class I antigen-presenting molecules. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3136-3145. | 3.3 | 5 |
| 448 | Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. Trends in Cell Biology, 2019, 29, 396-416. | 3.6 | 66 |
| 449 | Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. , 2019, 7, 38. | | 121 |
| 450 | What is the future of cancer care? A technology foresight assessment of experts' expectations. Economics of Innovation and New Technology, 2019, 28, 635-652. | 2.1 | 11 |
| 451 | Peptide Super-Agonist Enhances T-Cell Responses to Melanoma. Frontiers in Immunology, 2019, 10, 319. | 2.2 | 18 |
| 452 | Updates on Oncolytic Virus Immunotherapy for Cancers. Molecular Therapy - Oncolytics, 2019, 12, 259-262. | 2.0 | 14 |
| 453 | Natural T cell autoreactivity to melanoma antigens: clonally expanded melanoma-antigen specific CD8‰+‰memory T cells can be detected in healthy humans. Cancer Immunology, Immunotherapy, 2019, 68, 709-720. | 2.0 | 20 |
| 454 | Immunotherapy for skin cancer. International Immunology, 2019, 31, 465-475. | 1.8 | 47 |
| 455 | Immunotherapy in extensive small cell lung cancer. Experimental Hematology and Oncology, 2019, 8, 5. | 2.0 | 32 |
| 456 | New Strategies for Therapeutic Cancer Vaccines. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 213-221. | 0.9 | 8 |
| 457 | Harnessing the layer-by-layer assembly technique to design biomaterials vaccines for immune modulation in translational applications. Biomaterials Science, 2019, 7, 715-732. | 2.6 | 24 |
| 458 | New emerging targets in cancer immunotherapy: the role of neoantigens. ESMO Open, 2019, 4, e000684. | 2.0 | 20 |
| 459 | A Temperature Resistant Extracts Prepared from the Perinereis aibuhitensis and Its Antioxidative Characterization. Aquatic Science and Technology, 2019, 7, 17. | 0.1 | 1 |
| 460 | PAS-MUT with Somatic Mutations in Cancer and Classified Diseases for Clinical-Genomics Research: PAS-MUT & Somatic Mutations. , 2019, , . | | 0 |
| 461 | Cancer Vaccines. , 2019, , . | | 1 |
| 462 | TANTIGEN 2.0: an online database and analysis platform for tumor T cell antigens. , 2019, , . | | 2 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 463 | Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response. Genome Medicine, 2019, 11, 71. | 3.6 | 78 |
| 464 | Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. , 2019, 7, 309. | | 112 |
| 465 | Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display. Frontiers in Immunology, 2019, 10, 2766. | 2.2 | 23 |
| 466 | Ex vivo dendritic cell generationâ€"A critical comparison of current approaches. International Review of Cell and Molecular Biology, 2019, 349, 251-307. | 1.6 | 13 |
| 467 | Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23662-23670. | 3.3 | 40 |
| 468 | Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade. RSC Advances, 2019, 9, 33903-33911. | 1.7 | 17 |
| 469 | Inducing Tumor Suppressive Microenvironments through Genome Edited CD47âˆ'/âˆ' Syngeneic Cell Vaccination. Scientific Reports, 2019, 9, 20057. | 1.6 | 2 |
| 470 | Peptide-Major Histocompatibility Complex Class I Binding Prediction Based on Deep Learning With Novel Feature. Frontiers in Genetics, 2019, 10, 1191. | 1.1 | 21 |
| 471 | Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4. Genome Medicine, 2019, 11, 87. | 3.6 | 44 |
| 472 | A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. Journal of Translational Medicine, 2019, 17, 391. | 1.8 | 42 |
| 473 | A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets. BioMed Research International, 2019, 2019, 1-10. | 0.9 | 16 |
| 474 | Delivery strategies of cancer immunotherapy: recent advances and future perspectives. Journal of Hematology and Oncology, 2019, 12, 126. | 6.9 | 96 |
| 475 | The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma. Frontiers in Immunology, 2019, 10, 2472. | 2.2 | 15 |
| 476 | Single-Cell Profiling Defines Transcriptomic Signatures Specific to Tumor-Reactive versus Virus-Responsive CD4+ T Cells. Cell Reports, 2019, 29, 3019-3032.e6. | 2.9 | 50 |
| 477 | High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy. Cancers, 2019, 11, 1824. | 1.7 | 36 |
| 478 | Is immunotherapy the holy grail for pancreatic cancer?. Immunotherapy, 2019, 11, 1435-1438. | 1.0 | 11 |
| 479 | A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer. Frontiers in Immunology, 2019, 10, 2526. | 2.2 | 29 |
| 480 | Banking with precision: transfusion medicine as a potential universal application in clinical genomics. Current Opinion in Hematology, 2019, 26, 480-487. | 1.2 | 10 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 481 | Melanoma vaccines: clinical status and immune endpoints. Melanoma Research, 2019, 29, 109-118. | 0.6 | 19 |
| 482 | Human CD4+ T Cells Specific for Merkel Cell Polyomavirus Localize to Merkel Cell Carcinomas and Target a Required Oncogenic Domain. Cancer Immunology Research, 2019, 7, 1727-1739. | 1.6 | 23 |
| 483 | The Genomic Landscape of Antigenic Targets for T Cell-Based Leukemia Immunotherapy. Frontiers in Immunology, 2019, 10, 2934. | 2.2 | 5 |
| 484 | Neoantigens in Hematological Malignanciesâ€"Ultimate Targets for Immunotherapy?. Frontiers in Immunology, 2019, 10, 3004. | 2.2 | 18 |
| 485 | The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanomaâ€"Association with Clinical Outcome and Tumor Phenotypes. Cancers, 2019, 11, 1981. | 1.7 | 16 |
| 486 | MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature, 2019, 574, 696-701. | 13.7 | 563 |
| 487 | Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Nature Immunology, 2019, 20, 1494-1505. | 7.0 | 83 |
| 488 | Developing neoantigen-targeted T cellâ€"based treatments for solid tumors. Nature Medicine, 2019, 25, 1488-1499. | 15.2 | 173 |
| 489 | Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers, 2019, 11, 1926. | 1.7 | 27 |
| 490 | Immunotherapy â€" Strategies for Expanding Its Role in the Treatment of All Major Tumor Sites. Cureus, 2019, 11, e5938. | 0.2 | 9 |
| 491 | Characterization of a Novel Bispecific Antibody That Activates T Cells In Vitro and Slows Tumor Growth In Vivo. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2019, 38, 242-254. | 0.8 | 2 |
| 492 | Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies. Frontiers in Oncology, 2019, 9, 1237. | 1.3 | 106 |
| 493 | A cycle involving HMGB1, IFN-Î³ and dendritic cells plays a putative role in anti-tumor immunity. Cellular Immunology, 2019, 343, 103850. | 1.4 | 17 |
| 494 | A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis. Molecular Cancer Research, 2019, 17, 109-119. | 1.5 | 28 |
| 495 | A Cell-Specific Nuclear Factor-Kappa Bâ€"Activating Gene Expression Strategy for Delivering Cancer Immunotherapy. Human Gene Therapy, 2019, 30, 471-484. | 1.4 | 8 |
| 496 | Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches. CardioVascular and Interventional Radiology, 2019, 42, 1221-1229. | 0.9 | 5 |
| 497 | The Current Status of Immunotherapy in Thoracic Malignancies. , 2019, , 45-75. | | 0 |
| 498 | Future of Immune Checkpoint Inhibitors. , 2019, , 227-243. | | 2 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 499 | Dendritic Cell Membrane Vesicles for Activation and Maintenance of Antigenâ€Specific T Cells. Advanced Healthcare Materials, 2019, 8, e1801091. | 3.9 | 36 |
| 500 | Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy. Acta Biomaterialia, 2019, 85, 1-26. | 4.1 | 142 |
| 501 | Immune cells track hard-to-target brain tumours. Nature, 2019, 565, 170-171. | 13.7 | 14 |
| 502 | Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature, 2019, 565, 234-239. | 13.7 | 956 |
| 503 | Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature, 2019, 565, 240-245. | 13.7 | 637 |
| 504 | Predicting tumour response to anti-PD-1 immunotherapy with computational modelling. Physics in Medicine and Biology, 2019, 64, 025017. | 1.6 | 22 |
| 505 | Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nature Biotechnology, 2019, 37, 55-63. | 9.4 | 203 |
| 506 | Ushering in Integrated T Cell Repertoire Profiling in Cancer. Trends in Cancer, 2019, 5, 85-94. | 3.8 | 19 |
| 507 | Immunotherapy strategies for mesothelioma â€" the role of tumor specific neoantigens in a new era of precision medicine. Expert Review of Respiratory Medicine, 2019, 13, 181-192. | 1.0 | 13 |
| 508 | A non-functional neoepitope specific CD8$^{+}$ T-cell response induced by tumor derived antigen exposure *in vivo*. OncoImmunology, 2019, 8, 1553478. | 2.1 | 16 |
| 509 | Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nature Reviews Drug Discovery, 2019, 18, 197-218. | 21.5 | 2,005 |
| 510 | Deep learning enables de novo peptide sequencing from data-independent-acquisition mass spectrometry. Nature Methods, 2019, 16, 63-66. | 9.0 | 235 |
| 511 | Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 647-656. | 1.3 | 21 |
| 512 | Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Annals of Oncology, 2019, 30, 44-56. | 0.6 | 1,742 |
| 513 | Personalized Cancer Vaccine. , 2019, , 81-89. | | 0 |
| 514 | Candidate Cancers for Vaccination. , 2019, , 145-152. | | 2 |
| 515 | Concluding Remarks and Future Perspectives on Therapeutic Cancer Vaccines. , 2019, , 171-176. | | 1 |
| 516 | Cancer Immunotherapy: Beyond Checkpoint Blockade. Annual Review of Cancer Biology, 2019, 3, 55-75. | 2.3 | 102 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 517 | Cancer Exome-Based Identification of Tumor Neo-Antigens Using Mass Spectrometry. Methods in Molecular Biology, 2019, 1884, 203-214. | 0.4 | 5 |
| 518 | Updates in adjuvant systemic therapy for melanoma. Journal of Surgical Oncology, 2019, 119, 222-231. | 0.8 | 35 |
| 519 | High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions. Cancer Immunology Research, 2019, 7, 50-61. | 1.6 | 36 |
| 521 | Poly I:C-based rHBVvac therapeutic vaccine eliminates HBV via generation of HBV-specific CD8+ effector memory T cells. Gut, 2019, 68, 2032-2043. | 6.1 | 22 |
| 522 | Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity. OncoImmunology, 2019, 8, 1558663. | 2.1 | 20 |
| 523 | Tumor Microenvironmental pH and Enzyme Dual Responsive Polymer-Liposomes for Synergistic Treatment of Cancer Immuno-Chemotherapy. Biomacromolecules, 2019, 20, 882-892. | 2.6 | 68 |
| 524 | The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice. Cancer Immunology, Immunotherapy, 2019, 68, 455-466. | 2.0 | 31 |
| 525 | Novel Vaccine Targeting Colonic Adenoma: a Pre-clinical Model. Journal of Gastrointestinal Surgery, 2019, 23, 626-633. | 0.9 | 4 |
| 526 | Immunotherapy in pancreatic cancer: New hope or mission impossible?. Cancer Letters, 2019, 445, 57-64. | 3.2 | 26 |
| 527 | Neoepitopes-based vaccines: challenges and perspectives. European Journal of Cancer, 2019, 108, 55-60. | 1.3 | 20 |
| 528 | Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. , 2019, 7, 6. | | 190 |
| 529 | New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation. Annual Review of Medicine, 2019, 70, 409-424. | 5.0 | 50 |
| 530 | Antibody-based Delivery of TNF to the Tumor Neovasculature Potentiates the Therapeutic Activity of a Peptide Anticancer Vaccine. Clinical Cancer Research, 2019, 25, 698-709. | 3.2 | 32 |
| 531 | The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood, 2019, 133, 550-565. | 0.6 | 57 |
| 532 | The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference. Expert Review of Vaccines, 2019, 18, 1-3. | 2.0 | 6 |
| 533 | Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health. Pharmacological Reviews, 2019, 71, 1-19. | 7.1 | 47 |
| 534 | Cancer Neoantigens. Annual Review of Immunology, 2019, 37, 173-200. | 9.5 | 384 |
| 535 | Cancer immunoediting and resistance to T cell-based immunotherapy. Nature Reviews Clinical Oncology, 2019, 16, 151-167. | 12.5 | 1,093 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 536 | Accounting for proximal variants improves neoantigen prediction. Nature Genetics, 2019, 51, 175-179. | 9.4 | 43 |
| 537 | Cancer Immunosurveillance by T Cells. International Review of Cell and Molecular Biology, 2019, 342, 149-173. | 1.6 | 45 |
| 538 | Standard operating procedure for somatic variant refinement of sequencing data with paired tumor andÂnormal samples. Genetics in Medicine, 2019, 21, 972-981. | 1.1 | 67 |
| 539 | TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class Ilow cancers. Molecular Immunology, 2019, 113, 43-49. | 1.0 | 36 |
| 540 | <i>In situ</i> vaccination: Harvesting low hanging fruit on the cancer immunotherapy tree. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2019, 11, e1524. | 3.3 | 41 |
| 541 | Biomimetic Nanotechnology toward Personalized Vaccines. Advanced Materials, 2020, 32, e1901255. | 11.1 | 200 |
| 542 | A comprehensive review and performance evaluation of bioinformatics tools for HLA class I peptide-binding prediction. Briefings in Bioinformatics, 2020, 21, 1119-1135. | 3.2 | 127 |
| 543 | Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development. Genetic Testing and Molecular Biomarkers, 2020, 24, 59-66. | 0.3 | 24 |
| 544 | Precision immunization: a new trend in human vaccination. Human Vaccines and Immunotherapeutics, 2020, 16, 513-522. | 1.4 | 8 |
| 545 | Tumour-intrinsic resistance to immune checkpoint blockade. Nature Reviews Immunology, 2020, 20, 25-39. | 10.6 | 856 |
| 546 | Targeting mRNA processing as an anticancer strategy. Nature Reviews Drug Discovery, 2020, 19, 112-129. | 21.5 | 131 |
| 547 | Advances of functional nanomaterials for cancer immunotherapeutic applications. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1574. | 3.3 | 10 |
| 548 | Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. Oncologist, 2020, 25, e147-e159. | 1.9 | 220 |
| 549 | <tt>neoepiscope</tt>improves neoepitope prediction with multivariant phasing. Bioinformatics, 2020, 36, 713-720. | 1.8 | 23 |
| 550 | Immunity, Hypoxia, and Metabolismâ€"the Mã©nage Ã Trois of Cancer: Implications for Immunotherapy. Physiological Reviews, 2020, 100, 1-102. | 13.1 | 190 |
| 551 | At the bench: Engineering the next generation of cancer vaccines. Journal of Leukocyte Biology, 2020, 108, 1435-1453. | 1.5 | 22 |
| 552 | The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. Journal of Hepatology, 2020, 72, 167-182. | 1.8 | 116 |
| 553 | Neoantigen prediction from genomic and transcriptomic data. Methods in Enzymology, 2020, 635, 267-281. | 0.4 | 6 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 554 | Surgical Considerations and Systemic Therapy of Melanoma. Surgical Clinics of North America, 2020, 100, 141-159. | 0.5 | 4 |
| 555 | Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer. OncoImmunology, 2020, 9, 1673125. | 2.1 | 40 |
| 556 | PromPDD, a web-based tool for the prediction, deciphering and design of promiscuous peptides that bind to HLA class I molecules. Journal of Immunological Methods, 2020, 476, 112685. | 0.6 | 3 |
| 557 | Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma. Pigment Cell and Melanoma Research, 2020, 33, 390-402. | 1.5 | 19 |
| 558 | Non-covalent glycosylated gold nanoparticles/peptides nanovaccine as potential cancer vaccines. Chinese Chemical Letters, 2020, 31, 1162-1164. | 4.8 | 38 |
| 559 | MASS SPECTROMETRYâ€BASED PERSONALIZED DRUG THERAPY. Mass Spectrometry Reviews, 2020, 39, 523-552. | 2.8 | 31 |
| 560 | Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy. Nanoscale, 2020, 12, 413-436. | 2.8 | 49 |
| 561 | Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigenâ€"Specific T Cells. Clinical Cancer Research, 2020, 26, 679-689. | 3.2 | 49 |
| 562 | Recent progress in supramolecular peptide assemblies as virus mimics for cancer immunotherapy. Biomaterials Science, 2020, 8, 1045-1057. | 2.6 | 20 |
| 563 | Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 896-908. | 1.8 | 124 |
| 564 | Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 450-464. | 3.2 | 62 |
| 565 | Generation of affinity ranged antigen-expressing tumor cell lines. Methods in Enzymology, 2020, 632, 503-519. | 0.4 | 0 |
| 566 | Nanoparticle cancer vaccines: Design considerations and recent advances. Asian Journal of Pharmaceutical Sciences, 2020, 15, 576-590. | 4.3 | 58 |
| 567 | Impact of Viral Etiologies on the Development of Novel Immunotherapy for Hepatocellular Carcinoma. Seminars in Liver Disease, 2020, 40, 131-142. | 1.8 | 3 |
| 568 | Improved MHC II epitope prediction â€" a step towards personalized medicine. Nature Reviews Clinical Oncology, 2020, 17, 71-72. | 12.5 | 18 |
| 569 | A supramolecular protein chaperone for vaccine delivery. Theranostics, 2020, 10, 657-670. | 4.6 | 29 |
| 570 | A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nature Biotechnology, 2020, 38, 199-209. | 9.4 | 324 |
| 571 | The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases. Melanoma Research, 2020, 30, 85-101. | 0.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------| 
| 572 | Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy. Medicinal Research Reviews, 2020, 40, 1117-1141. | 5.0 | 90 |
| 573 | Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma. OncoImmunology, 2020, 9, 1684713. | 2.1 | 12 |
| 574 | Sustained Coevolution in a Stochastic Model of Cancer–Immune Interaction. Cancer Research, 2020, 80, 811-819. | 0.4 | 11 |
| 575 | POTN: A Human Leukocyte Antigen-A2 Immunogenic Peptides Screening Model and Its Applications in Tumor Antigens Prediction. Frontiers in Immunology, 2020, 11, 02193. | 2.2 | 3 |
| 576 | Human leukocyte antigen (HLA) and cancer immunotherapy: HLA-dependent and -independent adoptive immunotherapies. Annals of Blood, 0, 5, 14-14. | 0.4 | 13 |
| 577 | Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design. Cancers, 2020, 12, 2908. | 1.7 | 8 |
| 578 | The effects of p53 gene inactivation on mutant proteome expression in a human melanoma cell model. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129722. | 1.1 | 4 |
| 579 | Cancer neoantigen: Boosting immunotherapy. Biomedicine and Pharmacotherapy, 2020, 131, 110640. | 2.5 | 37 |
| 580 | Challenges and Opportunities for Pancreatic Cancer Immunotherapy. Cancer Cell, 2020, 38, 788-802. | 7.7 | 273 |
| 581 | Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth. Translational Oncology, 2020, 13, 100856. | 1.7 | 9 |
| 582 | Therapy of Primary Liver Cancer. Innovation(China), 2020, 1, 100032. | 5.2 | 46 |
| 583 | Adaptable antigen matrix platforms for peptide vaccination strategies and T cell-mediated anti-tumor immunity. Biomaterials, 2020, 262, 120342. | 5.7 | 7 |
| 584 | Recombination Monophosphoryl Lipid A-Derived Vacosome for the Development of Preventive Cancer Vaccines. ACS Applied Materials &amp; Interfaces, 2020, 12, 44554-44562. | 4.0 | 17 |
| 585 | Clusterization in acute myeloid leukemia based on prognostic alternative splicing signature to reveal the clinical characteristics in the bone marrow microenvironment. Cell and Bioscience, 2020, 10, 118. | 2.1 | 9 |
| 586 | Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features. Molecules, 2020, 25, 4641. | 1.7 | 7 |
| 587 | Detecting Tumor Antigen-Specific T Cells via Interaction-Dependent Fucosyl-Biotinylation. Cell, 2020, 183, 1117-1133.e19. | 13.5 | 66 |
| 588 | Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer. Chinese Medical Journal, 2020, 133, 2444-2455. | 0.9 | 7 |
| 590 | A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 2020, 183, 347-362.e24. | 13.5 | 349 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 591 | Can Personalized Neoantigens Raise the T Cell Bar?. Cell, 2020, 183, 301-302. | 13.5 | 4 |
| 592 | Clinical Grade Production of Wilms'™ Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation. Frontiers in Immunology, 2020, 11, 559152. | 2.2 | 9 |
| 593 | Main Strategies for the Identification of Neoantigens. Cancers, 2020, 12, 2879. | 1.7 | 32 |
| 594 | Lymph-directed immunotherapy '€" Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer. Advanced Drug Delivery Reviews, 2020, 160, 115-135. | 6.6 | 18 |
| 595 | The Resistance Mechanisms of Lung Cancer Immunotherapy. Frontiers in Oncology, 2020, 10, 568059. | 1.3 | 47 |
| 596 | Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Cell, 2020, 183, 818-834.e13. | 13.5 | 287 |
| 597 | Pilot Acute Safety Evaluation of Innocell„¢ Cancer Immunotherapy in Canine Subjects. Journal of Immunology Research, 2020, 2020, 1-8. | 0.9 | 4 |
| 599 | Promotion of CTL epitope presentation by a nanoparticle with environment-responsive stability and phagolysosomal escape capacity. Journal of Controlled Release, 2020, 328, 653-664. | 4.8 | 2 |
| 600 | Engineered T cells directed at tumors with defined allelic loss. Molecular Immunology, 2020, 128, 298-310. | 1.0 | 31 |
| 601 | A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability. Cancer Research, 2020, 80, 3972-3982. | 0.4 | 51 |
| 602 | Co-assembled Supramolecular Nanofibers With Tunable Surface Properties for Efficient Vaccine Delivery. Frontiers in Chemistry, 2020, 8, 500. | 1.8 | 4 |
| 603 | Immunoscore Guided Cold Tumors to Acquire "œTemperature"•Through Integrating Physicochemical and Biological Methods. BIO Integration, 2020, 1, . | 0.9 | 13 |
| 604 | Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites. Immunological Investigations, 2021, 50, 562-579. | 1.0 | 29 |
| 605 | T cell receptor therapy against melanoma'€"Immunotherapy for the future?. Scandinavian Journal of Immunology, 2020, 92, e12927. | 1.3 | 8 |
| 606 | MHCAttnNet: predicting MHC-peptide bindings for MHC alleles classes I and II using an attention-based deep neural model. Bioinformatics, 2020, 36, i399-i406. | 1.8 | 28 |
| 607 | Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. Journal of Immunology Research, 2020, 2020, 1-12. | 0.9 | 127 |
| 608 | CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages. Blood Advances, 2020, 4, 2595-2605. | 2.5 | 17 |
| 609 | Impact of age'€‚cancer'€‚and treatment'€‚driven inflammation on T cell function and immunotherapy. Journal of Leukocyte Biology, 2020, 108, 953-965. | 1.5 | 15 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 610 | Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy. Pharmaceutics, 2020, 12, 663. | 2.0 | 24 |
| 611 | Predicting Cross-Reactivity and Antigen Specificity of T Cell Receptors. Frontiers in Immunology, 2020, 11, 565096. | 2.2 | 45 |
| 612 | A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses. Npj Vaccines, 2020, 5, 106. | 2.9 | 30 |
| 613 | Inflammasomes within Hyperactive Murine Dendritic Cells Stimulate Long-Lived T Cell-Mediated Anti-tumor Immunity. Cell Reports, 2020, 33, 108381. | 2.9 | 86 |
| 614 | TruNeo: an integrated pipeline improves personalized true tumor neoantigen identification. BMC Bioinformatics, 2020, 21, 532. | 1.2 | 15 |
| 615 | Personalized deep learning of individual immunopeptidomes to identify neoantigens for cancer vaccines. Nature Machine Intelligence, 2020, 2, 764-771. | 8.3 | 22 |
| 616 | Research on road traffic situation awareness system based on image big data. Journal of Physics: Conference Series, 2020, 1650, 032170. | 0.3 | 2 |
| 617 | Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial. , 2020, 8, e001157. | | 28 |
| 618 | Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors. Cell, 2020, 183, 1634-1649.e17. | 13.5 | 103 |
| 619 | Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation. Frontiers in Immunology, 2020, 11, 576603. | 2.2 | 5 |
| 620 | DC-Based Vaccines for Cancer Immunotherapy. Vaccines, 2020, 8, 706. | 2.1 | 69 |
| 621 | New viral vectors for infectious diseases and cancer. Seminars in Immunology, 2020, 50, 101430. | 2.7 | 55 |
| 622 | A Roadmap Toward the Definition of Actionable Tumor-Specific Antigens. Frontiers in Immunology, 2020, 11, 583287. | 2.2 | 22 |
| 623 | Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved. Cancer Immunology Research, 2020, 8, 1465-1469. | 1.6 | 20 |
| 624 | RNA sequencing: new technologies and applications in cancer research. Journal of Hematology and Oncology, 2020, 13, 166. | 6.9 | 229 |
| 625 | SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705. | | 20 |
| 626 | Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting Î±CD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells. Frontiers in Immunology, 2020, 11, 602802. | 2.2 | 7 |
| 627 | Opportunities for Antigen Discovery in Metastatic Breast Cancer. Frontiers in Immunology, 2020, 11, 570049. | 2.2 | 1 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 628 | Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse. OncoImmunology, 2020, 9, 1841392. | 2.1 | 8 |
| 629 | Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. Immunity, 2020, 53, 564-580.e9. | 6.6 | 27 |
| 630 | Antitumour dendritic cell vaccination in a priming and boosting approach. Nature Reviews Drug Discovery, 2020, 19, 635-652. | 21.5 | 148 |
| 631 | The co-stimulation of anti-CD28 and IL-2 enhances the sensitivity of ELISPOT assays for detection of neoantigen-specific T cells in PBMC. Journal of Immunological Methods, 2020, 484-485, 112831. | 0.6 | 4 |
| 632 | A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nature Medicine, 2020, 26, 1468-1479. | 15.2 | 87 |
| 633 | Discovery through clinical sequencing in oncology. Nature Cancer, 2020, 1, 774-783. | 5.7 | 29 |
| 634 | The Ways of Isolating Neoantigen-Specific T Cells. Frontiers in Oncology, 2020, 10, 1347. | 1.3 | 19 |
| 635 | Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. Frontiers in Cell and Developmental Biology, 2020, 8, 672. | 1.8 | 205 |
| 636 | Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines. ACS Nano, 2020, 14, 9904-9916. | 7.3 | 97 |
| 637 | Progress in Neoantigen Targeted Cancer Immunotherapies. Frontiers in Cell and Developmental Biology, 2020, 8, 728. | 1.8 | 28 |
| 638 | Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nature Communications, 2020, 11, 3800. | 5.8 | 61 |
| 639 | Small Molecule Enhancers of Endosome-to-Cytosol Import Augment Anti-tumor Immunity. Cell Reports, 2020, 32, 107905. | 2.9 | 40 |
| 640 | Cell and tissue engineering in lymph nodes for cancer immunotherapy. Advanced Drug Delivery Reviews, 2020, 161-162, 42-62. | 6.6 | 43 |
| 641 | Engineering CD4+ T Cells to Enhance Cancer Immunity. Cells, 2020, 9, 1721. | 1.8 | 6 |
| 642 | Biotinylated Streptavidin Surface Coating Improves the Efficacy of a PLGA Microparticle-Based Cancer Vaccine. Bioconjugate Chemistry, 2020, 31, 2147-2157. | 1.8 | 11 |
| 643 | Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence. Advanced Science, 2020, 7, 2001447. | 5.6 | 30 |
| 644 | Structural dissimilarity from self drives neoepitope escape from immune tolerance. Nature Chemical Biology, 2020, 16, 1269-1276. | 3.9 | 53 |
| 645 | Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses. Frontiers in Immunology, 2020, 11, 584680. | 2.2 | 8 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 647 | Proton-driven transformable nanovaccine for cancer immunotherapy. Nature Nanotechnology, 2020, 15, 1053-1064. | 15.6 | 194 |
| 648 | Deciphering the Structural Enigma of HLA Class-II Binding Peptides for Enhanced Immunoinformatics-based Prediction of Vaccine Epitopes. Journal of Proteome Research, 2020, 19, 4655-4669. | 1.8 | 4 |
| 649 | The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study. Frontiers in Immunology, 2020, 11, 524968. | 2.2 | 7 |
| 650 | Selecting Target Antigens for Cancer Vaccine Development. Vaccines, 2020, 8, 615. | 2.1 | 59 |
| 651 | Mutation position is an important determinant for predicting cancer neoantigens. Journal of Experimental Medicine, 2020, 217, . | 4.2 | 73 |
| 652 | Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review. International Journal of Molecular Sciences, 2020, 21, 6176. | 1.8 | 19 |
| 653 | Tuberculosisâ€"Cancer Parallels in Immune Response Regulation. International Journal of Molecular Sciences, 2020, 21, 6136. | 1.8 | 9 |
| 654 | Combining Three-Dimensional Modeling with Artificial Intelligence to Increase Specificity and Precision in Peptideâ€"MHC Binding Predictions. Journal of Immunology, 2020, 205, 1962-1977. | 0.4 | 7 |
| 655 | Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors. Cancer Cell, 2020, 38, 454-472. | 7.7 | 190 |
| 656 | Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell, 2020, 38, 489-499.e3. | 7.7 | 216 |
| 657 | Oncolytic Immunotherapy: Canâ€™t Start a Fire Without a Spark. Cytokine and Growth Factor Reviews, 2020, 56, 94-101. | 3.2 | 9 |
| 658 | Innovative approaches to immunotherapy in breast cancer. Journal of Thoracic Disease, 2020, 12, 4536-4540. | 0.6 | 4 |
| 659 | Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology. Cells, 2020, 9, 2102. | 1.8 | 56 |
| 660 | HNSCC: Tumour Antigens and Their Targeting by Immunotherapy. Cells, 2020, 9, 2103. | 1.8 | 48 |
| 661 | Synthetic Particles for Cancer Vaccines: Connecting the Inherent Supply Chain. Accounts of Chemical Research, 2020, 53, 2068-2080. | 7.6 | 15 |
| 662 | Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma. Cancer Immunology Research, 2020, 8, 1322-1334. | 1.6 | 45 |
| 663 | A Systematic, Unbiased Mapping of CD8+ and CD4+ T Cell Epitopes in Yellow Fever Vaccinees. Frontiers in Immunology, 2020, 11, 1836. | 2.2 | 13 |
| 664 | Personalized Immuno-Oncology. Medical Principles and Practice, 2021, 30, 1-16. | 1.1 | 25 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 665 | Therapeutic vaccines for aggressive B-cell lymphoma. Leukemia and Lymphoma, 2020, 61, 3038-3051. | 0.6 | 6 |
| 666 | Antigen processing and presentation in cancer immunotherapy. , 2020, 8, e001111. | | 66 |
| 667 | Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. Lancet Oncology, The, 2020, 21, e419-e430. | 5.1 | 128 |
| 668 | Improving human cancer therapy through the evaluation of pet dogs. Nature Reviews Cancer, 2020, 20, 727-742. | 12.8 | 102 |
| 669 | The Origin and Immune Recognition of Tumor-Specific Antigens. Cancers, 2020, 12, 2607. | 1.7 | 30 |
| 670 | Breaking Bottlenecks for the TCR Therapy of Cancer. Cells, 2020, 9, 2095. | 1.8 | 35 |
| 671 | Neoantigen-specific CD4$^+$ T-cell response is critical for the therapeutic efficacy of cryo-thermal therapy. , 2020, 8, e000421. | | 23 |
| 672 | TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. Frontiers in Immunology, 2020, 11, 1689. | 2.2 | 63 |
| 673 | Efficient Lymph Node-Targeted Delivery of Personalized Cancer Vaccines with Reactive Oxygen Species-Inducing Reduced Graphene Oxide Nanosheets. ACS Nano, 2020, 14, 13268-13278. | 7.3 | 69 |
| 674 | Enhancing mucosal immunity by transient microbiota depletion. Nature Communications, 2020, 11, 4475. | 5.8 | 12 |
| 675 | Chemical Strategies to Boost Cancer Vaccines. Chemical Reviews, 2020, 120, 11420-11478. | 23.0 | 95 |
| 676 | Peptide vaccine with glucopyranosyl lipid A–stable oil-in-water emulsion for patients with resected melanoma. Immunotherapy, 2020, 12, 983-995. | 1.0 | 6 |
| 677 | The Application of Single-Cell RNA Sequencing in Vaccinology. Journal of Immunology Research, 2020, 2020, 1-19. | 0.9 | 30 |
| 678 | Current Trends in Cancer Immunotherapy. Biomedicines, 2020, 8, 621. | 1.4 | 34 |
| 679 | Robust Production of Merkel Cell Polyomavirus Oncogene Specific T Cells From Healthy Donors for Adoptive Transfer. Frontiers in Immunology, 2020, 11, 592721. | 2.2 | 8 |
| 680 | Neo-Antigen mRNA Vaccines. Vaccines, 2020, 8, 776. | 2.1 | 49 |
| 681 | Therapeutic strategies to remodel immunologically cold tumors. Clinical and Translational Immunology, 2020, 9, e1226. | 1.7 | 23 |
| 682 | Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. Respiration, 2020, 99, 903-929. | 1.2 | 18 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------| 
| 683 | Unveiling the Hidden Treasury: CIITA-Driven MHC Class II Expression in Tumor Cells to Dig up the Relevant Repertoire of Tumor Antigens for Optimal Stimulation of Tumor Specific CD4+ T Helper Cells. Cancers, 2020, 12, 3181. | 1.7 | 9 |
| 684 | Moderne Aspekte der Immuntherapie mit Checkpoint-Inhibitoren bei Melanom. Karger Kompass Dermatologie, 2020, 8, 92-101. | 0.0 | 0 |
| 685 | Immunomodulatory Effects of Radiotherapy. International Journal of Molecular Sciences, 2020, 21, 8151. | 1.8 | 34 |
| 686 | $Pam_3CSK_4$-CDG$^{SF}$ Augments Antitumor Immunotherapy by Synergistically Activating TLR1/2 and STING. Bioconjugate Chemistry, 2020, 31, 2499-2503. | 1.8 | 14 |
| 687 | The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy. Molecular Cancer, 2020, 19, 81. | 7.9 | 82 |
| 688 | Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer. Journal of Controlled Release, 2020, 323, 431-441. | 4.8 | 39 |
| 689 | Diverse Neoantigens and the Development of Cancer Therapies. Seminars in Radiation Oncology, 2020, 30, 113-128. | 1.0 | 15 |
| 690 | Heterogeneity of neoantigen landscape between primary lesions and their matched metastases in lung cancer. Translational Lung Cancer Research, 2020, 9, 246-256. | 1.3 | 17 |
| 691 | Immunotherapy for esophageal cancer: a 2019 update. Immunotherapy, 2020, 12, 203-218. | 1.0 | 30 |
| 692 | Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions. Frontiers in Immunology, 2020, 11, 777. | 2.2 | 2 |
| 693 | T Cell Receptor Engineered Lymphocytes for Cancer Therapy. Current Protocols in Immunology, 2020, 129, e97. | 3.6 | 7 |
| 694 | A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nature Reviews Immunology, 2020, 20, 651-668. | 10.6 | 2,160 |
| 695 | Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy. Pharmacogenomics, 2020, 21, 637-645. | 0.6 | 26 |
| 696 | MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma. , 2020, 8, e000262. | | 44 |
| 697 | Opportunities for Conventional and In Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review. Cancers, 2020, 12, 1121. | 1.7 | 31 |
| 698 | Pharmacokinetic tuning of protein–antigen fusions enhances the immunogenicity of T-cell vaccines. Nature Biomedical Engineering, 2020, 4, 636-648. | 11.6 | 44 |
| 699 | Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives. Theranostics, 2020, 10, 6011-6023. | 4.6 | 56 |
| 700 | An Immunological Glance on Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2020, 21, 3345. | 1.8 | 14 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 701 | An ultra-sensitive T-cell receptor detection method for TCR-Seq and RNA-Seq data. Bioinformatics, 2020, 36, 4255-4262. | 1.8 | 13 |
| 702 | A novel cancer immunotherapy utilizing autologous tumour tissue. Vox Sanguinis, 2020, 115, 525-535. | 0.7 | 5 |
| 703 | Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. , 2020, 8, e000404. | | 29 |
| 704 | Lipid-encapsulated oral therapeutic peptide vaccines reduce tumour growth in an orthotopic mouse model of colorectal cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 183-192. | 2.0 | 17 |
| 705 | Nanoengineered targeting strategy for cancer immunotherapy. Acta Pharmacologica Sinica, 2020, 41, 902-910. | 2.8 | 23 |
| 706 | Comparative study of Î±-helical and Î²-sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopes. Biomaterials Science, 2020, 8, 3522-3535. | 2.6 | 35 |
| 707 | Immune Therapy Opportunities in Ovarian Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e228-e240. | 1.8 | 25 |
| 708 | Promising Immuno-Oncology Options for the Future: Cellular Therapies and Personalized Cancer Vaccines. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e253-e258. | 1.8 | 8 |
| 709 | A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 4511-4520. | 3.2 | 56 |
| 710 | Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer. Nano Letters, 2020, 20, 4393-4402. | 4.5 | 93 |
| 711 | The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Research, 2020, 30, 507-519. | 5.7 | 480 |
| 712 | Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse. Molecular and Cellular Proteomics, 2020, 19, 1360-1374. | 2.5 | 12 |
| 713 | Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma. , 2020, 8, e000375. | | 14 |
| 714 | Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model. BMC Immunology, 2020, 21, 25. | 0.9 | 9 |
| 715 | A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future. Current Oncology, 2020, 27, 87-97. | 0.9 | 554 |
| 716 | Killing the â€œBADâ€: Challenges for immunotherapy in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188384. | 3.3 | 14 |
| 717 | Co-assembled and self-delivered epitope/CpG nanocomplex vaccine augments peptide immunogenicity for cancer immunotherapy. Chemical Engineering Journal, 2020, 399, 125854. | 6.6 | 29 |
| 718 | Genetically modified immune cells targeting tumor antigens. , 2020, 214, 107603. | | 17 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 719 | Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nature Reviews Clinical Oncology, 2020, 17, 595-610. | 12.5 | 124 |
| 720 | Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma. Nature Cancer, 2020, 1, 635-652. | 5.7 | 26 |
| 721 | Integrating context of tumor biology and vaccine design to shape multidimensional immunotherapies. Future Drug Discovery, 2020, 2, FDD25. | 0.8 | 1 |
| 722 | Robust Antiâ€Tumor T Cell Response with Efficient Intratumoral Infiltration by Nanodisc Cancer Immunotherapy. Advanced Therapeutics, 2020, 3, 2000094. | 1.6 | 11 |
| 723 | IConMHC: a deep learning convolutional neural network model to predict peptide and MHC-I binding affinity. Immunogenetics, 2020, 72, 295-304. | 1.2 | 4 |
| 724 | Mechanisms of immune escape in the cancer immune cycle. International Immunopharmacology, 2020, 86, 106700. | 1.7 | 85 |
| 725 | Hallmarks of Splicing Defects in Cancer: Clinical Applications in the Era of Personalized Medicine. Cancers, 2020, 12, 1381. | 1.7 | 14 |
| 726 | Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell, 2020, 181, 1612-1625.e13. | 13.5 | 436 |
| 728 | Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles. Nature Communications, 2020, 11, 2841. | 5.8 | 16 |
| 729 | Injectable Therapies for Regional Melanoma. Surgical Oncology Clinics of North America, 2020, 29, 433-444. | 0.6 | 5 |
| 730 | Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. Journal of Leukocyte Biology, 2020, 108, 1455-1489. | 1.5 | 22 |
| 731 | Identification of the Cryptic HLA-I Immunopeptidome. Cancer Immunology Research, 2020, 8, 1018-1026. | 1.6 | 80 |
| 732 | Dendritic Cells and Their Role in Immunotherapy. Frontiers in Immunology, 2020, 11, 924. | 2.2 | 253 |
| 733 | Trial watch: TLR3 agonists in cancer therapy. OncoImmunology, 2020, 9, 1771143. | 2.1 | 116 |
| 734 | An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nature Communications, 2020, 11, 1395. | 5.8 | 124 |
| 735 | Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells. Frontiers in Immunology, 2020, 11, 340. | 2.2 | 27 |
| 736 | Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Frontiers in Immunology, 2020, 11, 369. | 2.2 | 291 |
| 737 | Adoptive Cell Therapyâ€"Harnessing Antigen-Specific T Cells to Target Solid Tumours. Cancers, 2020, 12, 683. | 1.7 | 34 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 738 | Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nature Communications, 2020, 11, 1293. | 5.8 | 196 |
| 739 | Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine. Neuro-Oncology, 2020, 22, 1276-1288. | 0.6 | 51 |
| 740 | Peptide-Based Vaccination Therapy for Rheumatic Diseases. Journal of Immunology Research, 2020, 2020, 1-15. | 0.9 | 6 |
| 741 | The top 100 most cited articles in medical artificial intelligence: a bibliometric analysis. Journal of Medical Artificial Intelligence, 2020, 3, 3-3. | 1.1 | 5 |
| 742 | Preâ€existing heterologous Tâ€cell immunity and neoantigen immunogenicity. Clinical and Translational Immunology, 2020, 9, e01111. | 1.7 | 26 |
| 743 | Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial. British Journal of Cancer, 2020, 122, 1461-1466. | 2.9 | 24 |
| 744 | Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 8022-8031. | 3.3 | 84 |
| 745 | Recent Advances in Immunotherapy for Hepatocellular Carcinoma. Cancers, 2020, 12, 775. | 1.7 | 70 |
| 746 | ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection. BMC Medical Genomics, 2020, 13, 52. | 0.7 | 14 |
| 747 | Streamlined selection of cancer antigens for vaccine development through integrative multi-omics and high-content cell imaging. Scientific Reports, 2020, 10, 5885. | 1.6 | 5 |
| 748 | Personalized neoantigen vaccines: a glimmer of hope for glioblastoma. Expert Review of Vaccines, 2020, 19, 407-417. | 2.0 | 8 |
| 749 | Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Science Translational Medicine, 2020, 12, . | 5.8 | 108 |
| 750 | Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy. Expert Opinion on Biological Therapy, 2020, 20, 937-946. | 1.4 | 19 |
| 751 | Harnessing neoantigen specific CD4 T cells for cancer immunotherapy. Journal of Leukocyte Biology, 2020, 107, 625-633. | 1.5 | 40 |
| 752 | An altered HLA-A0201-restricted MUC1 epitope that could induce more efficient anti-tumor effects against gastric cancer. Experimental Cell Research, 2020, 390, 111953. | 1.2 | 5 |
| 753 | T Cell Dysfunction and Exhaustion in Cancer. Frontiers in Cell and Developmental Biology, 2020, 8, 17. | 1.8 | 226 |
| 754 | Computational Prediction and Validation of Tumor-Associated Neoantigens. Frontiers in Immunology, 2020, 11, 27. | 2.2 | 86 |
| 755 | Neoantigens in Hematologic Malignancies. Frontiers in Immunology, 2020, 11, 121. | 2.2 | 26 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 756 | Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. Frontiers in Immunology, 2020, 11, 159. | 2.2 | 73 |
| 757 | Tumor-Specific T Cell Activation in Malignant Brain Tumors. Frontiers in Immunology, 2020, 11, 205. | 2.2 | 36 |
| 758 | Melanoma-Secreted Lysosomes Trigger Monocyte-Derived Dendritic Cell Apoptosis and Limit Cancer Immunotherapy. Cancer Research, 2020, 80, 1942-1956. | 0.4 | 25 |
| 759 | Mesenchymal Stem Cells Beyond Regenerative Medicine. Frontiers in Cell and Developmental Biology, 2020, 8, 72. | 1.8 | 60 |
| 760 | Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal. Frontiers in Immunology, 2020, 11, 1215. | 2.2 | 32 |
| 761 | DeepAntigen: a novel method for neoantigen prioritization via 3D genome and deep sparse learning. Bioinformatics, 2020, 36, 4894-4901. | 1.8 | 17 |
| 762 | Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group. Annals of Oncology, 2020, 31, 978-990. | 0.6 | 87 |
| 763 | An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia. British Journal of Cancer, 2020, 123, 919-931. | 2.9 | 0 |
| 764 | Exploiting Cancer's Tactics to Make Cancer a Manageable Chronic Disease. Cancers, 2020, 12, 1649. | 1.7 | 3 |
| 765 | Endogenous retroviral proteins provide an immunodominant but not requisite antigen in a murine immunotherapy tumor model. OncoImmunology, 2020, 9, 1758602. | 2.1 | 12 |
| 766 | Generation of multiepitope cancer vaccines based on large combinatorial libraries of survivin-derived mutant epitopes. Immunology, 2020, 161, 123-138. | 2.0 | 15 |
| 767 | Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. Nanomaterials, 2020, 10, 1274. | 1.9 | 26 |
| 768 | Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. Cancers, 2020, 12, 1761. | 1.7 | 8 |
| 769 | INeo-Epp: A Novel T-Cell HLA Class-I Immunogenicity or Neoantigenic Epitope Prediction Method Based on Sequence-Related Amino Acid Features. BioMed Research International, 2020, 2020, 1-12. | 0.9 | 17 |
| 770 | Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process. Cancers, 2020, 12, 1660. | 1.7 | 29 |
| 772 | Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Cancer Letters, 2020, 490, 12-19. | 3.2 | 10 |
| 773 | Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro-Oncology, 2020, 22, 1425-1438. | 0.6 | 37 |
| 774 | Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nature Reviews Clinical Oncology, 2020, 17, 251-266. | 12.5 | 408 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 776 | Immunotherapy for glioma: Current management and future application. Cancer Letters, 2020, 476, 1-12. | 3.2 | 351 |
| 777 | Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, , . | 0.8 | 3 |
| 778 | Emerging Roles of ALK in Immunity and Insights for Immunotherapy. Cancers, 2020, 12, 426. | 1.7 | 12 |
| 779 | Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers, 2020, 12, 482. | 1.7 | 112 |
| 780 | Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens. Communications Biology, 2020, 3, 85. | 2.0 | 36 |
| 781 | dbPepNeo: a manually curated database for human tumor neoantigen peptides. Database: the Journal of Biological Databases and Curation, 2020, 2020, . | 1.4 | 43 |
| 782 | Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response. Nature Communications, 2020, 11, 1110. | 5.8 | 133 |
| 783 | Nanotechnology approaches in the current therapy of skin cancer. Advanced Drug Delivery Reviews, 2020, 153, 109-136. | 6.6 | 65 |
| 784 | Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma. Blood Cancer Journal, 2020, 10, 24. | 2.8 | 15 |
| 785 | Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH. Open Biology, 2020, 10, 190235. | 1.5 | 11 |
| 786 | T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies. Frontiers in Immunology, 2020, 11, 276. | 2.2 | 38 |
| 787 | Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Cancer Immunology, Immunotherapy, 2020, 69, 1375-1387. | 2.0 | 75 |
| 788 | Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. Science Immunology, 2020, 5, . | 5.6 | 39 |
| 789 | PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma. Leukemia, 2020, 34, 2405-2417. | 3.3 | 31 |
| 790 | Mechanisms of Resistance to PD-1 Checkpoint Blockade. Drugs, 2020, 80, 459-465. | 4.9 | 6 |
| 791 | PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses. Cancer Letters, 2020, 476, 170-182. | 3.2 | 15 |
| 792 | Multifunctional Protein Conjugates with Built-in Adjuvant (Adjuvant-Protein-Antigen) as Cancer Vaccines Boost Potent Immune Responses. IScience, 2020, 23, 100935. | 1.9 | 25 |
| 793 | Normalization Cancer Immunotherapy for Melanoma. Journal of Investigative Dermatology, 2020, 140, 1134-1142. | 0.3 | 13 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 794 | Nanotherapeutics for Immuno-Oncology: A Crossroad for New Paradigms. Trends in Cancer, 2020, 6, 288-298. | 3.8 | 27 |
| 795 | Development of tumour peptide vaccines: From universalization to personalization. Scandinavian Journal of Immunology, 2020, 91, e12875. | 1.3 | 19 |
| 796 | Potential New Therapeutic Approaches for Renal Cell Carcinoma. Seminars in Nephrology, 2020, 40, 86-97. | 0.6 | 30 |
| 797 | MAPDP: A Cloud-Based Computational Platform for Immunopeptidomics Analyses. Journal of Proteome Research, 2020, 19, 1873-1881. | 1.8 | 11 |
| 798 | HLA class I restricted epitopes prediction of common tumor antigens in white and East Asian populations: Implication on antigen selection for cancer vaccine design. PLoS ONE, 2020, 15, e0229327. | 1.1 | 4 |
| 799 | Mass Spectrometry-Based Identification of MHC-Associated Peptides. Cancers, 2020, 12, 535. | 1.7 | 29 |
| 800 | Comprehensive mutanome analysis of Lewis lung cancer reveals immunogenic neoantigens for therapeutic vaccines. Biochemical and Biophysical Research Communications, 2020, 525, 607-613. | 1.0 | 4 |
| 801 | IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Letters, 2020, 477, 19-30. | 3.2 | 47 |
| 802 | Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nature Biotechnology, 2020, 38, 420-425. | 9.4 | 48 |
| 803 | Cholesterol-modified DP7 enhances the effect of individualized cancer immunotherapy based on neoantigens. Biomaterials, 2020, 241, 119852. | 5.7 | 32 |
| 804 | Peptideâ€“TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. Nature Biotechnology, 2020, 38, 320-332. | 9.4 | 210 |
| 805 | Intratumoral heterogeneity and clonal evolution in liver cancer. Nature Communications, 2020, 11, 291. | 5.8 | 230 |
| 806 | Directing Traffic: How to Effectively Drive T Cells into Tumors. Cancer Discovery, 2020, 10, 185-197. | 7.7 | 68 |
| 807 | Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine. Vaccines, 2020, 8, 25. | 2.1 | 13 |
| 808 | Prediction of cancer neoepitopes needs new rules. Seminars in Immunology, 2020, 47, 101387. | 2.7 | 19 |
| 809 | Anti-tumor immune response varies among individuals: A gene expression profiling of mouse melanoma. International Immunopharmacology, 2020, 80, 106211. | 1.7 | 1 |
| 810 | Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nature Communications, 2020, 11, 524. | 5.8 | 29 |
| 811 | T cell receptors, mechanosensors, catch bonds and immunotherapy. Progress in Biophysics and Molecular Biology, 2020, 153, 23-27. | 1.4 | 13 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 812 | Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy. Scientific Reports, 2020, 10, 723. | 1.6 | 21 |
| 813 | Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Scientific Reports, 2020, 10, 643. | 1.6 | 124 |
| 814 | Tumor Immunology and Tumor Evolution: Intertwined Histories. Immunity, 2020, 52, 55-81. | 6.6 | 357 |
| 815 | Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. OncoImmunology, 2020, 9, 1703449. | 2.1 | 156 |
| 816 | Redox-Responsive Polycondensate Neoepitope for Enhanced Personalized Cancer Vaccine. ACS Central Science, 2020, 6, 404-412. | 5.3 | 45 |
| 817 | Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cellsâ€"An Update. Pharmaceutics, 2020, 12, 92. | 2.0 | 46 |
| 818 | Tumor immune microenvironment in head and neck cancers. Molecular Carcinogenesis, 2020, 59, 766-774. | 1.3 | 90 |
| 819 | Engineering T cells for immunotherapy of primary human hepatocellular carcinoma. Journal of Genetics and Genomics, 2020, 47, 1-15. | 1.7 | 15 |
| 820 | Progress and challenges of personalized neoantigens in the clinical treatment of tumors. Medicine in Drug Discovery, 2020, 6, 100030. | 2.3 | 3 |
| 821 | Immunogenic clearance-mediated cancer vaccination. , 2020, , 549-568. | | 1 |
| 822 | m6A-binding proteins: the emerging crucial performers in epigenetics. Journal of Hematology and Oncology, 2020, 13, 35. | 6.9 | 174 |
| 823 | Increasing Complexity to Simplify Clinical Care: High Resolution Mass Spectrometry as an Enabler of AI Guided Clinical and Therapeutic Monitoring. Advanced Therapeutics, 2020, 3, 1900163. | 1.6 | 1 |
| 824 | Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treatment Reviews, 2020, 86, 102019. | 3.4 | 327 |
| 825 | A tumor-specific neoepitope expressed in homologous/self or heterologous/viral antigens induced comparable effector CD8+ T-cell responses by DNA vaccination. Vaccine, 2020, 38, 3711-3719. | 1.7 | 9 |
| 826 | Cancer neoantigen prioritization through sensitive and reliable proteogenomics analysis. Nature Communications, 2020, 11, 1759. | 5.8 | 97 |
| 827 | Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies. Molecular and Cellular Proteomics, 2020, 19, 432-443. | 2.5 | 31 |
| 828 | A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Science Advances, 2020, 6, eaaw6071. | 4.7 | 152 |
| 829 | Talkinâ€™ Toxins: From Coleyâ€™s to Modern Cancer Immunotherapy. Toxins, 2020, 12, 241. | 1.5 | 47 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 830 | Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer. Vaccines, 2020, 8, 182. | 2.1 | 14 |
| 831 | DNT Cell-based Immunotherapy: Progress and Applications. Journal of Cancer, 2020, 11, 3717-3724. | 1.2 | 23 |
| 832 | The premise of personalized immunotherapy for cancer dormancy. Oncogene, 2020, 39, 4323-4330. | 2.6 | 17 |
| 833 | Polyomavirusâ€driven Merkel cell carcinoma: Prospects for therapeutic vaccine development. Molecular Carcinogenesis, 2020, 59, 807-821. | 1.3 | 32 |
| 834 | Chimeric antigen receptorâ€modified Tâ€cell therapy for plateletâ€derived growth factor receptor Î±â€positive rhabdomyosarcoma. Cancer, 2020, 126, 2093-2100. | 2.0 | 13 |
| 835 | Roles and mechanisms of alternative splicing in cancer â€" implications for care. Nature Reviews Clinical Oncology, 2020, 17, 457-474. | 12.5 | 400 |
| 836 | Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform. Cancer Immunology Research, 2020, 8, 672-684. | 1.6 | 25 |
| 837 | Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. Journal of Hematology and Oncology, 2020, 13, 29. | 6.9 | 146 |
| 838 | Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. Genome Medicine, 2020, 12, 32. | 3.6 | 32 |
| 839 | Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations. Frontiers in Immunology, 2020, 11, 373. | 2.2 | 27 |
| 840 | Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. International Journal of Molecular Sciences, 2020, 21, 2367. | 1.8 | 34 |
| 841 | Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?. Hepatology, 2021, 73, 414-421. | 3.6 | 37 |
| 842 | A review of glioblastoma immunotherapy. Journal of Neuro-Oncology, 2021, 151, 41-53. | 1.4 | 159 |
| 843 | Revisiting the role of CD4+ T cells in cancer immunotherapyâ€"new insights into old paradigms. Cancer Gene Therapy, 2021, 28, 5-17. | 2.2 | 444 |
| 844 | A Review of the Current State of Nanomedicines for Targeting and Treatment of Cancers: Achievements and Future Challenges. Advanced Therapeutics, 2021, 4, 2000186. | 1.6 | 7 |
| 845 | A biomimetic antitumor nanovaccine based on biocompatible calcium pyrophosphate and tumor cell membrane antigens. Asian Journal of Pharmaceutical Sciences, 2021, 16, 97-109. | 4.3 | 17 |
| 846 | Targeting Tumorâ€Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies. Hepatology, 2021, 73, 821-832. | 3.6 | 25 |
| 847 | Fundamentals of Cancer Immunology and Their Application to Cancer Vaccines. Clinical and Translational Science, 2021, 14, 120-131. | 1.5 | 3 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 848 | Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner. International Immunology, 2021, 33, 39-48. | 1.8 | 4 |
| 849 | Novel Peptide Inhibitors of Î²-Catenin Effectively Suppress the Tumorigenesis of Colorectal Cancer. International Journal of Peptide Research and Therapeutics, 2021, 27, 263-274. | 0.9 | 1 |
| 850 | Nanotechnologyâ€Based CARâ€T Strategies for Improving Efficacy and Safety of Tumor Immunotherapy. Advanced Functional Materials, 2021, 31, . | 7.8 | 13 |
| 851 | Steatohepatitis Impairs T-cellâ€"Directed Immunotherapies Against Liver Tumors in Mice. Gastroenterology, 2021, 160, 331-345.e6. | 0.6 | 46 |
| 852 | Combination therapies utilizing neoepitope-targeted vaccines. Cancer Immunology, Immunotherapy, 2021, 70, 875-885. | 2.0 | 12 |
| 853 | Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities. Molecular Therapy, 2021, 29, 555-570. | 3.7 | 130 |
| 854 | Immune Checkpoint Therapies for Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 99-109. | 0.9 | 4 |
| 855 | Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma. Biomaterials, 2021, 268, 120579. | 5.7 | 46 |
| 856 | Special Review: The future of Immunotherapy. Immunotherapy Advances, 2021, 1, . | 1.2 | 5 |
| 857 | Neoantigen prediction in human breast cancer using RNA sequencing data. Cancer Science, 2021, 112, 465-475. | 1.7 | 13 |
| 858 | Frontiers in cancer immunotherapyâ€"a symposium report. Annals of the New York Academy of Sciences, 2021, 1489, 30-47. | 1.8 | 39 |
| 859 | Efficacy of cancer vaccines in selected gynaecological breast and ovarianÂcancers: A 20-year systematic review and meta-analysis. European Journal of Cancer, 2021, 142, 63-82. | 1.3 | 19 |
| 860 | The Peptide Vaccine of the Future. Molecular and Cellular Proteomics, 2021, 20, 100022. | 2.5 | 94 |
| 861 | A New Pipeline to Predict and Confirm Tumor Neoantigens Predict Better Response to Immune Checkpoint Blockade. Molecular Cancer Research, 2021, 19, 498-506. | 1.5 | 8 |
| 862 | Selfâ€Adjuvanted Molecular Activator (SeaMac) Nanovaccines Promote Cancer Immunotherapy. Advanced Healthcare Materials, 2021, 10, e2002080. | 3.9 | 20 |
| 863 | The Changing Landscape of Therapeutic Cancer Vaccinesâ€"Novel Platforms and Neoantigen Identification. Clinical Cancer Research, 2021, 27, 689-703. | 3.2 | 113 |
| 864 | Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells. Nature Immunology, 2021, 22, 41-52. | 7.0 | 110 |
| 865 | Comparison of HLA ligand elution data and binding predictions reveals varying prediction performance for the multiple motifs recognized by HLAâ€ĐQ2.5. Immunology, 2021, 162, 235-247. | 2.0 | 6 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 866 | Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 667-677. | 2.0 | 34 |
| 867 | Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer. Expert Opinion on Drug Discovery, 2021, 16, 89-99. | 2.5 | 14 |
| 868 | CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens. Molecular and Cellular Proteomics, 2021, 20, 100032. | 2.5 | 22 |
| 869 | A DNA nanodevice-based vaccine for cancer immunotherapy. Nature Materials, 2021, 20, 421-430. | 13.3 | 320 |
| 870 | Recent developments of RNA-based vaccines in cancer immunotherapy. Expert Opinion on Biological Therapy, 2021, 21, 201-218. | 1.4 | 55 |
| 871 | Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer. Seminars in Cancer Biology, 2021, 72, 65-75. | 4.3 | 33 |
| 872 | IDENTIFICATION OF MHC PEPTIDES USING MASS SPECTROMETRY FOR NEOANTIGEN DISCOVERY AND CANCER VACCINE DEVELOPMENT. Mass Spectrometry Reviews, 2021, 40, 110-125. | 2.8 | 25 |
| 873 | Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy. Journal of Materials Chemistry B, 2021, 9, 3892-3899. | 2.9 | 18 |
| 874 | Biomedical overview of melanin. 1. Updating melanin biology and chemistry, physico-chemical properties, melanoma tumors, and photothermal therapy. Biocell, 2021, 45, 849-862. | 0.4 | 9 |
| 875 | The methods and advances of adaptive immune receptors repertoire sequencing. Theranostics, 2021, 11, 8945-8963. | 4.6 | 22 |
| 876 | Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy. OncoImmunology, 2021, 10, 1868130. | 2.1 | 17 |
| 877 | Cancer Vaccines: Antigen Selection Strategy. Vaccines, 2021, 9, 85. | 2.1 | 30 |
| 878 | Sensitive and Quantitative Detection of MHC-I Displayed Neoepitopes Using a Semiautomated Workflow and TOMAHAQ Mass Spectrometry. Molecular and Cellular Proteomics, 2021, 20, 100108. | 2.5 | 17 |
| 879 | An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth. Cancer Discovery, 2021, 11, 696-713. | 7.7 | 34 |
| 880 | Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma. Molecular and Cellular Proteomics, 2021, 20, 100136. | 2.5 | 19 |
| 881 | Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nature Reviews Clinical Oncology, 2021, 18, 215-229. | 12.5 | 486 |
| 882 | Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds. Advances in Experimental Medicine and Biology, 2021, 1295, 135-162. | 0.8 | 0 |
| 883 | Ex Vivo Study of Experimental Method Toward Future In Vivo Tissue Processing for Self-Anti-Tumoral Vaccinations. CardioVascular and Interventional Radiology, 2021, 44, 818-821. | 0.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 884 | Perspectives in immunotherapy: meeting report from the â€œImmunotherapy Bridgeâ€•(December 4thâ€"5th,) Tj ETQq0 0 0 rgBT /Over | 1.8 | 3 |
| 885 | Designing the nextâ€generation therapeutic vaccines to cure chronic hepatitis B: focus on antigen presentation, vaccine properties and effect measures. Clinical and Translational Immunology, 2021, 10, e1232. | 1.7 | 10 |
| 886 | MS-Based HLA-II Peptidomics Combined With Multiomics Will Aid the Development of Future Immunotherapies. Molecular and Cellular Proteomics, 2021, 20, 100116. | 2.5 | 13 |
| 887 | A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope. Npj Vaccines, 2021, 6, 12. | 2.9 | 8 |
| 888 | Neoantigen landscape in metastatic nasopharyngeal carcinoma. Theranostics, 2021, 11, 6427-6444. | 4.6 | 14 |
| 889 | Profiling of hepatocellular carcinoma neoantigens reveals immune microenvironment and clonal evolution related patterns. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 364-378. | 0.7 | 11 |
| 890 | Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development. Cancer Biology and Medicine, 2021, 18, 352-371. | 1.4 | 22 |
| 891 | MATHLA: a robust framework for HLA-peptide binding prediction integrating bidirectional LSTM and multiple head attention mechanism. BMC Bioinformatics, 2021, 22, 7. | 1.2 | 11 |
| 892 | Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies. Neuro-Oncology Advances, 2021, 3, vdab027. | 0.4 | 13 |
| 893 | Vaccine Therapies for Cancer: Then and Now. Targeted Oncology, 2021, 16, 121-152. | 1.7 | 90 |
| 895 | Integrating CD4 <sup>+</sup> T cell help for therapeutic cancer vaccination in a preclinical head and neck cancer model. OncoImmunology, 2021, 10, 1958589. | 2.1 | 9 |
| 896 | The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy. Cancers, 2021, 13, 134. | 1.7 | 67 |
| 897 | Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids. , 2021, , . | | 0 |
| 898 | TSNAD v2.0: A one-stop software solution for tumor-specific neoantigen detection. Computational and Structural Biotechnology Journal, 2021, 19, 4510-4516. | 1.9 | 13 |
| 899 | Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples. Molecular and Cellular Proteomics, 2021, 20, 100133. | 2.5 | 32 |
| 900 | The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets. BMB Reports, 2021, 54, 31-43. | 1.1 | 33 |
| 901 | Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report. , 2021, 9, e001406. | | 7 |
| 902 | Research advance in tumor specific antigens: a narrative review. AME Medical Journal, 0, 6, 35-35. | 0.4 | 3 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 903 | Cell therapies in ovarian cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110083. | 1.4 | 20 |
| 904 | A simple and general strategy for postsurgical personalized cancer vaccine therapy based on an injectable dynamic covalent hydrogel. Biomaterials Science, 2021, 9, 6879-6888. | 2.6 | 10 |
| 905 | Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nature Medicine, 2021, 27, 515-525. | 15.2 | 248 |
| 906 | Development of a Metastasis-Related Immune Prognostic Model of Metastatic Colorectal Cancer and Its Usefulness to Immunotherapy. Frontiers in Cell and Developmental Biology, 2020, 8, 577125. | 1.8 | 13 |
| 907 | Research Interest and Public Interest in Melanoma: A Bibliometric and Google Trends Analysis. Frontiers in Oncology, 2021, 11, 629687. | 1.3 | 15 |
| 908 | Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms. Frontiers in Oncology, 2020, 10, 584367. | 1.3 | 8 |
| 909 | Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy. Frontiers in Immunology, 2020, 11, 622509. | 2.2 | 148 |
| 910 | Neoantigenâ€based vaccines as a promising strategy in cancer immunotherapeutics. Immunomedicine, 2021, 1, e1021. | 0.7 | 1 |
| 911 | CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy. Cancers, 2021, 13, 596. | 1.7 | 24 |
| 912 | Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy. Nature Communications, 2021, 12, 951. | 5.8 | 50 |
| 913 | Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model. Pharmaceutics, 2021, 13, 257. | 2.0 | 7 |
| 914 | Immunotherapeutic advances in gastric cancer. Surgery Today, 2021, 51, 1727-1735. | 0.7 | 14 |
| 915 | mRNA vaccine for cancer immunotherapy. Molecular Cancer, 2021, 20, 41. | 7.9 | 445 |
| 916 | Dog leukocyte antigenâ€88*034:01 presents nonamer peptides from canine distemper virus hemagglutinin, large polymerase, and matrix proteins. Hla, 2021, 97, 428-434. | 0.4 | 1 |
| 918 | Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers. Frontiers in Oncology, 2021, 11, 614332. | 1.3 | 33 |
| 919 | Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting. Cell Reports Medicine, 2021, 2, 100194. | 3.3 | 77 |
| 920 | Nanodevices for cancer vaccination. Nature Materials, 2021, 20, 286-287. | 13.3 | 4 |
| 921 | Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Science Advances, 2021, 7, . | 4.7 | 157 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 922 | Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines. Pharmaceutics, 2021, 13, 206. | 2.0 | 122 |
| 923 | Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduction and Targeted Therapy, 2021, 6, 72. | 7.1 | 191 |
| 924 | Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives. Cancers, 2021, 13, 549. | 1.7 | 13 |
| 925 | Artificial intelligence in cancer research: learning at different levels of data granularity. Molecular Oncology, 2021, 15, 817-829. | 2.1 | 15 |
| 926 | Personal Neoantigen Vaccines for the Treatment of Cancer. Annual Review of Cancer Biology, 2021, 5, 259-276. | 2.3 | 13 |
| 927 | Clinical Trial of a Cancer Vaccine Targeting VEGF and KIF20A in Advanced Biliary Tract Cancer. Anticancer Research, 2021, 41, 1485-1496. | 0.5 | 8 |
| 928 | Nanobiomaterial-based vaccination immunotherapy of cancer. Biomaterials, 2021, 270, 120709. | 5.7 | 77 |
| 929 | Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review). Experimental and Therapeutic Medicine, 2021, 21, 535. | 0.8 | 6 |
| 930 | Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches. Cancers, 2021, 13, 1476. | 1.7 | 21 |
| 931 | Irradiated whole‐cell vaccine suppresses hepatocellular carcinoma growth in mice via Th9 cells. Oncology Letters, 2021, 21, 409. | 0.8 | 4 |
| 932 | Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation. Science China Life Sciences, 2021, 64, 2144-2152. | 2.3 | 6 |
| 933 | Mucin 4 mutation is associated with tumor mutation burden and promotes antitumor immunity in colon cancer patients. Aging, 2021, 13, 9043-9055. | 1.4 | 18 |
| 934 | Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-$\gamma$+ CD4+ T Cells Through Enhancing I$\kappa$B$\alpha$ Degradation and NF-$\kappa$B Activation. Frontiers in Cell and Developmental Biology, 2021, 9, 647713. | 1.8 | 4 |
| 935 | Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy. Expert Opinion on Investigational Drugs, 2021, 30, 529-541. | 1.9 | 26 |
| 936 | Cancer Vaccines, Adjuvants, and Delivery Systems. Frontiers in Immunology, 2021, 12, 627932. | 2.2 | 78 |
| 937 | Rational nanocarrier design towards clinical translation of cancer nanotherapy. Biomedical Materials (Bristol), 2021, 16, 032005. | 1.7 | 14 |
| 938 | Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nature Reviews Cancer, 2021, 21, 298-312. | 12.8 | 553 |
| 939 | Identification of bacteria-derived HLA-bound peptides in melanoma. Nature, 2021, 592, 138-143. | 13.7 | 187 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 940 | A combination of PDâ€'1/PDâ€'L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review). Molecular Medicine Reports, 2021, 23, . | 1.1 | 16 |
| 941 | Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. Cellular Oncology (Dordrecht), 2021, 44, 261-278. | 2.1 | 16 |
| 942 | Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. Frontiers in Oncology, 2021, 11, 589680. | 1.3 | 23 |
| 944 | Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer. Human Vaccines and Immunotherapeutics, 2022, 18, 1-11. | 1.4 | 14 |
| 945 | Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells. , 2021, 9, e002128. |  | 20 |
| 946 | Machine learning optimization of peptides for presentation by class II MHCs. Bioinformatics, 2021, 37, 3160-3167. | 1.8 | 8 |
| 947 | Clinical and immunological effects of mRNA vaccines in malignant diseases. Molecular Cancer, 2021, 20, 52. | 7.9 | 90 |
| 948 | Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. Journal of Clinical Investigation, 2021, 131, . | 3.9 | 111 |
| 949 | Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches. Cancer Discovery, 2021, 11, 1024-1039. | 7.7 | 56 |
| 950 | CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. Cellular Oncology (Dordrecht), 2021, 44, 495-523. | 2.1 | 32 |
| 951 | Therapeutic applications of the cancer immunoediting hypothesis. Seminars in Cancer Biology, 2022, 78, 63-77. | 4.3 | 29 |
| 952 | Nanomedicineâ€Boosting Tumor Immunogenicity for Enhanced Immunotherapy. Advanced Functional Materials, 2021, 31, 2011171. | 7.8 | 84 |
| 953 | Nanovaccineâ€Based Strategies to Overcome Challenges in the Whole Vaccination Cascade for Tumor Immunotherapy. Small, 2021, 17, e2006000. | 5.2 | 53 |
| 954 | Clinical cancer genomic profiling. Nature Reviews Genetics, 2021, 22, 483-501. | 7.7 | 79 |
| 955 | A minimal model of T cell avidity may identify subtherapeutic vaccine schedules. Mathematical Biosciences, 2021, 334, 108556. | 0.9 | 0 |
| 956 | Cationic Nanoparticle-Based Cancer Vaccines. Pharmaceutics, 2021, 13, 596. | 2.0 | 21 |
| 957 | Precision and personalized vaccines needed to face COVID-19 pandemic. Insights in Clinical and Cellular Immunology, 2021, 5, 003-003. | 0.1 | 0 |
| 958 | Advances in immunotherapy for pancreatic ductal adenocarcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 419-430. | 1.4 | 9 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 960 | A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer. Cancer Immunology, Immunotherapy, 2021, 70, 3451-3460. | 2.0 | 9 |
| 961 | Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine. Advanced Science, 2021, 8, 2100166. | 5.6 | 18 |
| 962 | The synergistic strategies for the <scp>immunoâ€oncotherapy</scp> with photothermal nanoagents. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1717. | 3.3 | 9 |
| 963 | Challenges and perspectives for immunotherapy inÂoesophageal cancer: A look to the future (Review). International Journal of Molecular Medicine, 2021, 47, . | 1.8 | 3 |
| 964 | Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses. Frontiers in Oncology, 2021, 11, 628456. | 1.3 | 14 |
| 965 | Advances in immunotherapy for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 525-543. | 8.2 | 609 |
| 966 | Therapeutic cancer vaccines. Nature Reviews Cancer, 2021, 21, 360-378. | 12.8 | 630 |
| 967 | Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation. Genome Medicine, 2021, 13, 56. | 3.6 | 34 |
| 968 | Virus-Like Particleâ€"Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens. Cancer Immunology Research, 2021, 9, 693-706. | 1.6 | 18 |
| 969 | Neoantigen: A New Breakthrough in Tumor Immunotherapy. Frontiers in Immunology, 2021, 12, 672356. | 2.2 | 115 |
| 970 | The Next Decade of Immune Checkpoint Therapy. Cancer Discovery, 2021, 11, 838-857. | 7.7 | 363 |
| 971 | Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology. Nature Communications, 2021, 12, 2041. | 5.8 | 207 |
| 972 | Effect of physicochemical properties on inÂvivo fate of nanoparticle-based cancer immunotherapies. Acta Pharmaceutica Sinica B, 2021, 11, 886-902. | 5.7 | 42 |
| 973 | HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. , 2021, 9, e002071. | | 126 |
| 974 | Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy. Frontiers in Oncology, 2021, 11, 672677. | 1.3 | 48 |
| 975 | Tumour neoantigen mimicry by microbial species in cancer immunotherapy. British Journal of Cancer, 2021, 125, 313-323. | 2.9 | 29 |
| 976 | Envisioning the immune system to determine its role in pancreatic ductal adenocarcinoma: Culprit or victim?. Immunology Letters, 2021, 232, 48-59. | 1.1 | 2 |
| 977 | In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden. Cytotherapy, 2021, 23, 320-328. | 0.3 | 8 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 978 | TANTIGEN 2.0: a knowledge base of tumor T cell antigens and epitopes. BMC Bioinformatics, 2021, 22, 40. | 1.2 | 24 |
| 980 | Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses. Cancers, 2021, 13, 1805. | 1.7 | 2 |
| 981 | Towards customized cancer vaccines: a promising filed in personalized cancer medicine. Expert Review of Vaccines, 2021, 20, 545-557. | 2.0 | 2 |
| 982 | NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 644637. | 2.2 | 34 |
| 984 | Safety and Efficacy of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. Frontiers in Oncology, 2021, 11, 663264. | 1.3 | 19 |
| 985 | YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy. Frontiers in Oncology, 2021, 11, 607224. | 1.3 | 64 |
| 986 | Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy. Vaccines, 2021, 9, 509. | 2.1 | 14 |
| 987 | Challenges of Neoantigen Targeting in Lynch Syndrome and Constitutional Mismatch Repair Deficiency Syndrome. Cancers, 2021, 13, 2345. | 1.7 | 3 |
| 988 | cIAP1/2 antagonism eliminates MHC class Iâ€"negative tumors through T cellâ€"dependent reprogramming of mononuclear phagocytes. Science Translational Medicine, 2021, 13, . | 5.8 | 25 |
| 989 | CD40 and CD80/86 signaling in cDC1s mediate effective neoantigen vaccination and generation of antigen-specific CX3CR1+ CD8+ T cells. Cancer Immunology, Immunotherapy, 2022, 71, 137-151. | 2.0 | 10 |
| 990 | Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer. Vaccines, 2021, 9, 454. | 2.1 | 11 |
| 991 | Rapid assessment of T-cell receptor specificity of the immune repertoire. Nature Computational Science, 2021, 1, 362-373. | 3.8 | 20 |
| 992 | Multi-step screening of neoantigensâ€™ HLA- and TCR-interfaces improves prediction of survival. Scientific Reports, 2021, 11, 9983. | 1.6 | 4 |
| 993 | Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6. Cancers, 2021, 13, 2600. | 1.7 | 11 |
| 995 | Deciphering Human Leukocyte Antigen Susceptibility Maps From Immunopeptidomics Characterization in Oncology and Infections. Frontiers in Cellular and Infection Microbiology, 2021, 11, 642583. | 1.8 | 7 |
| 996 | Preclinical models and technologies to advance nanovaccine development. Advanced Drug Delivery Reviews, 2021, 172, 148-182. | 6.6 | 18 |
| 997 | Inmunoterapia personalizada contra el cÃ¡ncer basada en neoantÃgenos. RevisiÃ³n de la literatura. Revista Facultad De Medicina, 2021, 69, e81633. | 0.0 | 0 |
| 998 | Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors. , 2021, 9, e001912. | | 10 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 999 | Vaccines and immune checkpoint inhibitors: a promising combination strategy in gastrointestinal cancers. Immunotherapy, 2021, 13, 561-564. | 1.0 | 4 |
| 1000 | Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 669474. | 2.2 | 124 |
| 1001 | Improvement of Neoantigen Identification Through Convolution Neural Network. Frontiers in Immunology, 2021, 12, 682103. | 2.2 | 4 |
| 1002 | Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. Clinical and Translational Oncology, 2021, 23, 2237-2252. | 1.2 | 7 |
| 1003 | Development of Effective Tumor Vaccine Strategies Based on Immune Response Cascade Reactions. Advanced Healthcare Materials, 2021, 10, e2100299. | 3.9 | 20 |
| 1005 | Vaccines for immunoprevention of cancer. Journal of Clinical Investigation, 2021, 131, . | 3.9 | 39 |
| 1006 | Gene fusion neoantigens: Emerging targets for cancer immunotherapy. Cancer Letters, 2021, 506, 45-54. | 3.2 | 42 |
| 1007 | Intratumoral (Poly-ICLC) Therapy for Dogs with Advanced Cancers: First Report on Clinical Effectiveness, Quality of Life, and Adverse Events. Cancers, 2021, 13, 2237. | 1.7 | 1 |
| 1008 | Targeting the KRAS Î±4-Î±5 allosteric interface inhibits pancreatic cancer tumorigenesis. Small GTPases, 2021, , 1-14. | 0.7 | 11 |
| 1009 | Use of a Novel Peptide Welding Technology Platform for the Development of B- and T-Cell Epitope-Based Vaccines. Vaccines, 2021, 9, 526. | 2.1 | 1 |
| 1010 | Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treatment Reviews, 2021, 101, 102227. | 3.4 | 42 |
| 1011 | N6-methyladenosine Steers RNA Metabolism and Regulation in Cancer. Cancer Communications, 2021, 41, 538-559. | 3.7 | 24 |
| 1012 | Navigating CAR-T cells through the solid-tumour microenvironment. Nature Reviews Drug Discovery, 2021, 20, 531-550. | 21.5 | 236 |
| 1013 | Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 5736. | 1.8 | 29 |
| 1014 | In situ vaccination and gene-mediated PD-L1 blockade for enhanced tumor immunotherapy. Chinese Chemical Letters, 2021, 32, 1770-1774. | 4.8 | 41 |
| 1015 | Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation. Npj Vaccines, 2021, 6, 71. | 2.9 | 23 |
| 1016 | Evolution of Cancer Vaccinesâ€"Challenges, Achievements, and Future Directions. Vaccines, 2021, 9, 535. | 2.1 | 38 |
| 1017 | Current management of melanoma patients with nodal metastases. Clinical and Experimental Metastasis, 2022, 39, 181-199. | 1.7 | 8 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 1018 | Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance. Frontiers in Immunology, 2021, 12, 674048. | 2.2 | 26 |
| 1019 | Therapeutic dendritic cell cancer vaccines in hematologic malignancies. Immunomedicine, 2021, 1, e1022. | 0.7 | 0 |
| 1020 | Nanotechnology synergized immunoengineering for cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 163, 72-101. | 2.0 | 8 |
| 1021 | MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. International Journal of Molecular Sciences, 2021, 22, 6741. | 1.8 | 28 |
| 1022 | Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement. Cancer Immunology, Immunotherapy, 2021, , 1. | 2.0 | 5 |
| 1023 | Artificial intelligence in early drug discovery enabling precision medicine. Expert Opinion on Drug Discovery, 2021, 16, 991-1007. | 2.5 | 35 |
| 1024 | Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics. Nature Communications, 2021, 12, 3346. | 5.8 | 90 |
| 1025 | 60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy. Cancer Research, 2021, 81, 4373-4384. | 0.4 | 19 |
| 1027 | Challenges targeting cancer neoantigens in 2021: a systematic literature review. Expert Review of Vaccines, 2021, 20, 827-837. | 2.0 | 13 |
| 1028 | Palmitoylated antigens for the induction of anti-tumor CD8+ TÂcells and enhanced tumor recognition. Molecular Therapy - Oncolytics, 2021, 21, 315-328. | 2.0 | 3 |
| 1030 | The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. Frontiers in Oncology, 2021, 11, 641428. | 1.3 | 32 |
| 1031 | Emerging self-assembling peptide nanomaterial for anti-cancer therapy. Journal of Biomaterials Applications, 2021, 36, 882-901. | 1.2 | 5 |
| 1032 | Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 3.3 | 62 |
| 1033 | CD8 + T cell immunity blocks the metastasis of carcinogen-exposed breast cancer. Science Advances, 2021, 7, . | 4.7 | 24 |
| 1034 | Symphony of nanomaterials and immunotherapy based on the cancer–immunity cycle. Acta Pharmaceutica Sinica B, 2022, 12, 107-134. | 5.7 | 70 |
| 1035 | Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms. Cancer Letters, 2021, 507, 55-69. | 3.2 | 53 |
| 1037 | Immunogenomics in personalized cancer treatments. Journal of Human Genetics, 2021, 66, 901-907. | 1.1 | 10 |
| 1038 | Rejection of benign melanocytic nevi by nevus-resident CD4 + T cells. Science Advances, 2021, 7, . | 4.7 | 6 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1039 | Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell, 2021, 39, 845-865.e7. | 7.7 | 503 |
| 1040 | Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines. Frontiers in Immunology, 2021, 12, 696791. | 2.2 | 58 |
| 1041 | Antiâ€‰JMH alloantibody in inherited JMHâ€negative patients leads to immunogenic destruction of JMHâ€positive RBCs. Clinical and Experimental Immunology, 2021, 205, 182-197. | 1.1 | 2 |
| 1042 | A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust TÂcell generation. Molecular Therapy - Oncolytics, 2021, 21, 278-287. | 2.0 | 7 |
| 1043 | Advancing to the era of cancer immunotherapy. Cancer Communications, 2021, 41, 803-829. | 3.7 | 90 |
| 1044 | Ovarian Cancer Immunotherapy and Personalized Medicine. International Journal of Molecular Sciences, 2021, 22, 6532. | 1.8 | 128 |
| 1045 | Physio-pathological effects of m6A modification and its potential contribution to melanoma. Clinical and Translational Oncology, 2021, 23, 2269-2279. | 1.2 | 12 |
| 1046 | Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy. AAPS Journal, 2021, 23, 90. | 2.2 | 19 |
| 1047 | Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival. Cancers, 2021, 13, 2879. | 1.7 | 8 |
| 1048 | Vaccination for cancer: Myth or reality. Immunomedicine, 2021, 1, e1026. | 0.7 | 0 |
| 1049 | Screening and Validation of the Hypoxia-Related Signature of Evaluating Tumor Immune Microenvironment and Predicting Prognosis in Gastric Cancer. Frontiers in Immunology, 2021, 12, 705511. | 2.2 | 28 |
| 1050 | Immunotherapy in endometrial cancer: rationale, practice and perspectives. Biomarker Research, 2021, 9, 49. | 2.8 | 53 |
| 1051 | Cancer Vaccines: Promising Therapeutics or an Unattainable Dream. Vaccines, 2021, 9, 668. | 2.1 | 32 |
| 1052 | The Current Lung Cancer Neoantigen Landscape and Implications for Therapy. Journal of Thoracic Oncology, 2021, 16, 922-932. | 0.5 | 19 |
| 1053 | CD8+ T Cell Exhaustion in Cancer. Frontiers in Immunology, 2021, 12, 715234. | 2.2 | 163 |
| 1054 | Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 3.3 | 30 |
| 1055 | Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repairâ€"deficient colorectal cancer tissue. JCI Insight, 2021, 6, . | 2.3 | 17 |
| 1057 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. , 2021, 9, e002531. | | 24 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1058 | Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis. Anticancer Research, 2021, 41, 4101-4115. | 0.5 | 3 |
| 1059 | Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 673-683. | 0.8 | 9 |
| 1060 | Mucosal vaccines â€" fortifying the frontiers. Nature Reviews Immunology, 2022, 22, 236-250. | 10.6 | 301 |
| 1061 | Personalized Neoantigen-Pulsed DC Vaccines: Advances in Clinical Applications. Frontiers in Oncology, 2021, 11, 701777. | 1.3 | 21 |
| 1062 | Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nature Communications, 2021, 12, 4365. | 5.8 | 53 |
| 1063 | CD8+ T cell differentiation and dysfunction in cancer. Nature Reviews Immunology, 2022, 22, 209-223. | 10.6 | 345 |
| 1064 | The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients. Frontiers in Immunology, 2021, 12, 701636. | 2.2 | 6 |
| 1065 | An MRI-trackable therapeutic nanovaccine preventing cancer liver metastasis. Biomaterials, 2021, 274, 120893. | 5.7 | 24 |
| 1066 | Neoantigen Controversies. Annual Review of Biomedical Data Science, 2021, 4, 227-253. | 2.8 | 9 |
| 1067 | Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach. International Journal of Molecular Sciences, 2021, 22, 8035. | 1.8 | 30 |
| 1068 | Therapeutic cancer vaccine therapy for acute myeloid leukemia. Immunotherapy, 2021, 13, 863-877. | 1.0 | 6 |
| 1069 | Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 498-508. | 0.8 | 0 |
| 1070 | Development of neoantigens: from identification in cancer cells to application in cancer vaccines. Expert Review of Vaccines, 2022, 21, 941-955. | 2.0 | 11 |
| 1071 | HLA-B and cysteinylated ligands distinguish the antigen presentation landscape of extracellular vesicles. Communications Biology, 2021, 4, 825. | 2.0 | 9 |
| 1072 | Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential. Frontiers in Immunology, 2021, 12, 682492. | 2.2 | 18 |
| 1073 | Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage. Clinical Cancer Research, 2022, 28, 13-22. | 3.2 | 4 |
| 1074 | Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines. Science Translational Medicine, 2021, 13, . | 5.8 | 109 |
| 1075 | Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy. Frontiers in Oncology, 2021, 11, 679095. | 1.3 | 7 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 1077 | Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery. Frontiers in Immunology, 2021, 12, 592031. | 2.2 | 6 |
| 1078 | Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8+ T cells. Biomaterials, 2021, 274, 120844. | 5.7 | 19 |
| 1079 | Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma. European Journal of Cancer, 2021, 151, 25-34. | 1.3 | 59 |
| 1080 | NLRP3 inflammasomes that induce antitumor immunity. Trends in Immunology, 2021, 42, 575-589. | 2.9 | 29 |
| 1081 | Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides. Cell Reports, 2021, 36, 109312. | 2.9 | 13 |
| 1082 | Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature, 2021, 596, 119-125. | 13.7 | 239 |
| 1083 | Global mapping of cancers: The Cancer Genome Atlas and beyond. Molecular Oncology, 2021, 15, 2823-2840. | 2.1 | 55 |
| 1084 | Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia. Frontiers in Immunology, 2021, 12, 705974. | 2.2 | 22 |
| 1085 | Photothermal Therapy Combined with Neoantigen Cancer Vaccination for Effective Immunotherapy against Large Established Tumors and Distant Metastasis. Advanced Therapeutics, 2021, 4, 2100093. | 1.6 | 20 |
| 1086 | An Integrated Approach for Discovering Noncanonical MHC-I Peptides Encoded by Small Open Reading Frames. Journal of the American Society for Mass Spectrometry, 2021, 32, 2346-2357. | 1.2 | 10 |
| 1087 | EVALUATION OF IMMUNOGENICITY OF SYNTHETIC NEOANTIGEN PEPTIDES FOR THE MELANOMA VACCINE MODEL. , 2021, 20, 61-68. | 0.3 | 2 |
| 1088 | Targeting neoantigens for cancer immunotherapy. Biomarker Research, 2021, 9, 61. | 2.8 | 29 |
| 1091 | Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response. , 2021, 9, e003132. | | 17 |
| 1092 | Pancreatic Cancer and Immunotherapy: A Clinical Overview. Cancers, 2021, 13, 4138. | 1.7 | 49 |
| 1093 | Splicing modulators: on the way from nature to clinic. Journal of Antibiotics, 2021, 74, 603-616. | 1.0 | 17 |
| 1094 | Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing. BMC Cancer, 2021, 21, 972. | 1.1 | 6 |
| 1095 | Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy. Cancers, 2021, 13, 4245. | 1.7 | 13 |
| 1096 | A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment. Frontiers in Immunology, 2021, 12, 691605. | 2.2 | 25 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1098 | PopCover-2.0. Improved Selection of Peptide Sets With Optimal HLA and Pathogen Diversity Coverage. Frontiers in Immunology, 2021, 12, 728936. | 2.2 | 5 |
| 1099 | Emerging targets for anticancer vaccination: IDH. ESMO Open, 2021, 6, 100214. | 2.0 | 15 |
| 1100 | Tumor-reactive T cells are licensed by dendritic cells located in spatially different tissues: implications for dendritic cell vaccines. Oncotarget, 2021, 12, 1631-1633. | 0.8 | 0 |
| 1101 | Know thy immune self and nonâ€self: Proteomics informs on the expanse of self and nonâ€self, and how and where they arise. Proteomics, 2021, , 2000143. | 1.3 | 6 |
| 1102 | Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: A randomized clinical trial. Hepatology, 2022, 75, 182-195. | 3.6 | 18 |
| 1103 | DLpTCR: an ensemble deep learning framework for predicting immunogenic peptide recognized by T cell receptor. Briefings in Bioinformatics, 2021, 22, . | 3.2 | 43 |
| 1104 | PolyTLR7/8a-conjugated, antigen-trapping gold nanorods elicit anticancer immunity against abscopal tumors by photothermal therapy-induced in situ vaccination. Biomaterials, 2021, 275, 120921. | 5.7 | 40 |
| 1105 | VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigensâ€™ Prediction. Vaccines, 2021, 9, 880. | 2.1 | 8 |
| 1106 | Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence. Signal Transduction and Targeted Therapy, 2021, 6, 312. | 7.1 | 50 |
| 1107 | The Role of Neoantigens in Cancer Immunotherapy. Frontiers in Oncology, 2021, 11, 682325. | 1.3 | 14 |
| 1108 | Peptide-MHC I complex stability measured by nanoscale differential scanning fluorimetry reveals molecular mechanism of thermal denaturation. Molecular Immunology, 2021, 136, 73-81. | 1.0 | 11 |
| 1109 | A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells. Journal of Clinical Investigation, 2021, 131, . | 3.9 | 12 |
| 1110 | Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure. Cancers, 2021, 13, 4529. | 1.7 | 10 |
| 1111 | Building Personalized Cancer Therapeutics through Multi-Omics Assays and Bacteriophage-Eukaryotic Cell Interactions. International Journal of Molecular Sciences, 2021, 22, 9712. | 1.8 | 2 |
| 1112 | IFNÎ² Is a Potent Adjuvant for Cancer Vaccination Strategies. Frontiers in Immunology, 2021, 12, 735133. | 2.2 | 11 |
| 1113 | Farnesylthiosalicylic acid-derivatized PEI-based nanocomplex for improved tumor vaccination. Molecular Therapy - Nucleic Acids, 2021, 26, 594-602. | 2.3 | 6 |
| 1114 | Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses. Clinical Cancer Research, 2021, 27, 6405-6412. | 3.2 | 8 |
| 1115 | Engineered Attenuated <i>Salmonella typhimurium</i> Expressing Neoantigen Has Anticancer Effects. ACS Synthetic Biology, 2021, 10, 2478-2487. | 1.9 | 13 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1116 | Efficacy and Safety of Actively Personalized Neoantigen Vaccination in the Management of Newly Diagnosed Glioblastoma: A Systematic Review. International Journal of General Medicine, 2021, Volume 14, 5209-5220. | 0.8 | 4 |
| 1117 | Virusâ€Mimic mRNA Vaccine for Cancer Treatment. Advanced Therapeutics, 2021, 4, 2100144. | 1.6 | 11 |
| 1118 | Systematic discovery and validation of Tâcell targets directed against oncogenic KRAS mutations. Cell Reports Methods, 2021, 1, 100084. | 1.4 | 24 |
| 1119 | Tumor eradicated by combination of imiquimod and OX40 agonist for <i>in situ</i> vaccination. Cancer Science, 2021, 112, 4490-4500. | 1.7 | 8 |
| 1120 | Current Immunotherapeutic Strategies for the Treatment of Glioblastoma. Cancers, 2021, 13, 4548. | 1.7 | 16 |
| 1121 | Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human. Cancers, 2021, 13, 4553. | 1.7 | 6 |
| 1122 | Antigen dominance hierarchies shape TCF1+ progenitor CD8 Tâcell phenotypes in tumors. Cell, 2021, 184, 4996-5014.e26. | 13.5 | 84 |
| 1124 | Amateur antigenâ€presenting cells in the tumor microenvironment. Molecular Carcinogenesis, 2022, 61, 153-164. | 1.3 | 12 |
| 1125 | Role of Different Peptides for Cancer Immunotherapy. International Journal of Peptide Research and Therapeutics, 2021, 27, 2777-2793. | 0.9 | 7 |
| 1126 | Harnessing the Immune System to Fight Multiple Myeloma. Cancers, 2021, 13, 4546. | 1.7 | 10 |
| 1127 | Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma. , 2021, 9, e002754. | | 7 |
| 1128 | hnRNPâ€A1 binds to the IRES of MELOEâ€1 antigen to promote MELOEâ€1 translation in stressed melanoma cells. Molecular Oncology, 2022, 16, 594-606. | 2.1 | 9 |
| 1129 | High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4<sup>+</sup>and CD8<sup>+</sup>neoantigen-specific T cells to promote antitumor immunity. , 2021, 9, e002865. | | 16 |
| 1130 | Innate immune detection of lipid oxidation as a threat assessment strategy. Nature Reviews Immunology, 2022, 22, 322-330. | 10.6 | 57 |
| 1131 | Bioinformatics Analyses Reveal the Prognostic Value and Biological Roles of SEPHS2 in Various Cancers. International Journal of General Medicine, 2021, Volume 14, 6059-6076. | 0.8 | 4 |
| 1132 | Evolution of CD8+ T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer. Cells, 2021, 10, 2379. | 1.8 | 23 |
| 1133 | Splicing modulators elicit global translational repression by condensate-prone proteins translated from introns. Cell Chemical Biology, 2022, 29, 259-275.e10. | 2.5 | 9 |
| 1134 | Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity. Advanced Drug Delivery Reviews, 2021, 176, 113889. | 6.6 | 48 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1135 | Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer and Metastasis Reviews, 2021, 40, 819-835. | 2.7 | 41 |
| 1136 | T Cell Epitope Prediction and Its Application to Immunotherapy. Frontiers in Immunology, 2021, 12, 712488. | 2.2 | 27 |
| 1137 | Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance. Cancer and Metastasis Reviews, 2021, 40, 837-862. | 2.7 | 8 |
| 1138 | Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma. Immunological Investigations, 2022, 51, 1498-1514. | 1.0 | 8 |
| 1139 | Combination strategies to maximize the benefits of cancer immunotherapy. Journal of Hematology and Oncology, 2021, 14, 156. | 6.9 | 202 |
| 1140 | Therapeutic cancer vaccines revamping: technology advancements and pitfalls. Annals of Oncology, 2021, 32, 1537-1551. | 0.6 | 36 |
| 1141 | mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients. Vaccines, 2021, 9, 1060. | 2.1 | 39 |
| 1142 | pepsickle rapidly and accurately predicts proteasomal cleavage sites for improved neoantigen identification. Bioinformatics, 2021, 37, 3723-3733. | 1.8 | 6 |
| 1143 | Role of CD4$^+$CD25$^+$FOXP3$^+$T$_{Reg}$cells on tumor immunity. Immunological Medicine, 2022, 45, 94-107. | 1.4 | 12 |
| 1144 | Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole‐Cell Components of Tumor Tissues or Cells. Advanced Materials, 2021, 33, e2104849. | 11.1 | 52 |
| 1145 | Mathematical model of a personalized neoantigen cancer vaccine and the human immune system. PLoS Computational Biology, 2021, 17, e1009318. | 1.5 | 7 |
| 1146 | Cyclophosphamide loaded thermo-responsive hydrogel system synergize with a hydrogel cancer vaccine to amplify cancer immunotherapy in a prime-boost manner. Bioactive Materials, 2021, 6, 3036-3048. | 8.6 | 36 |
| 1147 | Immunotherapy for HPV Malignancies. Seminars in Radiation Oncology, 2021, 31, 361-370. | 1.0 | 5 |
| 1148 | Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy. International Journal of Pharmaceutics, 2021, 608, 121091. | 2.6 | 11 |
| 1149 | Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies. , 2021, 9, e003001. | | 8 |
| 1150 | Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors. Advanced Drug Delivery Reviews, 2021, 177, 113927. | 6.6 | 34 |
| 1151 | Synthetic multiepitope neoantigen DNA vaccine for personalized cancer immunotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 37, 102443. | 1.7 | 24 |
| 1152 | Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors. , 2021, 9, e003404. | | 11 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1153 | Generation of cancer vaccine immunogens derived from Oncofetal antigen (OFA/iLRP) using variable epitope libraries tested in an aggressive breast cancer model. Molecular Immunology, 2021, 139, 65-75. | 1.0 | 5 |
| 1154 | Supramolecular co-assembly of self-adjuvanting nanofibrious peptide hydrogel enhances cancer vaccination by activating MyD88-dependent NF-κB signaling pathway without inflammation. Bioactive Materials, 2021, 6, 3924-3934. | 8.6 | 23 |
| 1155 | Native Mitochondria-Targeting polymeric nanoparticles for mild photothermal therapy rationally potentiated with immune checkpoints blockade to inhibit tumor recurrence and metastasis. Chemical Engineering Journal, 2021, 424, 130171. | 6.6 | 36 |
| 1156 | Advances in clinical immunotherapy for gastric cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188615. | 3.3 | 153 |
| 1157 | Personalized cancer immunotherapy. , 2022, , 399-426. | | 0 |
| 1158 | Stromal modulation strategies to improve immunotherapy response in cancer. , 2022, , 241-291. | | 0 |
| 1159 | Applied cancer immunogenomics in glioblastoma. , 2022, , 19-38. | | 0 |
| 1160 | Immune responses to CRISPR-Cas protein. Progress in Molecular Biology and Translational Science, 2021, 178, 213-229. | 0.9 | 1 |
| 1161 | Tumor microenvironment-triggered *in situ* cancer vaccines inducing dual immunogenic cell death for elevated antitumor and antimetastatic therapy. Nanoscale, 2021, 13, 10906-10915. | 2.8 | 15 |
| 1162 | Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment. Cancers, 2021, 13, 373. | 1.7 | 18 |
| 1163 | Personalized immunotherapy in cancer precision medicine. Cancer Biology and Medicine, 2021, 18, 0-0. | 1.4 | 20 |
| 1164 | Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduction and Targeted Therapy, 2021, 6, 26. | 7.1 | 112 |
| 1165 | Precision Medicine: Enabling Healthcare Progress in the Twenty-First Century. , 2021, , 9-19. | | 0 |
| 1166 | Self-assembling, self-adjuvanting and fully synthetic peptide nanovaccine for cancer immunotherapy. Smart Materials in Medicine, 2021, 2, 237-249. | 3.7 | 14 |
| 1167 | Nanoparticle-mediated tumor vaccines for personalized therapy: preparing tumor antigens *in vivo* or *ex vivo*?. Journal of Materials Chemistry B, 2021, 9, 2352-2366. | 2.9 | 6 |
| 1168 | Modularly Programmable Nanoparticle Vaccine Based on Polyethyleneimine for Personalized Cancer Immunotherapy. Advanced Science, 2021, 8, 2002577. | 5.6 | 46 |
| 1169 | Residue substitution enhances the immunogenicity of neoepitopes from gastric cancers. Cancer Biology and Medicine, 2021, 18, 0-0. | 1.4 | 1 |
| 1170 | Intratumoral injection of caerin 1.1 and 1.9 peptides increases the efficacy of vaccinated TC−1 tumor−bearing mice with PD−1 blockade by modulating macrophage heterogeneity and the activation of CD8+ T cells in the tumor microenvironment. Clinical and Translational Immunology, 2021, 10, e1335. | 1.7 | 12 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1171 | Personalized cancer vaccination in head and neck cancer. Cancer Science, 2021, 112, 978-988. | 1.7 | 34 |
| 1172 | Beyond conventional immune-checkpoint inhibition â€" novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology, 2021, 18, 199-214. | 12.5 | 179 |
| 1174 | Cytotoxic CD8+ Lymphocytes in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1224, 53-62. | 0.8 | 56 |
| 1175 | Multiple Dynamics in Tumor Microenvironment Under Radiotherapy. Advances in Experimental Medicine and Biology, 2020, 1263, 175-202. | 0.8 | 5 |
| 1176 | Mechanisms of Resistance to Checkpoint Blockade Therapy. Advances in Experimental Medicine and Biology, 2020, 1248, 83-117. | 0.8 | 22 |
| 1177 | Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome. OncoImmunology, 2020, 9, 1684714. | 2.1 | 12 |
| 1178 | Joint epitope selection and spacer design for string-of-beads vaccines. Bioinformatics, 2020, 36, i643-i650. | 1.8 | 5 |
| 1204 | Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in nonâ€"small cell lung cancer. Cancer Science, 2020, 111, 2736-2746. | 1.7 | 12 |
| 1205 | BSA-modified gold nanorods for combined photothermal therapy and immunotherapy of melanoma. , 2019, , . | | 3 |
| 1206 | Optimized combinatorial pMHC class II multimer labeling for precision immune monitoring of tumor-specific CD4 T cells in patients. , 2020, 8, e000435. | | 4 |
| 1207 | Endogenous HLA-DQ8Î±Î² programs superantigens (SEG/SEI) to silence toxicity and unleash a tumoricidal network with long-term melanoma survival. , 2020, 8, e001493. | | 3 |
| 1208 | Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas. Clinical Cancer Research, 2020, 26, 4369-4380. | 3.2 | 48 |
| 1209 | Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. JCI Insight, 2018, 3, . | 2.3 | 120 |
| 1210 | Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development. JCI Insight, 2020, 5, . | 2.3 | 20 |
| 1211 | IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy. JCI Insight, 2018, 3, . | 2.3 | 42 |
| 1212 | Emerging strategies for combination checkpoint modulators in cancer immunotherapy. Journal of Clinical Investigation, 2018, 128, 3209-3218. | 3.9 | 170 |
| 1213 | Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. Journal of Clinical Investigation, 2018, 128, 4804-4820. | 3.9 | 210 |
| 1214 | Cellular therapy against public neoantigens. Journal of Clinical Investigation, 2019, 129, 506-508. | 3.9 | 8 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 1215 | Immune escape and immunotherapy of acute myeloid leukemia. Journal of Clinical Investigation, 2020, 130, 1552-1564. | 3.9 | 160 |
| 1216 | Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. Journal of Clinical Investigation, 2020, 130, 1595-1607. | 3.9 | 10 |
| 1217 | mRNA vaccineâ€"induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. Journal of Clinical Investigation, 2020, 130, 5976-5988. | 3.9 | 218 |
| 1218 | CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia. Journal of Clinical Investigation, 2020, 130, 5127-5141. | 3.9 | 49 |
| 1219 | Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy. Journal of Clinical Investigation, 2018, 128, 1971-1984. | 3.9 | 73 |
| 1220 | Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia. Journal of Clinical Investigation, 2019, 129, 774-785. | 3.9 | 128 |
| 1221 | Strategies for developing and optimizing cancer vaccines. F1000Research, 2019, 8, 654. | 0.8 | 43 |
| 1222 | Graph-theoretical formulation of the generalized epitope-based vaccine design problem. PLoS Computational Biology, 2020, 16, e1008237. | 1.5 | 6 |
| 1223 | THERAPY OF ENDOCRINE DISEASE Immunotherapy of advanced thyroid cancer: from bench to bedside. European Journal of Endocrinology, 2020, 183, R41-R55. | 1.9 | 20 |
| 1224 | Neoantigens in tumor immunotherapy. , 2018, 17, 6-14. | 0.3 | 8 |
| 1225 | Identification of immunogenic mutant neoantigens in the genome of murine melanoma. , 2019, 18, 23-30. | 0.3 | 6 |
| 1226 | EVALUATION OF THE ANTITUMOR EFFICACY OF SYNTHETIC NEOANTIGEN PEPTIDES FOR THE MELANOMA VACCINE MODEL. , 2019, 18, 76-81. | 0.3 | 6 |
| 1227 | Prognostic value of immune-related genes in clear cell renal cell carcinoma. Aging, 2019, 11, 11474-11489. | 1.4 | 56 |
| 1228 | Prognostic value of immune-related genes in clear cell renal cell carcinoma. Aging, 2019, 11, 11474-11489. | 1.4 | 6 |
| 1229 | Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. Oncotarget, 2018, 9, 4109-4119. | 0.8 | 34 |
| 1230 | Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment. Oncotarget, 2018, 9, 35394-35407. | 0.8 | 6 |
| 1231 | Cancer vaccines: whatâ€™s next?. Oncotarget, 2019, 10, 3985-3987. | 0.8 | 2 |
| 1232 | New trends in antitumor vaccines in melanoma. Annals of Translational Medicine, 2017, 5, 384-384. | 0.7 | 16 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1233 | Advances and challenges in immunotherapy of small cell lung cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 115-128. | 0.7 | 19 |
| 1234 | Cancer Biomarker Discovery for Precision Medicine: New Progress. Current Medicinal Chemistry, 2020, 26, 7655-7671. | 1.2 | 51 |
| 1235 | The Roles of Alternative Splicing in Tumor-immune Cell Interactions. Current Cancer Drug Targets, 2020, 20, 729-740. | 0.8 | 8 |
| 1236 | Current Progresses of Functional Nanomaterials for Imaging Diagnosis and Treatment of Melanoma. Current Topics in Medicinal Chemistry, 2019, 19, 2494-2506. | 1.0 | 6 |
| 1237 | Biological therapy in the treatment of melanoma. Journal of Mind and Medical Sciences, 2018, 5, 169-175. | 0.1 | 2 |
| 1238 | Global scenario on ovarian cancer â€" Its dynamics, relative survival, treatment, and epidemiology. , 0, 2, 17-25. | | 15 |
| 1239 | Use of immunotherapy in the treatment of gastric cancer (Review). Oncology Letters, 2019, 18, 5681-5690. | 0.8 | 31 |
| 1240 | IL-27p28 Production by XCR1+ Dendritic Cells and Monocytes Effectively Predicts Adjuvant-Elicited CD8+ T Cell Responses. ImmunoHorizons, 2018, 2, 1-11. | 0.8 | 26 |
| 1241 | Advances in personalized neoantigen vaccines for cancer immunotherapy. BioScience Trends, 2020, 14, 349-353. | 1.1 | 8 |
| 1242 | Rejection of immunogenic tumor clones is limited by clonal fraction. ELife, 2018, 7, . | 2.8 | 88 |
| 1243 | Cancer systems immunology. ELife, 2020, 9, . | 2.8 | 14 |
| 1244 | Design of Nanostructure Materials to Modulate Immunosuppressive Tumour Microenvironments and Enhance Cancer Immunotherapy. Bioanalysis, 2021, , 143-172. | 0.1 | 0 |
| 1246 | Precisely Shaped Self-Adjuvanting Peptide Vaccines with Enhanced Immune Responses for HPV-Associated Cancer Therapy. ACS Applied Materials &amp; Interfaces, 2021, 13, 49737-49753. | 4.0 | 7 |
| 1247 | Toward a postbiotic era of microbiome science: opportunities to advance immunotherapies for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2021, , . | 1.4 | 3 |
| 1248 | Vaccines for Non-Viral Cancer Prevention. International Journal of Molecular Sciences, 2021, 22, 10900. | 1.8 | 4 |
| 1249 | The Current Application and Future Prospects of Astragalus Polysaccharide Combined With Cancer Immunotherapy: A Review. Frontiers in Pharmacology, 2021, 12, 737674. | 1.6 | 7 |
| 1250 | DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor. Frontiers in Immunology, 2021, 12, 763086. | 2.2 | 9 |
| 1251 | Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer. Frontiers in Immunology, 2021, 12, 749369. | 2.2 | 7 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1252 | Localized delivery of immunotherapeutics: A rising trend in the field. Journal of Controlled Release, 2021, 340, 149-167. | 4.8 | 14 |
| 1253 | Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. Journal of Clinical Investigation, 2021, 131, . | 3.9 | 15 |
| 1254 | Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell, 2021, 184, 5309-5337. | 13.5 | 588 |
| 1255 | Identification and Mitigation of Defensins in the Immunopurification of Peptide MHC-I Antigens from Lung Tissue. Journal of the American Society for Mass Spectrometry, 2021, , . | 1.2 | 0 |
| 1256 | Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nature Biotechnology, 2022, 40, 209-217. | 9.4 | 127 |
| 1257 | LN Monocytes Limit DC-Poly I:C Induced Cytotoxic T Cell Response via IL-10 and Induction of Suppressor CD4 T Cells. Frontiers in Immunology, 2021, 12, 763379. | 2.2 | 3 |
| 1258 | Cell membrane-coated nanoparticles for immunotherapy. Chinese Chemical Letters, 2022, 33, 1673-1680. | 4.8 | 27 |
| 1259 | Microbiome Crosstalk in Immunotherapy and Antiangiogenesis Therapy. Frontiers in Immunology, 2021, 12, 747914. | 2.2 | 17 |
| 1260 | Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinoma. , 2021, 9, e002170. | | 3 |
| 1261 | Identification of tumor antigens with immunopeptidomics. Nature Biotechnology, 2022, 40, 175-188. | 9.4 | 93 |
| 1262 | Identification of Novel Modalities Through Bibliometric Analysis for Timely Development of Regulatory Guidance: A Case Study of T Cell Immunity. Frontiers in Medicine, 2021, 8, 756870. | 1.2 | 2 |
| 1263 | Novel immunotherapeutic drugs for the treatment of lung cancer. Current Opinion in Oncology, 2022, 34, 89-94. | 1.1 | 9 |
| 1264 | The Prediction and Function of Neoantigen in Oncobiology. , 2017, , . | | 0 |
| 1265 | Tailor-made T cells for cancer therapy. Science Translational Medicine, 2017, 9, . | 5.8 | 0 |
| 1266 | Personalized cancer vaccines show glimmers of success. Nature, 0, , . | 13.7 | 1 |
| 1267 | Papers of note in *Nature* **547** (7662). Science Signaling, 2017, 10, . | 1.6 | 0 |
| 1269 | MHC class II restricted neoepitope vaccine: Promising strategy for immunotherapy.. , 2018, 03, . | | 0 |
| 1270 | The Present Status and Future Prospects of Cancer Immunotherapy Using Active Immunization of Tumor-Associated Antigens. Major Histocompatibility Complex, 2018, 25, 40-49. | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1272 | CongrÃ¨s de lâ€™association amÃ©ricaine de recherche contre le cancer â€" AACR 2018. Oncologie, 2018, 20, 49-70. | 0.2 | 0 |
| 1273 | Cancer Precision Medicine; Where We Should Go?. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1688-1695. | 0.0 | 0 |
| 1274 | Melanoma Vaccines. , 2019, , 1-23. | | 0 |
| 1275 | Genomic Applications in Melanoma. , 2019, , 509-540. | | 0 |
| 1276 | Innate and Adaptive Immune Responses to Cancer. , 2019, , 111-159. | | 3 |
| 1278 | The Current Strategies and Developing Directions of Tumor Immunotherapy. World Journal of Cancer Research, 2019, 09, 98-103. | 0.1 | 0 |
| 1279 | Novel Immunotherapies and Novel Combinations of Immunotherapy. , 2019, , 1-22. | | 0 |
| 1280 | Cancer vaccine adjuvants. , 2019, 17, 36-44. | 0.3 | 2 |
| 1281 | Complexities of the Lung Tumor Microenvironment. Current Cancer Research, 2019, , 179-194. | 0.2 | 0 |
| 1283 | Immunotherapeutic strategies in patients with advanced head and neck squamous cell carcinoma. Annals of Translational Medicine, 2019, 7, S22-S22. | 0.7 | 2 |
| 1284 | Application of neoantigens in malignant tumor treatment and prognosis evaluation. World Chinese Journal of Digestology, 2019, 27, 287-292. | 0.0 | 0 |
| 1295 | Treatment: Future Directions. , 2020, , 265-277. | | 0 |
| 1306 | Point mutation screening of tumor neoantigens and peptideâ€‘induced specific cytotoxic T lymphocytes using The Cancer Genome Atlas database. Oncology Letters, 2020, 20, 1-1. | 0.8 | 2 |
| 1307 | The role of tumor microenvironment and exosomes in dormancy and relapse. Seminars in Cancer Biology, 2022, 78, 35-44. | 4.3 | 24 |
| 1308 | Positionâ€Scanning Peptide Libraries as Particle Immunogens for Improving CD8 + Tâ€Cell Responses. Advanced Science, 2021, , 2103023. | 5.6 | 5 |
| 1309 | Analyzing the Immune Response of Neoepitopes for Personalized Vaccine Design. Lecture Notes in Computer Science, 2020, , 40-48. | 1.0 | 0 |
| 1310 | Identification of WDFY3 Neoantigens as Prognostic Markers in Longterm Survivors of Extrahepatic Cholangiocarcinoma. Current Cancer Drug Targets, 2020, 20, 875-886. | 0.8 | 2 |
| 1311 | Cancer and COVID-19: On the Quest for Effective Vaccines. Blood Cancer Discovery, 2021, 2, 13-18. | 2.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 1314 | Biomimetic nanomedicine toward personalized disease theranostics. Nano Research, 2021, 14, 2491-2511. | 5.8 | 17 |
| 1315 | Personalized Immuno-Oncology. , 2021, , 479-508. | | 2 |
| 1317 | A tale of solving two computational challenges in protein science: neoantigen prediction and protein structure prediction. Briefings in Bioinformatics, 2022, 23, . | 3.2 | 7 |
| 1318 | Criteria to make animal studies more relevant to treating human cancer. Current Opinion in Immunology, 2022, 74, 25-31. | 2.4 | 3 |
| 1319 | Melanoma Vaccines. , 2020, , 1243-1265. | | 0 |
| 1320 | Novel Immunotherapies and Novel Combinations of Immunotherapy for Metastatic Melanoma. , 2020, , 1165-1186. | | 0 |
| 1321 | CHAPTER 14. Cell and Immune Therapy. RSC Detection Science, 2020, , 303-344. | 0.0 | 0 |
| 1322 | Cellular Therapy for Melanoma. , 2020, , 1267-1299. | | 0 |
| 1325 | Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope. Nature Communications, 2021, 12, 6423. | 5.8 | 18 |
| 1326 | In Silico Model Estimates the Clinical Trial Outcome of Cancer Vaccines. Cells, 2021, 10, 3048. | 1.8 | 4 |
| 1333 | Vacunas basadas en neoantÃgenos y control del cÃ¡ncer: perspectivas. Revista Colombiana De CancerologÃa, 2020, 24, 178-88. | 0.0 | 0 |
| 1334 | La implementaciÃ³n de las vacunas basadas en neoantÃgenos tumorales: un desafÃo para la medicina de precisiÃ³n en oncologÃa. Revista Colombiana De CancerologÃa, 2020, 24, 154-56. | 0.0 | 0 |
| 1335 | Double-Stranded RNA Immunomodulators in Prostate Cancer. Urologic Clinics of North America, 2020, 47, e1-e8. | 0.8 | 2 |
| 1336 | Immunization with glypican-3 nanovaccine containing TLR7 agonist prevents the development of carcinogen-induced precancerous hepatic lesions to cancer in a murine model. American Journal of Translational Research (discontinued), 2018, 10, 1736-1749. | 0.0 | 4 |
| 1338 | ï¼œEditors' Choiceï¼ž Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity. Nagoya Journal of Medical Science, 2019, 81, 1-18. | 0.6 | 18 |
| 1339 | Extracorporeal Photochemotherapy: Mechanistic Insights Driving Recent Advances and Future Directions. Yale Journal of Biology and Medicine, 2020, 93, 145-159. | 0.2 | 3 |
| 1340 | Strategy and clinical application of up-regulating cross presentation by DCs in anti-tumor therapy. Journal of Controlled Release, 2022, 341, 184-205. | 4.8 | 18 |
| 1341 | Xenograft cancer vaccines prepared from immunodeficient mice increase tumor antigen diversity and host T cell efficiency against colorectal cancers. Cancer Letters, 2022, 526, 66-75. | 3.2 | 3 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 1342 | Is There a Role for Immunotherapy in Central Nervous System Cancers?. Hematology/Oncology Clinics of North America, 2022, 36, 237-252. | 0.9 | 5 |
| 1343 | Identification and <i>in vitro</i> validation of neoantigens for immune activation against high-risk pediatric leukemia cells. Human Vaccines and Immunotherapeutics, 2024, 17, 5558-5562. | 1.4 | 1 |
| 1344 | Role of Tumor-Associated Neutrophils in the Molecular Carcinogenesis of the Lung. Cancers, 2021, 13, 5972. | 1.7 | 11 |
| 1345 | Neoantigen-driven B cell and CD4ÂT follicular helper cell collaboration promotes anti-tumor CD8 TÂcell responses. Cell, 2021, 184, 6101-6118.e13. | 13.5 | 192 |
| 1346 | Directing the Future Breakthroughs in Immunotherapy: The Importance of a Holistic Approach to the Tumour Microenvironment. Cancers, 2021, 13, 5911. | 1.7 | 1 |
| 1348 | A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma. Cancers, 2021, 13, 5801. | 1.7 | 2 |
| 1350 | Commensal Bifidobacterium Strains Enhance the Efficacy of Neo-Epitope Based Cancer Vaccines. Vaccines, 2021, 9, 1356. | 2.1 | 10 |
| 1351 | Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. Pharmacological Research, 2022, 175, 105997. | 3.1 | 43 |
| 1352 | Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?. Frontiers in Oncology, 2021, 11, 769305. | 1.3 | 13 |
| 1353 | Novel Tumor-Specific Antigens for Immunotherapy Identified From Multi-omics Profiling in Thymic Carcinomas. Frontiers in Immunology, 2021, 12, 748820. | 2.2 | 3 |
| 1354 | Computational cancer neoantigen prediction: current status and recent advances. Immuno-Oncology Technology, 2021, 12, 100052. | 0.2 | 14 |
| 1355 | Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy. Leukemia, 2022, 36, 994-1005. | 3.3 | 33 |
| 1356 | HLA AND CANCER. Physical and Rehabilitation Medicine Medical Rehabilitation, 0, , . | 0.1 | 0 |
| 1357 | Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. Nature Cancer, 2021, 2, 1224-1242. | 5.7 | 37 |
| 1358 | <i>In Silico</i> Epitope Prediction Analyses Highlight the Potential for Distracting Antigen Immunodominance with Allogeneic Cancer Vaccines. Cancer Research Communications, 2021, 1, 115-126. | 0.7 | 1 |
| 1359 | Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion. , 2021, 9, e003480. | | 4 |
| 1360 | The HLA Ligandome Comprises a Limited Repertoire of O-GlcNAcylated Antigens Preferentially Associated With HLA-B*07:02. Frontiers in Immunology, 2021, 12, 796584. | 2.2 | 7 |
| 1361 | Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy. Cancers, 2021, 13, 6061. | 1.7 | 5 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1362 | Immunization with short peptide particles reveals a functional CD8<sup>+</sup> T-cell neoepitope in a murine renal carcinoma model. , 2021, 9, e003101. | | 7 |
| 1363 | Cancer-Specific T Helper Shared and Neo-Epitopes Uncovered by Expression of the MHC Class II Master Regulator CIITA. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 1364 | External stimuli-responsive nanomedicine for cancer immunotherapy. , 2021, , . | | 0 |
| 1365 | Applications of CRISPR-Cas System in Tumor Biology. Oncologie, 2021, 23, 463-492. | 0.2 | 1 |
| 1366 | A Minimalist Binary Vaccine Carrier for Personalized Postoperative Cancer Vaccine Therapy. Advanced Materials, 2022, 34, e2109254. | 11.1 | 44 |
| 1367 | Subclonal landscape of cancer drives resistance to immune therapy. Cancer Treatment and Research Communications, 2022, 30, 100507. | 0.7 | 8 |
| 1368 | Targets and Strategies for Cancer. Methods in Molecular Biology, 2022, 2435, 7-17. | 0.4 | 0 |
| 1369 | Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAFÂ®09b, in patients with metastatic melanoma. OncoImmunology, 2022, 11, 2023255. | 2.1 | 18 |
| 1370 | Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma. , 2022, 10, e002927. | | 14 |
| 1371 | Nanomaterials with changeable physicochemical property for boosting cancer immunotherapy. Journal of Controlled Release, 2022, 342, 210-227. | 4.8 | 16 |
| 1372 | Irradiation conditioning of adjuvanted, autologous cancer cell membrane nanoparticle vaccines. Chemical Engineering Journal, 2022, 433, 134437. | 6.6 | 9 |
| 1373 | Perspective on the Immunotherapy of Pancreatic Cancer. , 2021, , 257-270. | | 0 |
| 1374 | Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8+ T Cell Responses with Antitumor Activity. Journal of Immunology, 2022, 208, 929-940. | 0.4 | 11 |
| 1375 | Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies. Vaccines, 2022, 10, 196. | 2.1 | 12 |
| 1376 | Immunotherapeutic Strategies in Cancer and Atherosclerosisâ€"Two Sides of the Same Coin. Frontiers in Cardiovascular Medicine, 2021, 8, 812702. | 1.1 | 2 |
| 1377 | Bystander CD4<sup>+</sup> T cells infiltrate human tumors and are phenotypically distinct. OncoImmunology, 2022, 11, . | 2.1 | 13 |
| 1378 | Individually unique dynamics of cortical connectivity reflect the ongoing intensity of chronic pain. Pain, 2022, 163, 1987-1998. | 2.0 | 10 |
| 1379 | Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma. Cancers, 2022, 14, 271. | 1.7 | 18 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1380 | Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data. Seminars in Cancer Biology, 2022, 86, 799-815. | 4.3 | 28 |
| 1381 | Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons. World Journal of Gastrointestinal Oncology, 2022, 14, 163-180. | 0.8 | 12 |
| 1382 | Dynamic Cancer Cell Heterogeneity: Diagnostic and Therapeutic Implications. Cancers, 2022, 14, 280. | 1.7 | 12 |
| 1383 | Targeting the â€œundruggableâ€•RAS with biologics. Advances in Cancer Research, 2022, 153, 237-266. | 1.9 | 4 |
| 1384 | Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer. Journal of Ovarian Research, 2022, 15, 18. | 1.3 | 7 |
| 1385 | B Cell Function in the Tumor Microenvironment. Annual Review of Immunology, 2022, 40, 169-193. | 9.5 | 84 |
| 1386 | Neoantigen cancer vaccine augments anti-CTLA-4 efficacy. Npj Vaccines, 2022, 7, 15. | 2.9 | 17 |
| 1387 | Identification of neoantigens for individualized therapeutic cancer vaccines. Nature Reviews Drug Discovery, 2022, 21, 261-282. | 21.5 | 173 |
| 1388 | Mechanisms of immune activation and regulation: lessons from melanoma. Nature Reviews Cancer, 2022, 22, 195-207. | 12.8 | 101 |
| 1389 | Nanovaccines with cell-derived components for cancer immunotherapy. Advanced Drug Delivery Reviews, 2022, 182, 114107. | 6.6 | 41 |
| 1390 | Neoantigens and their potential applications in tumor immunotherapy (Review). Oncology Letters, 2022, 23, 88. | 0.8 | 10 |
| 1391 | Noninvasive Imaging of CD4+ T Cells in Humanized Mice. Molecular Cancer Therapeutics, 2022, 21, 658-666. | 1.9 | 3 |
| 1392 | Case Report: Pathological Complete Response in a Lung Metastasis of Phyllodes Tumor Patient Following Treatment Containing Peptide Neoantigen Nano-Vaccine. Frontiers in Oncology, 2022, 12, 800484. | 1.3 | 4 |
| 1393 | Adoptive cell therapies in thoracic malignancies. Cancer Immunology, Immunotherapy, 2022, 71, 2077-2098. | 2.0 | 4 |
| 1394 | Remodeling Tumorâ€Associated Neutrophils to Enhance Dendritic Cellâ€Based HCC Neoantigen Nanoâ€Vaccine Efficiency. Advanced Science, 2022, 9, e2105631. | 5.6 | 51 |
| 1395 | Development of antigenâ€prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse. Cancer Science, 2022, , . | 1.7 | 4 |
| 1396 | CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy. Human Vaccines and Immunotherapeutics, 2022, , 1-10. | 1.4 | 0 |
| 1397 | Cytotoxic CD4+ Tâcells in cancer: Expanding the immune effector toolbox. Immunity, 2021, 54, 2701-2711. | 6.6 | 170 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1398 | T cell receptor (TCR) signaling in health and disease. Signal Transduction and Targeted Therapy, 2021, 6, 412. | 7.1 | 127 |
| 1399 | A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nature Medicine, 2021, 27, 2212-2223. | 15.2 | 88 |
| 1400 | Adoptive T-cell Immunotherapy: Perfecting Self-Defenses. Experientia Supplementum (2012), 2022, 113, 253-294. | 0.5 | 1 |
| 1401 | Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. Experientia Supplementum (2012), 2022, 113, 295-350. | 0.5 | 3 |
| 1402 | Approaches to cancer vaccination. , 2022, , 177-199. | | 0 |
| 1403 | Personalized peptide vaccines. , 2022, , 175-191. | | 0 |
| 1404 | Tumor RNA transfected DCs derived from iPS cells elicit cytotoxicity against cancer cells induced from colorectal cancer patients in vitro. Scientific Reports, 2022, 12, 3295. | 1.6 | 7 |
| 1405 | Valid-NEO: A Multi-Omics Platform for Neoantigen Detection and Quantification from Limited Clinical Samples. Cancers, 2022, 14, 1243. | 1.7 | 3 |
| 1406 | Immunological Classification of Tumor Types and Advances in Precision Combination Immunotherapy. Frontiers in Immunology, 2022, 13, 790113. | 2.2 | 23 |
| 1407 | Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. Cell Research, 2022, 32, 530-542. | 5.7 | 54 |
| 1408 | TSAFinder: exhaustive tumor-specific antigen detection with RNAseq. Bioinformatics, 2022, 38, 2422-2427. | 1.8 | 3 |
| 1409 | Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978. | | 16 |
| 1410 | Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities. Current Cancer Drug Targets, 2022, 22, 437-453. | 0.8 | 2 |
| 1411 | An Immunological Perspective of Circulating Tumor Cells as Diagnostic Biomarkers and Therapeutic Targets. Life, 2022, 12, 323. | 1.1 | 4 |
| 1412 | Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy. International Journal of Molecular Sciences, 2022, 23, 2594. | 1.8 | 14 |
| 1413 | Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3KÎ³ inhibitor can enhance immunogenicity and eradicate tumors. , 2022, 10, e003564. | | 6 |
| 1414 | Whatâ€™s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination. OncoImmunology, 2022, 11, 2038403. | 2.1 | 7 |
| 1415 | Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?. International Journal of Molecular Sciences, 2022, 23, 2022. | 1.8 | 13 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 1417 | Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report. Frontiers in Immunology, 2022, 13, 799026. | 2.2 | 4 |
| 1418 | Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens. , 2022, 10, e003572. | | 9 |
| 1419 | A transformer-based model to predict peptideâ€"HLA class I binding and optimize mutated peptides for vaccine design. Nature Machine Intelligence, 2022, 4, 300-311. | 8.3 | 55 |
| 1420 | Strategies for Manipulating T Cells in Cancer Immunotherapy. Biomolecules and Therapeutics, 2022, , . | 1.1 | 0 |
| 1421 | The Interplay between Tumour Microenvironment Components in Malignant Melanoma. Medicina (Lithuania), 2022, 58, 365. | 0.8 | 8 |
| 1422 | The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma. Biomedicines, 2022, 10, 822. | 1.4 | 18 |
| 1423 | Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation. Frontiers in Oncology, 2022, 12, 836821. | 1.3 | 20 |
| 1424 | Messenger RNA vaccines for cancer immunotherapy: progress promotes promise. Journal of Clinical Investigation, 2022, 132, . | 3.9 | 27 |
| 1425 | A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nature Immunology, 2022, 23, 660-670. | 7.0 | 191 |
| 1426 | Emerging Strategies in TCR-Engineered T Cells. Frontiers in Immunology, 2022, 13, 850358. | 2.2 | 20 |
| 1427 | NeoScore Integrates Characteristics of the Neoantigen:MHC Class I Interaction and Expression to Accurately Prioritize Immunogenic Neoantigens. Journal of Immunology, 2022, 208, 1813-1827. | 0.4 | 4 |
| 1429 | Generation of Tumor-Specific Cytotoxic T Cells From Blood via InÂVitro Expansion Using Autologous Dendritic Cells Pulsed With Neoantigen-Coupled Microbeads. Frontiers in Oncology, 2022, 12, 866763. | 1.3 | 2 |
| 1430 | Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2022, 11, 1855. | 1.0 | 11 |
| 1431 | Proposed Models for Prediction of Mortality in Stage-I and Stage-II Gastric Cancer and 5â€‰Years after Radical Gastrectomy. Journal of Oncology, 2022, 2022, 1-14. | 0.6 | 7 |
| 1432 | Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment. Journal of Immunology Research, 2022, 2022, 1-9. | 0.9 | 20 |
| 1433 | Hallmarks of Resistance to Immune-Checkpoint Inhibitors. Cancer Immunology Research, 2022, 10, 372-383. | 1.6 | 36 |
| 1434 | A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets. Frontiers in Oncology, 2022, 12, 786438. | 1.3 | 6 |
| 1435 | Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer. , 2022, 10, e003821. | | 12 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1436 | Development of Peptide-Based Vaccines for Cancer. Journal of Oncology, 2022, 2022, 1-17. | 0.6 | 32 |
| 1437 | Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy. Journal of Oncology, 2022, 2022, 1-13. | 0.6 | 13 |
| 1438 | The Development of Chiral Nanoparticles to Target NK Cells and CD8$^+$ T Cells for Cancer Immunotherapy. Advanced Materials, 2022, 34, e2109354. | 11.1 | 41 |
| 1439 | Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity. Nature Cancer, 2022, 3, 437-452. | 5.7 | 19 |
| 1440 | Chasing neoantigens; invite naïve T cells to the party. Current Opinion in Immunology, 2022, 75, 102172. | 2.4 | 3 |
| 1441 | Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens. Nature Biotechnology, 2022, 40, 1276-1284. | 9.4 | 25 |
| 1443 | Physical and chemical advances of synthetic delivery vehicles to enhance mRNA vaccine efficacy. Journal of Controlled Release, 2022, 345, 405-416. | 4.8 | 5 |
| 1444 | The current clinical landscape of personalized cancer vaccines. Cancer Treatment Reviews, 2022, 106, 102383. | 3.4 | 25 |
| 1445 | A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA. Journal of Controlled Release, 2022, 345, 354-370. | 4.8 | 14 |
| 1446 | Patients with chronic pain exhibit individually unique cortical signatures of pain encoding. Human Brain Mapping, 2022, 43, 1676-1693. | 1.9 | 27 |
| 1448 | Fast DNA Vaccination Strategy Elicits a Stronger Immune Response Dependent on CD8+CD11c+ Cell Accumulation. Frontiers in Oncology, 2021, 11, 752444. | 1.3 | 2 |
| 1449 | Targeting Cross-Presentation as a Route to Improve the Efficiency of Peptide-Based Cancer Vaccines. Cancers, 2021, 13, 6189. | 1.7 | 9 |
| 1450 | Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer. Frontiers in Immunology, 2021, 12, 689076. | 2.2 | 21 |
| 1451 | Focus on organoids: cooperation and interconnection with extracellular vesicles â€" Is this the future of in vitro modeling?. Seminars in Cancer Biology, 2022, 86, 367-381. | 4.3 | 5 |
| 1452 | Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines. Methods in Molecular Biology, 2022, 2410, 649-670. | 0.4 | 11 |
| 1453 | Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy. Expert Review of Vaccines, 2022, 21, 173-184. | 2.0 | 17 |
| 1455 | Emerging immunological strategies: recent advances and future directions. Frontiers of Medicine, 2021, 15, 805-828. | 1.5 | 5 |
| 1456 | Immunotherapies and their moderation. , 2022, , 461-502. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------| 
| 1457 | Designing Personalized Antigen-Specific Immunotherapies for Autoimmune Diseasesâ€"The Case for Using Ignored Target Cell Antigen Determinants. Cells, 2022, 11, 1081. | 1.8 | 3 |
| 1458 | Altering Landscape of Cancer Vaccines: Unique Platforms, Research on Therapeutic Applications and Recent Patents. Recent Patents on Anti-Cancer Drug Discovery, 2023, 18, 133-146. | 0.8 | 1 |
| 1459 | Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma. Journal of Nanobiotechnology, 2022, 20, 190. | 4.2 | 25 |
| 1460 | Report of the First International Symposium on NUT Carcinoma. Clinical Cancer Research, 2022, 28, 2493-2505. | 3.2 | 23 |
| 1461 | Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter. Frontiers in Oncology, 2022, 12, 880876. | 1.3 | 21 |
| 1462 | Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma. Frontiers in Molecular Biosciences, 2022, 9, 777775. | 1.6 | 3 |
| 1463 | DNA Engineered Lymphocyte-Based Homologous Targeting Artificial Antigen-Presenting Cells for Personalized Cancer Immunotherapy. Journal of the American Chemical Society, 2022, 144, 7634-7645. | 6.6 | 21 |
| 1464 | Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers. Pharmaceutics, 2022, 14, 867. | 2.0 | 9 |
| 1465 | Neoantigen-specific CD4+ TÂcells in human melanoma have diverse differentiation states and correlate with CD8+ TÂcell, macrophage, and B cell function. Cancer Cell, 2022, 40, 393-409.e9. | 7.7 | 59 |
| 1466 | Reinvigorating therapeutic cancer vaccines. Current Opinion in Immunology, 2022, 76, 102176. | 2.4 | 3 |
| 1547 | Clinical wholeâ€genome sequencing in cancer diagnosis. Human Mutation, 2022, 43, 1519-1530. | 1.1 | 8 |
| 1548 | Deep Tumor Penetrating Gold Nanoâ€Adjuvant for NIRâ€IIâ€Triggered In Situ Tumor Vaccination. Small, 2022, 18, e2200993. | 5.2 | 18 |
| 1549 | Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer. Human Vaccines and Immunotherapeutics, 2022, 18, 1-11. | 1.4 | 9 |
| 1550 | Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer. Disease Markers, 2022, 2022, 1-11. | 0.6 | 16 |
| 1551 | Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8+ T cells for cancer immunotherapy. Molecular Cancer, 2022, 21, 102. | 7.9 | 12 |
| 1552 | Heterogeneity of the tumor immune microenvironment and its clinical relevance. Experimental Hematology and Oncology, 2022, 11, 24. | 2.0 | 40 |
| 1555 | Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study. Clinical Cancer Research, 2022, 28, 2818-2829. | 3.2 | 12 |
| 1556 | Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma. Cancer Immunology Research, 2022, 10, 728-744. | 1.6 | 27 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1557 | Multiple-Allele MHC Class II Epitope Engineering by a Molecular Dynamics-Based Evolution Protocol. Frontiers in Immunology, 2022, 13, 862851. | 2.2 | 7 |
| 1558 | HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients. Cancers, 2022, 14, 2260. | 1.7 | 5 |
| 1559 | Physicochemical Heuristics for Identifying High Fidelity, Near-Native Structural Models of Peptide/MHC Complexes. Frontiers in Immunology, 2022, 13, 887759. | 2.2 | 4 |
| 1560 | NeoSplice: a bioinformatics method for prediction of splice variant neoantigens. Bioinformatics Advances, 2022, 2, . | 0.9 | 13 |
| 1561 | Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature, 2022, 605, 532-538. | 13.7 | 70 |
| 1562 | T Cell Epitope Discovery in the Context of Distinct and Unique Indigenous HLA Profiles. Frontiers in Immunology, 2022, 13, . | 2.2 | 4 |
| 1564 | Multiaspect Examinations of Possible Alternative Mappings of Identified Variant Peptides: A Case Study on the HEK293 Cell Line. ACS Omega, 0, , . | 1.6 | 1 |
| 1565 | PANDORA: A Fast, Anchor-Restrained Modelling Protocol for Peptide: MHC Complexes. Frontiers in Immunology, 2022, 13, . | 2.2 | 14 |
| 1566 | CAD v1.0: Cancer Antigens Database Platform for Cancer Antigen Algorithm Development and Information Exploration. Frontiers in Bioengineering and Biotechnology, 2022, 10, . | 2.0 | 2 |
| 1567 | Comprehensive Analysis of the Potential Immune-Related Biomarker ATG101 that Regulates Apoptosis of Cholangiocarcinoma Cells After Photodynamic Therapy. Frontiers in Pharmacology, 2022, 13, 857774. | 1.6 | 1 |
| 1568 | Neoantigens â€" the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders. Blood Reviews, 2022, 56, 100969. | 2.8 | 2 |
| 1569 | The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines. Cancer Treatment Reviews, 2022, 107, 102405. | 3.4 | 28 |
| 1570 | Considerations for personalized neoantigen vaccination in Malignant glioma. Advanced Drug Delivery Reviews, 2022, 186, 114312. | 6.6 | 13 |
| 1571 | Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance. Journal of Controlled Release, 2022, 347, 175-182. | 4.8 | 22 |
| 1572 | The dynamics of an immunotherapy duo. Nature Cancer, 2022, 3, 376-378. | 5.7 | 2 |
| 1573 | Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 730-737. | 1.8 | 1 |
| 1574 | Identification of shared neoantigens in esophageal carcinoma by the combination of comprehensive analysis of genomic data and in silico neoantigen prediction. Cellular Immunology, 2022, 377, 104537. | 1.4 | 1 |
| 1575 | Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity. Frontiers in Oncology, 2022, 12, . | 1.3 | 4 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1576 | Cancer vaccines: past, present and future; a review article. Discover Oncology, 2022, 13, 31. | 0.8 | 24 |
| 1577 | The role of biomarkers in personalized immunotherapy. Biomarker Research, 2022, 10, 32. | 2.8 | 27 |
| 1578 | Function and therapeutic development of exosomes for cancer therapy. Archives of Pharmacal Research, 2022, 45, 295-308. | 2.7 | 15 |
| 1579 | Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics. Vaccines, 2022, 10, 816. | 2.1 | 7 |
| 1580 | Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials. , 2022, 10, e004345. | | 15 |
| 1581 | Double Trouble: Immunotherapy Doublets in Melanomaâ€"Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 745-766. | 1.8 | 6 |
| 1582 | mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduction and Targeted Therapy, 2022, 7, . | 7.1 | 160 |
| 1585 | Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy. , 2022, 10, e003960. | | 22 |
| 1586 | Recent Progress on Therapeutic Vaccines for Breast Cancer. Frontiers in Oncology, 0, 12, . | 1.3 | 6 |
| 1587 | Targeted therapies in nonâ€small cell lung cancer and the potential role of AI interventions in cancer treatment. Biotechnology and Applied Biochemistry, 2023, 70, 344-356. | 1.4 | 3 |
| 1588 | Progress in the Treatment of Advanced Melanoma. Advances in Clinical Medicine, 2022, 12, 5256-5262. | 0.0 | 0 |
| 1590 | Low-Dose JAK3 Inhibition Improves Antitumor T-Cell Immunity and Immunotherapy Efficacy. Molecular Cancer Therapeutics, 2022, 21, 1393-1405. | 1.9 | 3 |
| 1591 | Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, . | 3.3 | 15 |
| 1592 | Vaccines for immunoprevention of DNA mismatch repair deficient cancers. , 2022, 10, e004416. | | 21 |
| 1593 | A Highly Effective System for Predicting MHC-II Epitopes With Immunogenicity. Frontiers in Oncology, 0, 12, . | 1.3 | 5 |
| 1594 | Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nature Reviews Drug Discovery, 2022, 21, 529-540. | 21.5 | 134 |
| 1595 | A Potent Micron Neoantigen Tumor Vaccine GPâ€Neoantigen Induces Robust Antitumor Activity in Multiple Tumor Models. Advanced Science, 2022, 9, . | 5.6 | 17 |
| 1596 | | | |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1597 | A Therapeutic Whole-Tumor-Cell Vaccine Covalently Conjugated with a TLR7 Agonist. Cells, 2022, 11, 1986. | 1.8 | 8 |
| 1598 | Personalized Neoantigen Vaccine Against Cancer. , 2022, 1, 96-100. | | 1 |
| 1599 | Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptorâ€"Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors. Cancer Immunology Research, 2022, 10, 932-946. | 1.6 | 52 |
| 1600 | A Novel Proteogenomic Integration Strategy Expands the Breadth of Neo-Epitope Sources. Cancers, 2022, 14, 3016. | 1.7 | 3 |
| 1601 | Tumour burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy. European Journal of Cancer, 2022, 171, 96-105. | 1.3 | 3 |
| 1602 | Bioinspired nano-vaccine construction by antigen pre-degradation for boosting cancer personalized immunotherapy. Biomaterials, 2022, 287, 121628. | 5.7 | 13 |
| 1603 | Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials. Cancer Treatment Reviews, 2022, 109, 102429. | 3.4 | 30 |
| 1605 | Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nature Cancer, 2022, 3, 665-680. | 5.7 | 18 |
| 1606 | Facts and Hopes in the Relationship of EBV with Cancer Immunity and Immunotherapy. Clinical Cancer Research, 2022, 28, 4363-4369. | 3.2 | 3 |
| 1607 | Current Advancements in Antitumor Properties and Mechanisms of Medicinal Components in Edible Mushrooms. Nutrients, 2022, 14, 2622. | 1.7 | 9 |
| 1608 | Enhancement of tumor immunogenicity by the introduction of non- proteinogenic amino acid azetidine-2-carboxylic acid. OncoImmunology, 2022, 11, . | 2.1 | 0 |
| 1609 | GM-CSF: A Double-Edged Sword in Cancer Immunotherapy. Frontiers in Immunology, 0, 13, . | 2.2 | 61 |
| 1610 | Therapeutic Cancer Vaccinesâ€"Antigen Discovery and Adjuvant Delivery Platforms. Pharmaceutics, 2022, 14, 1448. | 2.0 | 6 |
| 1611 | Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins. , 2022, 10, e004159. | | 5 |
| 1612 | NAIRscore as a biomarker for the quality of immune response to neoantigens is related with an increased overall survival in multiple myeloma. Molecular Therapy - Nucleic Acids, 2022, 29, 285-295. | 2.3 | 5 |
| 1614 | In Situ Antigenâ€Capturing Nanochaperone Toward Personalized Nanovaccine for Cancer Immunotherapy. Small, 2022, 18, . | 5.2 | 15 |
| 1615 | Neoantigens and NK Cells: â€œTrick or Treatâ€•the Cancers?. Frontiers in Immunology, 0, 13, . | 2.2 | 4 |
| 1616 | Cancer vaccines: Building a bridge over troubled waters. Cell, 2022, 185, 2770-2788. | 13.5 | 82 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1617 | <scp>mRNA</scp> vaccines: a transformative technology with applications beyond <scp>COVID</scp> â€‘19. Medical Journal of Australia, 2022, 217, 71-75. | 0.8 | 2 |
| 1618 | Imaging-guided/improved diseases management for immune-strategies and beyond. Advanced Drug Delivery Reviews, 2022, 188, 114446. | 6.6 | 8 |
| 1619 | LCOR Reverses Immune-Checkpoint Inhibitors Therapy Resistance Out of IFN Constraint in Triple-Negative Breast Cancer. Frontiers in Oncology, 0, 12, . | 1.3 | 0 |
| 1620 | Machine Learning Approaches to TCR Repertoire Analysis. Frontiers in Immunology, 0, 13, . | 2.2 | 8 |
| 1621 | Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. Clinical Cancer Research, 2022, 28, 5013-5020. | 3.2 | 8 |
| 1622 | Neoantigens in precision cancer immunotherapy: from identification to clinical applications. Chinese Medical Journal, 2022, 135, 1285-1298. | 0.9 | 12 |
| 1623 | A high-throughput yeast display approach to profile pathogen proteomes for MHC-II binding. ELife, 0, 11, . | 2.8 | 12 |
| 1624 | Prioritizing Candidate Peptides for Cancer Vaccines Through Predicting Peptide Presentation by HLA-I Proteins. Biometrics, 2023, 79, 2664-2676. | 0.8 | 3 |
| 1625 | Trends in the Development of Digital Technologies in Medicine. Bio-Medical Engineering, 2022, 56, 137-141. | 0.3 | 2 |
| 1626 | Cancer Immunotherapy â€“ The Target is Precisely on The Cancer and Also Not. Annals of the Academy of Medicine, Singapore, 2018, 47, 381-387. | 0.2 | 10 |
| 1627 | Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer. Pharmaceutics, 2022, 14, 1515. | 2.0 | 5 |
| 1628 | Nanocarriers based on bacterial membrane materials for cancer vaccine delivery. Nature Protocols, 2022, 17, 2240-2274. | 5.5 | 42 |
| 1629 | Geospatial Immune Heterogeneity Reflects the Diverse Tumorâ€“Immune Interactions in Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2022, 12, 2350-2371. | 7.7 | 28 |
| 1630 | Immune Checkpoint Inhibitors in Cancer Therapyâ€”How to Overcome Drug Resistance?. Cancers, 2022, 14, 3575. | 1.7 | 18 |
| 1632 | Across-Cancer Immune Responses Induced by Nanovaccines or Microvaccines to PreventÂDifferent Cancers and Cancer Metastasis. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 1633 | Boosting Antitumor Immunity with an Expanded Neoepitope Landscape. Cancer Research, 2022, 82, 3637-3649. | 0.4 | 4 |
| 1634 | Nanomedicine approaches for treatment of hematologic and oncologic malignancies. World Journal of Clinical Oncology, 2022, 13, 553-566. | 0.9 | 2 |
| 1635 | Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune System. Biomedicines, 2022, 10, 1842. | 1.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1636 | Multiepitope supramolecular peptide nanofibers eliciting coordinated humoral and cellular antitumor immune responses. Science Advances, 2022, 8, . | 4.7 | 10 |
| 1637 | Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC. Cancer Cell, 2022, , . | 7.7 | 2 |
| 1638 | Prediction of peptide mass spectral libraries with machine learning. Nature Biotechnology, 2023, 41, 33-43. | 9.4 | 31 |
| 1639 | Recent Advances and Challenges in Cancer Immunotherapy. Cancers, 2022, 14, 3972. | 1.7 | 26 |
| 1640 | Bias and inconsistency in the estimation of tumour mutation burden. BMC Cancer, 2022, 22, . | 1.1 | 8 |
| 1642 | A synthetic DNA template for fast manufacturing of versatile single epitope mRNA. Molecular Therapy - Nucleic Acids, 2022, 29, 943-954. | 2.3 | 8 |
| 1643 | Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes and Diseases, 2023, 10, 1318-1350. | 1.5 | 11 |
| 1644 | Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nature Medicine, 2022, 28, 1619-1629. | 15.2 | 56 |
| 1645 | mRNA vaccines in the prevention and treatment of diseases. MedComm, 2022, 3, . | 3.1 | 14 |
| 1647 | Cancer vaccines: the next immunotherapy frontier. Nature Cancer, 2022, 3, 911-926. | 5.7 | 207 |
| 1648 | Biomineralized hydrogel DC vaccine for cancer immunotherapy: A boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironment. Biomaterials, 2022, 288, 121722. | 5.7 | 20 |
| 1649 | Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, . | 3.3 | 20 |
| 1650 | Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities. Immunological Investigations, 2022, 51, 2133-2158. | 1.0 | 20 |
| 1651 | Next Steps for Immunotherapy in Glioblastoma. Cancers, 2022, 14, 4023. | 1.7 | 9 |
| 1652 | Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell, 2022, 40, 1010-1026.e11. | 7.7 | 47 |
| 1653 | Neoantigenâ€based cancer vaccination using chimeric RNAâ€loaded dendritic cellâ€derived extracellular vesicles. Journal of Extracellular Vesicles, 2022, 11, . | 5.5 | 18 |
| 1654 | Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 420-429. | 0.6 | 9 |
| 1655 | Immunotherapeutic Strategies for Head and Neck Squamous Cell Carcinoma (HNSCC): Current Perspectives and Future Prospects. Vaccines, 2022, 10, 1272. | 2.1 | 2 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 1656 | Flagellated bacterial porter for in situ tumor vaccine. Microbial Cell, 2022, 9, 158-161. | 1.4 | 1 |
| 1659 | Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma. , 2022, 10, e005328. | | 6 |
| 1660 | Suppression of high mobility group box 1 in <scp>B16F10</scp> tumor does not inhibit the induction of neoantigenâ€specific T cells. Cancer Science, 0, , . | 1.7 | 1 |
| 1661 | Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system. Frontiers in Genetics, 0, 13, . | 1.1 | 4 |
| 1662 | Development of an exosome-related and immune microenvironment prognostic signature in colon adenocarcinoma. Frontiers in Genetics, 0, 13, . | 1.1 | 4 |
| 1663 | Harnessing gene fusion-derived neoantigens for â€˜coldâ€™Âbreast and prostate tumor immunotherapy. Immunotherapy, 2022, 14, 1165-1179. | 1.0 | 4 |
| 1664 | Research progress of neoantigens in gynecologic cancers. International Immunopharmacology, 2022, 112, 109236. | 1.7 | 5 |
| 1665 | Research Advances of Traditional Chinese Medicine in Cancer Immunotherapy. Chinese Medicine and Culture, 2020, 3, 245-253. | 0.2 | 5 |
| 1666 | Engineering neoantigen vaccines to improve cancer personalized immunotherapy. International Journal of Biological Sciences, 2022, 18, 5607-5623. | 2.6 | 15 |
| 1667 | Biomimetic Nanoparticles for DC Vaccination: A Top-Down Approach to Boost Cancer Immunotherapy. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 1668 | CD47KO/CRT Dual-Bioengineered Cell Membrane-Coated Nanovaccine Combined with Anti-PD-L1 Antibody for Boosting Tumor Immunotherapy. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 1669 | Research progress on classification, characteristics and mechanism of antitumor drugs. AIP Conference Proceedings, 2022, , . | 0.3 | 1 |
| 1670 | Peptide therapeutics in the management of metastatic cancers. RSC Advances, 2022, 12, 21353-21373. | 1.7 | 7 |
| 1671 | Targeting Metastatic Disease: Challenges and New Opportunities. , 2022, , 51-68. | | 0 |
| 1672 | CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy. Bioactive Materials, 2023, 22, 211-224. | 8.6 | 9 |
| 1673 | The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy. Cancers, 2022, 14, 4255. | 1.7 | 3 |
| 1674 | CDK2AP1 influences immune infiltrates and serves as a prognostic indicator for hepatocellular carcinoma. Frontiers in Genetics, 0, 13, . | 1.1 | 2 |
| 1675 | Neoantigen vaccine and neoantigenâ€specific cell adoptive transfer therapy in solid tumors: Challenges and future directions. , 2022, 1, 168-182. | | 1 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1676 | Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. Journal of Hematology and Oncology, 2022, 15, . | 6.9 | 42 |
| 1677 | Comparative Transcriptomic Analyses Revealed the Effects of Poly (I:C) on the Liver and Spleen of Argyrosomus japonicus. International Journal of Molecular Sciences, 2022, 23, 9801. | 1.8 | 4 |
| 1678 | Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduction and Targeted Therapy, 2022, 7, . | 7.1 | 97 |
| 1679 | Personalized neoantigen vaccine combined with PD-1 blockade increases CD8$^+$ tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models. , 2022, 10, e004389. | | 12 |
| 1680 | Dithranol as novel co-adjuvant for non-invasive dermal vaccination. Npj Vaccines, 2022, 7, . | 2.9 | 3 |
| 1681 | KEYNOTE â€" D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma. Future Oncology, 0, , . | 1.1 | 7 |
| 1682 | Identification of neoantigens in oesophageal adenocarcinoma. Immunology, 2023, 168, 420-431. | 2.0 | 6 |
| 1683 | Sources of Cancer Neoantigens beyond Single-Nucleotide Variants. International Journal of Molecular Sciences, 2022, 23, 10131. | 1.8 | 16 |
| 1684 | Application of dendritic cells in tumor immunotherapy and progress in the mechanism of anti-tumor effect of Astragalus polysaccharide (APS) modulating dendritic cells: a review. Biomedicine and Pharmacotherapy, 2022, 155, 113541. | 2.5 | 19 |
| 1685 | High-Throughput, Quantitative Analysis of Peptide-Exchanged MHCI Complexes by Native Mass Spectrometry. Analytical Chemistry, 2022, 94, 14593-14602. | 3.2 | 4 |
| 1687 | Current therapeutic options for glioblastoma and future perspectives. Expert Opinion on Pharmacotherapy, 2022, 23, 1629-1640. | 0.9 | 5 |
| 1688 | Identification of tumor antigens and immune subtypes in lung squamous cell carcinoma for mRNA vaccine development. Journal of Thoracic Disease, 2022, 14, 3517-3530. | 0.6 | 4 |
| 1689 | Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy. Frontiers in Immunology, 0, 13, . | 2.2 | 8 |
| 1690 | Efficient Tumor Immunotherapy through a Single Injection of Injectable Antigen/Adjuvant-Loaded Macroporous Silk Fibroin Microspheres. ACS Applied Materials &amp; Interfaces, 2022, 14, 42950-42962. | 4.0 | 6 |
| 1691 | Bacterial outer membrane vesicle-based cancer nanovaccines. Cancer Biology and Medicine, 2022, 19, 1290-1300. | 1.4 | 14 |
| 1692 | Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients. OncoImmunology, 2022, 11, . | 2.1 | 1 |
| 1693 | Tumor antigens and vaccines in colorectal cancer. Medicine in Drug Discovery, 2022, 16, 100144. | 2.3 | 1 |
| 1694 | Personalized Cancer Vaccines Targeting Neoantigens. , 2022, , 1-21. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1695 | A dual-adjuvant neoantigen nanovaccine loaded with imiquimod and magnesium enhances anti-tumor immune responses of melanoma. Biomaterials Science, 2022, 10, 6740-6748. | 2.6 | 5 |
| 1696 | Simultaneous Identification of Functional Antigen-Specific CD8+ and CD4+ Cells after In Vitro Expansion Using Elongated Peptides. Cells, 2022, 11, 3451. | 1.8 | 2 |
| 1697 | Comparison of Ridostin Pro and Poly(I:C) as adjuvant for a cancer neoantigen peptide vaccine. , 2022, 21, 82-89. | 0.3 | 0 |
| 1698 | Neoantigen Vaccines; Clinical Trials, Classes, Indications, Adjuvants and Combinatorial Treatments. Cancers, 2022, 14, 5163. | 1.7 | 15 |
| 1699 | Update on immune checkpoint therapy for melanoma. Dermatological Reviews, 0, , . | 0.3 | 0 |
| 1700 | A Novel Engineered AAV-Based Neoantigen Vaccine in Combination with Radiotherapy Eradicates Tumors. Cancer Immunology Research, 2023, 11, 123-136. | 1.6 | 5 |
| 1701 | Subcellular location of source proteins improves prediction of neoantigens for immunotherapy. EMBO Journal, 2022, 41, . | 3.5 | 2 |
| 1702 | Mannose and Hyaluronic Acid Dual-Modified Iron Oxide Enhances Neoantigen-Based Peptide Vaccine Therapy by Polarizing Tumor-Associated Macrophages. Cancers, 2022, 14, 5107. | 1.7 | 6 |
| 1704 | Cancer-specific T helper shared and neo-epitopes uncovered by expression of the MHC class II master regulator CIITA. Cell Reports, 2022, 41, 111485. | 2.9 | 5 |
| 1706 | Clinical cancer immunotherapy: Current progress and prospects. Frontiers in Immunology, 0, 13, . | 2.2 | 39 |
| 1707 | Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions. , 2022, 10, e005016. | | 9 |
| 1708 | Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant. Npj Vaccines, 2022, 7, . | 2.9 | 6 |
| 1709 | Clinical and Translational Advances in Glioma Immunotherapy. Neurotherapeutics, 2022, 19, 1799-1817. | 2.1 | 14 |
| 1710 | A Novel Identified Necroptosis-Related Risk Signature for Prognosis Prediction and Immune Infiltration Indication in Acute Myeloid Leukemia Patients. Genes, 2022, 13, 1837. | 1.0 | 5 |
| 1711 | Changes in the Immune Cell Repertoire for the Treatment of Malignant Melanoma. International Journal of Molecular Sciences, 2022, 23, 12991. | 1.8 | 3 |
| 1712 | Construction of the prognostic signature of alternative splicing revealed the prognostic predictor and immune microenvironment in head and neck squamous cell carcinoma. Frontiers in Genetics, 0, 13, . | 1.1 | 1 |
| 1714 | The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nature Communications, 2022, 13, . | 5.8 | 15 |
| 1715 | Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy. Cancer Cell, 2022, 40, 1173-1189.e6. | 7.7 | 10 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1716 | Mining the Immunopeptidome for Antigenic Peptides in Cancer. Cancers, 2022, 14, 4968. | 1.7 | 8 |
| 1717 | A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2Âand GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. European Journal of Cancer, 2022, 176, 155-163. | 1.3 | 4 |
| 1718 | Cancer stem cell antigen nanodisc cocktail elicits anti-tumor immune responses in melanoma. Journal of Controlled Release, 2022, 351, 872-882. | 4.8 | 7 |
| 1719 | Sulfonium-Driven Neoantigen-Released DNA Nanodevice as a Precise Vaccine for Tumor Immunotherapy and Prevention. ACS Nano, 2022, 16, 19509-19522. | 7.3 | 11 |
| 1720 | The MHC Motif Atlas: a database of MHC binding specificities and ligands. Nucleic Acids Research, 2023, 51, D428-D437. | 6.5 | 12 |
| 1721 | Human T lymphocytes at tumor sites. Seminars in Immunopathology, 2022, 44, 883-901. | 2.8 | 10 |
| 1723 | Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic. Clinical Cancer Research, 2023, 29, 843-857. | 3.2 | 4 |
| 1724 | Across-cancer specific immune responses induced by nanovaccines or microvaccines to prevent different cancers and cancer metastasis. IScience, 2022, 25, 105511. | 1.9 | 2 |
| 1725 | Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy. Frontiers in Immunology, 0, 13, . | 2.2 | 2 |
| 1726 | Non-viral precision Tâ€‰cell receptor replacement for personalized cell therapy. Nature, 2023, 615, 687-696. | 13.7 | 85 |
| 1727 | Characterization of genomic alterations and neoantigens and analysis of immune infiltration identified therapeutic and prognostic biomarkers in adenocarcinoma at the gastroesophageal junction. Frontiers in Oncology, 0, 12, . | 1.3 | 1 |
| 1728 | Dual-Responsive Glycopolymers for Intracellular Codelivery of Antigen and Lipophilic Adjuvants. Molecular Pharmaceutics, 2022, 19, 4705-4716. | 2.3 | 2 |
| 1729 | Adjuvant Treatment for Breast Cancer Patients Using Individualized Neoantigen Peptide Vaccinationâ€"A Retrospective Observation. Vaccines, 2022, 10, 1882. | 2.1 | 1 |
| 1732 | Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with Highâ€‹Risk Gastric/Gastroesophageal Junction Cancer. Advanced Science, 2023, 10, . | 5.6 | 6 |
| 1733 | Engineering Energyâ€‹Responsive Magnetic Nanomaterials to Improve the Efficacy of Dendritic Cellâ€‹Based Immunotherapy. Advanced Therapeutics, 2023, 6, . | 1.6 | 0 |
| 1734 | Challenges in neoantigen-directed therapeutics. Cancer Cell, 2023, 41, 15-40. | 7.7 | 27 |
| 1735 | Neoepitopes prediction strategies: an integration of cancer genomics and immunoinformatics approaches. Briefings in Functional Genomics, 0, , . | 1.3 | 1 |
| 1736 | Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies. Journal of Controlled Release, 2023, 353, 423-433. | 4.8 | 23 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1737 | Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines. Chemical Engineering Journal, 2023, 456, 140930. | 6.6 | 14 |
| 1738 | Neoantigen personalized vaccine plus anti-PD-1 antibody in cancer patients. Annals of Translational Medicine, 2022, . | 0.7 | 0 |
| 1739 | Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. , 2023, 20, 51-64. | | 13 |
| 1740 | Modern aspects of immunotherapy with checkpoint inhibitors in melanoma. Medical Alphabet, 2022, , 35-40. | 0.0 | 2 |
| 1741 | Comprehensive analysis of the expression, prognostic significance, and regulation pathway of G2E3 in breast cancer. World Journal of Surgical Oncology, 2022, 20, . | 0.8 | 1 |
| 1742 | Machine Learning for Lung Cancer Diagnosis, Treatment, and Prognosis. Genomics, Proteomics and Bioinformatics, 2022, 20, 850-866. | 3.0 | 25 |
| 1744 | CD8+ T cell exhaustion and cancer immunotherapy. Cancer Letters, 2023, 559, 216043. | 3.2 | 18 |
| 1745 | Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer. Frontiers in Immunology, 0, 13, . | 2.2 | 6 |
| 1746 | Initial characterization of immune microenvironment in pheochromocytoma and paraganglioma. Frontiers in Genetics, 0, 13, . | 1.1 | 2 |
| 1747 | Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer. Frontiers in Immunology, 0, 13, . | 2.2 | 5 |
| 1748 | Cancer Immunotherapy Beyond Checkpoint Blockade. JACC: CardioOncology, 2022, 4, 563-578. | 1.7 | 1 |
| 1749 | Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises. Exploration of Targeted Anti-tumor Therapy, 0, , 746-762. | 0.5 | 0 |
| 1750 | Pan-Cancer Landscape of NEIL3 in Tumor Microenvironment: A Promising Predictor for Chemotherapy and Immunotherapy. Cancers, 2023, 15, 109. | 1.7 | 0 |
| 1751 | What do cancer-specific T cells â€˜seeâ€™?. , 2023, 2, . | | 1 |
| 1752 | Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution. Genome Medicine, 2022, 14, . | 3.6 | 15 |
| 1753 | Advanced Nanomedicine for High-Risk HPV-Driven Head and Neck Cancer. Viruses, 2022, 14, 2824. | 1.5 | 3 |
| 1754 | Pathogenesis to management of hepatocellular carcinoma. Genes and Cancer, 2022, 13, 72-87. | 0.6 | 2 |
| 1755 | Technological aspects of creating neopeptide vaccines. , 2022, 21, 10-21. | 0.3 | 1 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1756 | Current status and challenges of immunotherapy in ALK rearranged NSCLC. Frontiers in Oncology, 0, 12, . | 1.3 | 0 |
| 1758 | Immunotherapies targeting neoantigens are effective in <scp>PD</scp>â€‘1 blockadeâ€‘resistant tumors. International Journal of Cancer, 2023, 152, 1463-1475. | 2.3 | 2 |
| 1760 | Regression in cutaneous melanoma: histological assessment, immune mechanisms and clinical implications. Pathology, 2023, 55, 227-235. | 0.3 | 3 |
| 1761 | The Function of DNA and RNA Nanovaccines in the Treatment of Cancer. , 2023, , 229-252. | | 0 |
| 1762 | Cell membrane-camouflaged liposomes and neopeptide-loaded liposomes with TLR agonist R848 provides a prime and boost strategy for efficient personalized cancer vaccine therapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2023, 48, 102648. | 1.7 | 4 |
| 1763 | Development of therapeutic vaccines for the treatment of diseases. Molecular Biomedicine, 2022, 3, . | 1.7 | 11 |
| 1764 | Regulatory Landscapes in Approval of Cancer Vaccines. , 2022, , 325-347. | | 0 |
| 1765 | Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy. Expert Opinion on Drug Delivery, 2023, 20, 323-333. | 2.4 | 4 |
| 1766 | Identification of tumour antigens and immune subtypes in the development of an antiâ€‘cancer vaccine for endometrial carcinoma. Scandinavian Journal of Immunology, 0, , . | 1.3 | 0 |
| 1767 | Effective personalized neoantigen vaccine plus anti-PD-1 in a PD-1 blockade-resistant lung cancer patient. Immunotherapy, 0, , . | 1.0 | 2 |
| 1768 | Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy. Acta Biomaterialia, 2023, 158, 535-546. | 4.1 | 8 |
| 1769 | Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens. Nature Biotechnology, 2023, 41, 783-787. | 9.4 | 10 |
| 1770 | Advanced T and Natural Killer Cell Therapy for Glioblastoma. Journal of Korean Neurosurgical Society, 2023, 66, 356-381. | 0.5 | 0 |
| 1771 | The Future of Nanomedicine. Micro/Nano Technologies, 2023, , 847-873. | 0.1 | 0 |
| 1772 | Melanoma antigens recognized by T cells and their use for immunotherapy. Experimental Dermatology, 0, , . | 1.4 | 3 |
| 1773 | Nanoparticle drug delivery systems and their applications as targeted therapies for triple negative breast cancer. Progress in Materials Science, 2023, 134, 101070. | 16.0 | 31 |
| 1774 | Analysis of tumor-immune functional responses in a mathematical model of neoantigen cancer vaccines. Mathematical Biosciences, 2023, 356, 108966. | 0.9 | 3 |
| 1775 | Neoantigens: promising targets for cancer therapy. Signal Transduction and Targeted Therapy, 2023, 8, . | 7.1 | 112 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 1776 | A Universal Antigen-Ranking Method to Design Personalized Vaccines Targetting Neoantigens against Melanoma. Life, 2023, 13, 155. | 1.1 | 0 |
| 1777 | Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8+ T-cell epitopes. Cell Systems, 2023, 14, 72-83.e5. | 2.9 | 18 |
| 1778 | Wnt/β-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers. Biomedicines, 2023, 11, 190. | 1.4 | 9 |
| 1779 | MHC II immunogenicity shapes the neoepitope landscape in human tumors. Nature Genetics, 2023, 55, 221-231. | 9.4 | 5 |
| 1780 | Advancing our knowledge of antigen processing with computational modelling, structural biology, and immunology. Biochemical Society Transactions, 0, , . | 1.6 | 1 |
| 1781 | Deciphering the Clinical Trials of Immunotherapy in Glioblastoma: What a Neuroradiologist Needs to Know. Neurographics, 2022, 12, 176-187. | 0.0 | 1 |
| 1783 | Perspektiven der medikamentösen Tumortherapie. , 2022, , 335-357. |  | 0 |
| 1784 | Impact of Precision Medicine in Oncology. Cancer Journal (Sudbury, Mass ), 2023, 29, 15-19. | 1.0 | 1 |
| 1785 | mRNA—From COVID-19 Treatment to Cancer Immunotherapy. Biomedicines, 2023, 11, 308. | 1.4 | 3 |
| 1786 | Tumor immunology. , 2023, , 245-452. |  | 0 |
| 1787 | Cellular and Vaccine-Based Immunotherapy for Hematologic Malignancies. , 2023, , . |  | 0 |
| 1788 | Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines. Genes and Cancer, 2023, 14, 3-11. | 0.6 | 2 |
| 1789 | Decoupling peptide binding from T cell receptor recognition with engineered chimeric MHC-I molecules. Frontiers in Immunology, 0, 14, . | 2.2 | 3 |
| 1790 | Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor—Based Cellular Therapy. Annual Review of Cancer Biology, 2023, 7, . | 2.3 | 1 |
| 1792 | Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer. Frontiers in Immunology, 0, 14, . | 2.2 | 1 |
| 1793 | Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy. Current Opinion in Oncology, 2023, 35, 94-99. | 1.1 | 4 |
| 1794 | A Highly Sensitive Flow Cytometric Approach to Detect Rare Antigen-Specific T Cells: Development and Comparison to Standard Monitoring Tools. Cancers, 2023, 15, 574. | 1.7 | 0 |
| 1797 | The application of RNA sequencing in precision cancer medicine. , 2024, , 46-58. |  | 0 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1798 | Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy. Pharmaceutics, 2023, 15, 452. | 2.0 | 3 |
| 1799 | mRNA-Based Therapeutics in Cancer Treatment. Pharmaceutics, 2023, 15, 622. | 2.0 | 11 |
| 1800 | Carbon ion irradiation induces DNA damage in melanoma and optimizes the tumor microenvironment based on the cGAS–STING pathway. Journal of Cancer Research and Clinical Oncology, 2023, 149, 6315-6328. | 1.2 | 2 |
| 1801 | Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes. Immunity, 2023, 56, 1359-1375.e13. | 6.6 | 12 |
| 1802 | Circular RNAs as a potential source of neoepitopes in cancer. Frontiers in Oncology, 0, 13, . | 1.3 | 2 |
| 1803 | Strategy and application of manipulating DCs chemotaxis in disease treatment and vaccine design. Biomedicine and Pharmacotherapy, 2023, 161, 114457. | 2.5 | 3 |
| 1804 | Immunogenic cell death inducer peptides: A new approach for cancer therapy, current status and future perspectives. Biomedicine and Pharmacotherapy, 2023, 161, 114503. | 2.5 | 3 |
| 1805 | Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity. Biomaterials, 2023, 296, 122062. | 5.7 | 6 |
| 1806 | Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy. Bioactive Materials, 2023, 26, 169-180. | 8.6 | 3 |
| 1807 | Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches. Biomarker Research, 2023, 11, . | 2.8 | 2 |
| 1808 | Fluorescence labeling of anchor–modified Mart–1 peptide for increasing its affinity for HLA–A*0201: Hit two targets with one arrow. Journal of Peptide Science, 0, , . | 0.8 | 0 |
| 1809 | Multi-antigen spherical nucleic acid cancer vaccines. Nature Biomedical Engineering, 2023, 7, 911-927. | 11.6 | 19 |
| 1810 | Labyrinthin Expression Is Associated with Poor Prognosis in Patients with Non-Small-Cell Lung Cancer. Cancers, 2023, 15, 924. | 1.7 | 1 |
| 1811 | IFN-γ Signaling Sensitizes Melanoma Cells to BH3 Mimetics. Journal of Investigative Dermatology, 2023, 143, 1246-1256.e8. | 0.3 | 1 |
| 1812 | Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer. Science Immunology, 2023, 8, . | 5.6 | 27 |
| 1813 | Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3. Cancers, 2023, 15, 1031. | 1.7 | 0 |
| 1814 | Anti-Helicobacter pylori antibody status is associated with cancer mortality: A longitudinal analysis from the Japanese DAIKO prospective cohort study. PLOS Global Public Health, 2023, 3, e0001125. | 0.5 | 2 |
| 1815 | Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells. Cancer Immunology Research, 2023, 11, 450-465. | 1.6 | 2 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1816 | Designing neoantigen cancer vaccines, trials, and outcomes. Frontiers in Immunology, 0, 14, . | 2.2 | 12 |
| 1817 | Engineered Norovirus-Derived Nanoparticles as a Plug-and-Play Cancer Vaccine Platform. ACS Nano, 2023, 17, 3412-3429. | 7.3 | 8 |
| 1818 | The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma. Human Vaccines and Immunotherapeutics, 2023, 19, . | 1.4 | 4 |
| 1819 | Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer. Cancer Immunology, Immunotherapy, 2023, 72, 2045-2056. | 2.0 | 1 |
| 1820 | Altered HLA–A2–restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma. European Journal of Immunology, 0, , 2250054. | 1.6 | 2 |
| 1821 | Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention. Frontiers in Immunology, 0, 14, . | 2.2 | 1 |
| 1822 | Dynamic Covalent Dextran Hydrogels as Injectable, Self-Adjuvating Peptide Vaccine Depots. ACS Chemical Biology, 2023, 18, 652-659. | 1.6 | 4 |
| 1823 | Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies. Cancers, 2023, 15, 1297. | 1.7 | 4 |
| 1824 | In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer. Vaccine, 2023, 41, 2073-2083. | 1.7 | 7 |
| 1825 | Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines. Frontiers in Immunology, 0, 14, . | 2.2 | 1 |
| 1826 | Autologous-cancer-cryoablation-mediated nanovaccine augments systematic immunotherapy. Materials Horizons, 2023, 10, 1661-1677. | 6.4 | 9 |
| 1827 | Advanced Biomaterials with Intrinsic Immunomodulation Effects for Cancer Immunotherapy. Small Methods, 2023, 7, . | 4.6 | 3 |
| 1828 | Antigen discovery for the development of cancer immunotherapy. Seminars in Immunology, 2023, 66, 101733. | 2.7 | 9 |
| 1829 | Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines. Cancer Immunology, Immunotherapy, 2023, 72, 2113-2125. | 2.0 | 1 |
| 1830 | Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity. IScience, 2023, 26, 106288. | 1.9 | 0 |
| 1831 | Development of synthetic, self-adjuvanting, and self-assembling anticancer vaccines based on a minimal saponin adjuvant and the tumor-associated MUC1 antigen. Chemical Science, 2023, 14, 3501-3513. | 3.7 | 2 |
| 1832 | PGNneo: A Proteogenomics-Based Neoantigen Prediction Pipeline in Noncoding Regions. Cells, 2023, 12, 782. | 1.8 | 2 |
| 1833 | Vaccines as treatments for prostate cancer. Nature Reviews Urology, 2023, 20, 544-559. | 1.9 | 8 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1834 | Transgenic HA-1-Specific CD8+ T-Lymphocytes Selectively Target Leukemic Cells. Cancers, 2023, 15, 1592. | 1.7 | 0 |
| 1835 | Current Trends in Neoantigen-Based Cancer Vaccines. Pharmaceuticals, 2023, 16, 392. | 1.7 | 6 |
| 1836 | Pan-Peptide Meta Learning for T-cell receptor–antigen binding recognition. Nature Machine Intelligence, 2023, 5, 236-249. | 8.3 | 27 |
| 1837 | Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment. Frontiers in Pharmacology, 0, 14, . | 1.6 | 1 |
| 1838 | KIT A502_Y503 duplication mutation serves as a potential and universal target for neoantigen peptide in Chinese GIST patients. Journal of Gastroenterology and Hepatology (Australia), 2023, 38, 1123-1130. | 1.4 | 0 |
| 1840 | Treatment of Recurrent Melanoma Following Adjuvant Therapy. American Journal of Clinical Dermatology, 0, , . | 3.3 | 0 |
| 1841 | MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression. Frontiers in Immunology, 0, 14, . | 2.2 | 5 |
| 1843 | Development of a Cancer Nanovaccine to Induce Antigen-specific Immune Responses Based on Large-Sized Porous Silica Nanoparticles. ACS Applied Materials &amp; Interfaces, 0, , . | 4.0 | 2 |
| 1844 | Biomimetic nanoparticles for DC vaccination: a versatile approach to boost cancer immunotherapy. Nanoscale, 2023, 15, 6432-6455. | 2.8 | 5 |
| 1845 | Mesoporous nanodrug delivery system: a powerful tool for a new paradigm of remodeling of the tumor microenvironment. Journal of Nanobiotechnology, 2023, 21, . | 4.2 | 2 |
| 1846 | Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire. Cancer Immunology, Immunotherapy, 2023, 72, 2375-2392. | 2.0 | 2 |
| 1847 | Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies. Frontiers in Oncology, 0, 13, . | 1.3 | 5 |
| 1848 | A Therapeutic Vaccine Targeting Rat BORIS (CTCFL) for the Treatment of Rat Breast Cancer Tumors. International Journal of Molecular Sciences, 2023, 24, 5976. | 1.8 | 1 |
| 1849 | Roles of Virus-like particles in particularcancer vaccines. , 0, 36, 1517-1524. | | 0 |
| 1850 | TLimmuno2: predicting MHC class II antigen immunogenicity through transfer learning. Briefings in Bioinformatics, 2023, 24, . | 3.2 | 1 |
| 1851 | CD4+ T cells in cancer. Nature Cancer, 2023, 4, 317-329. | 5.7 | 68 |
| 1852 | Immunotherapy in Gastrointestinal Malignancies. , 2023, , 1-23. | | 0 |
| 1853 | Hydrogel-enabled, local administration and combinatorial delivery of immunotherapies for cancer treatment. Materials Today, 2023, 65, 227-243. | 8.3 | 9 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 1854 | CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer. Frontiers in Immunology, 0, 14, . | 2.2 | 0 |
| 1855 | Worth a Pound of Cure? Emerging Strategies and Challenges in Cancer Immunoprevention. Cancer Prevention Research, 2023, 16, 483-495. | 0.7 | 1 |
| 1856 | The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2023, 24, 6710. | 1.8 | 7 |
| 1857 | The peptide woods are lovely, dark and deep: Hunting for novel cancer antigens. Seminars in Immunology, 2023, 67, 101758. | 2.7 | 4 |
| 1858 | General considerations on artificial intelligence. , 2023, , 9-34. | | 0 |
| 1859 | Computational prediction of MHC anchor locations guides neoantigen identification and prioritization. Science Immunology, 2023, 8, . | 5.6 | 8 |
| 1861 | Targeting the tumor microenvironment by liposomal Epacadostat in combination with liposomal gp100 vaccine. Scientific Reports, 2023, 13, . | 1.6 | 0 |
| 1862 | Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic Exploitation. Cancers, 2023, 15, 2206. | 1.7 | 2 |
| 1863 | Neoantigen-directed therapeutics in the clinic: where are we?. Trends in Cancer, 2023, 9, 503-519. | 3.8 | 4 |
| 1864 | Research Progress of Immunotherapy for Gastric Cancer. Technology in Cancer Research and Treatment, 2023, 22, 153303382211505. | 0.8 | 2 |
| 1865 | Dynamics and specificities of T cells in cancer immunotherapy. Nature Reviews Cancer, 2023, 23, 295-316. | 12.8 | 49 |
| 1866 | Novel strategies for cancer immunotherapy: counter-immunoediting therapy. Journal of Hematology and Oncology, 2023, 16, . | 6.9 | 14 |
| 1867 | Immune responses to citrullinated and homocitrullinated peptides in healthy donors are not restricted to the HLA SE shared allele and can be selected into the memory pool. Immunology, 2023, 169, 467-486. | 2.0 | 0 |
| 1868 | Melanoma stem cell vaccine induces effective tumor immunity against melanoma. Human Vaccines and Immunotherapeutics, 2023, 19, . | 1.4 | 4 |
| 1869 | Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial. Clinical Cancer Research, 2023, 29, 1783-1793. | 3.2 | 2 |
| 1870 | DeepNeo: a webserver for predicting immunogenic neoantigens. Nucleic Acids Research, 2023, 51, W134-W140. | 6.5 | 5 |
| 1871 | Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen. , 2023, 11, e006334. | | 0 |
| 1872 | Intratumor childhood vaccine-specific CD4$^+$ T-cell recall coordinates antitumor CD8$^+$ T cells and eosinophils. , 2023, 11, e006463. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1874 | The regulation of the programmed death ligand 1 (PD-L1) by nitric oxide in breast cancer: Immunotherapeutic implication. , 2023, , 173-192. | | 0 |
| 1875 | Neoantigen vaccination augments antitumor effects of anti-PD-1 on mouse hepatocellular carcinoma. Cancer Letters, 2023, 563, 216192. | 3.2 | 4 |
| 1898 | Vaccines and active immunization against cancer. , 2024, , 177-194.e3. | | 0 |
| 1907 | Cancer Antigens: Sources, Generation, and Presentation. , 2023, , 1-40. | | 0 |
| 1912 | Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response. British Journal of Cancer, 2023, 129, 572-585. | 2.9 | 4 |
| 1929 | The landscape of T cell antigens for cancer immunotherapy. Nature Cancer, 2023, 4, 937-954. | 5.7 | 14 |
| 1935 | Cancer Vaccines. , 2023, , 191-210.e9. | | 0 |
| 1937 | â€œDeep learningâ€•for healthcare: Opportunities, threats, and challenges. , 2023, , 225-244. | | 0 |
| 1959 | Challenges in developing personalized neoantigen cancer vaccines. Nature Reviews Immunology, 2024, 24, 213-227. | 10.6 | 6 |
| 1961 | Heterogeneity of the tumor immune microenvironment and clinical interventions. Frontiers of Medicine, 2023, 17, 617-648. | 1.5 | 0 |
| 1967 | Stem-like exhausted and memory CD8+ T cells in cancer. Nature Reviews Cancer, 2023, 23, 780-798. | 12.8 | 5 |
| 1982 | Potential of Biotechnology in Cancer Management. , 2023, , 9-44. | | 0 |
| 1991 | Cancer Among the Elderly. , 2023, , 1-31. | | 0 |
| 1994 | Immunotherapies landscape and associated inhibitors for the treatment of cervical cancer. , 2023, 40, . | | 0 |
| 1995 | Deep Learning Models for Vaccinology: Predicting T-cell Epitopes in C57BL/6 Mice. Lecture Notes of the Institute for Computer Sciences, Social-Informatics and Telecommunications Engineering, 2023, , 182-192. | 0.2 | 0 |
| 2004 | Computational immunogenomic approaches to predict response to cancer immunotherapies. Nature Reviews Clinical Oncology, 2024, 21, 28-46. | 12.5 | 1 |
| 2013 | Recent advances in immunopeptidomic-based tumor neoantigen discovery. Advances in Immunology, 2023, , 1-36. | 1.1 | 0 |
| 2030 | Immunization: Unveiling the Power of Vaccines in Shaping Global Health. , 0, , . | | 0 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 2032 | Nanomaterials for Precision Medicine. , 2023, , 269-290. | | 0 |
| 2033 | Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nature Reviews Immunology, 0, , . | 10.6 | 2 |
| 2046 | Molecular Mechanisms of Immune Checkpoints as an Immunotherapy Tool in Hematological Malignancies. , 2024, , . | | 0 |
| 2062 | mRNA vaccines: a promising solution for incurable diseases. , 2024, , . | | 0 |
| 2074 | Recent advances in light-triggered cancer immunotherapy. Journal of Materials Chemistry B, 2024, 12, 2650-2669. | 2.9 | 0 |
| 2093 | Case report: A case of advanced gastric cancer with multiple skin metastases, with significant relief from immunotherapy. Frontiers in Immunology, 0, 15, . | 2.2 | 0 |
| 2103 | Immunotherapy of Solid Tumors Based on Neoantigen Vaccines. , 2024, , 1-19. | | 0 |
| 2105 | Revolutionizing Lung Cancer Treatment: Recent Breakthroughs in Immunotherapy. , 2024, , 45-64. | | 0 |